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 A deeper understanding of dysregulated glycosylation in pancreatic cancer can provide 
insights into disease mechanisms and the identification of novel disease markers. Recent 
improvements in mass spectrometry techniques have been instrumental in profiling biologically 
relevant tissue sections in order to identify disease marker candidates, but have either not yet been 
adopted for studying glycosylation or applied directly to pancreatic cancer. In the dissertation 
herein, new methods have been developed and adapted to the study of aberrant glycosylation in 
pancreatic cancer, with the ultimate goal of identifying novel disease marker candidates. For the 
first time, we describe a mass spectrometry imaging approach to study the localization of N-
glycans. This technique demonstrated a histology-derived localization of N-glycans across tissue 
sections, with identifications displaying remarkable consistency with documented studies. 
Furthermore, the technique provides superior structural information compared to preexisting 
methodologies. In the analysis of diseased specimen, changes in glycosylation can be linked to 
aberrations in glycosyltransferase expression. When applied to pancreatic cancer in a high-
throughput and high-dimensional analysis, panels of glycans displayed an improved ability to 
differentiate tumor from non-tumor tissues compared to current disease markers. Furthermore, the 
data suggest that glycosylation can identify premalignant lesions, as well as differentiate between 
malignant and benign conditions. These observations overcome significant limitations that hinder 
the efficacy of current disease markers. In an effort to link aberrant glycosylation to the modified 
protein, a subset of glycosylated proteins were enriched and analyzed by mass spectrometry to 
identify proteins that are integral to disease progression and can be probed for the early detection 
iv 
 
of pancreatic cancer. Known disease markers were among the glycoproteins identified, validating 
the utility of the enrichment and detection strategy outlined. This approach also differentiated the 
role of N- and O-glycosylation in antigen expression. Finally, we outline an integrated workflow 
that takes advantage of the unique capabilities of high resolution mass spectrometers. This 
workflow can capitalize on prior glycomic and proteomic experiments to provide a 
comprehensive analysis of dysregulated protein glycosylation in pancreatic cancer.  
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Chapter 1: Literature Review 
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1.1 Introduction to Pancreatic Cancer 
1.1.1 Symptoms, Mortality, and Standard of Care 
 As annual cancer death rates continue to decline for a majority of cancers due to a 
reduction in disease-causing behaviors, improvements in early detection and screening 
approaches, and improved treatments for the major cancer sites, pancreatic cancer has seen a rise 
in death rates (1,2). Average 5-year survival rates for pancreatic cancer remain at a dismal level, 
around 6%, and the disease accounts for the fourth most cancer related deaths in the United States 
(2). For pancreatic cancer, poor clinical outcome is related to a poor understanding of the disease, 
rapid progression, limited effective treatment options, and resistance to therapeutic interventions. 
These factors are further enhanced by a pattern of delayed diagnosis, attributed to mild and 
ambiguous clinical presentations. As the pancreas is located deep in the abdomen, tumor growth 
may persist for extended periods of time before pressure or discomfort is detected. In addition to 
pain and discomfort, other symptoms include jaundice, digestive difficulties, ascites, unexpected 
weight loss and sudden onset diabetes (3,4). However, these symptoms are not specific to 
pancreatic cancer, and are therefore often attributed to other diseases or conditions. For these 
reasons, many patients remain asymptomatic until the disease has already progressed to late 
stages. The difficulty in detecting pancreatic cancer translates to approximately 9% of patients 
being diagnosed with localized cancer (5). For the remaining patients, the cancer has already 
spread to regional lymph nodes or metastasized to distant sites by the time of detection.  
 Unfortunately, 5-year survival rates and median lengths of survival are dramatically 
impacted by the stage of pancreatic cancer at the time of diagnosis. Stages of pancreatic cancer 
range from stage 0 to stage IV, with certain stages being further divided (6). The stage is 
determined at the time of diagnosis and is primarily based on the size of the tumor and the spread 
of the cancer to other sites (Table 1). Stage 0, or carcinoma in situ, refers to abnormal cells found 
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in the pancreas that may become cancerous. Pancreatic cancer is classified as stage IA if the 
tumor is less than 2 centimeters and is not found outside of the pancreas. Stage IV pancreatic 
cancer refers to cancer that has metastasized to distant organs (6). For the largest subtype of 
pancreatic cancer, 5-year survival decreases from 14% when the patient is diagnosed at with stage 
IA pancreatic cancer, to 1% when the patient is diagnosed with stage IV cancer (7). The greatest 
benefit of detecting pancreatic cancer early is the potential for complete surgical resection of the 
tumor, which is the only chance of curative treatment. However, surgical resection is only 
available for the 15-20% of pancreatic cancer patients that are deemed able to survive the surgery 
and are determined not to have locally invasive or metastatic cancer (3,8). Even with surgical 
resection, 5-year survival rates remain below 25% (2). A majority of tumors of the pancreas head 
and proximal neck are resected using the Whipple procedure followed by adjuvant chemotherapy 
(3,8). Patients with more advanced cancer are limited to chemotherapy. Gemcitabine, alone or in 
combination with 5-fluorouracil (5-FU), has traditionally been considered the standard of care 
chemotherapy for patients with locally advanced or metastatic cancer (8). However, gemcitabine 
treatment results in only modest patient benefits due to limited drug uptake and acquired 
resistance (9). Newer chemotherapy combinations, FOLFIRINOX and a combination of 
gemcitabine plus nanoparticle albumin-bound paclitaxel (nab-paclitaxel), have been adopted as 
the new standard of care based off of improved survival statistics (8). FOLFIRINOX, a 
combination of leucovorin, 5-FU, irinotecan and oxaliplatin, showed an increase in survival to 
11.1 months compared to 6.8 months for gemcitabine alone (10). Unfortunately, the toxicity of 
FOLFIRINOX limits the therapeutic use. The combination of gemcitabine and nab-paclitaxel 
outperformed gemcitabine alone in survival and progression-free survival (11). While therapeutic 
intervention has been improved for more advanced stages of pancreatic cancer, these efforts have 
only a modest effect on life expectancy.  
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Table 1. Stage, Resectability and Survival of Pancreatic Cancer 
 
1.1.2 Pancreatic Cancer Subtypes 
 The pancreas is characterized as having both an exocrine and endocrine function. 
Exocrine cells, which constitute a majority of the cells in the pancreas, are responsible for the 
production and release of pancreatic juices involved in digestion. A majority of pancreatic 
cancers are exocrine in nature; including ductal adenocarcinomas, cystic tumors and cancer of 
acinar cells. Among the forms of exocrine pancreatic cancer, pancreatic ductal adenocarcinoma 
(PDAC) is estimated to account for 90% of all pancreatic cancer instances. Ultimately, PDAC is 
the exocrine tumor with the worst prognosis, as other exocrine tumors are slower growing and 
have higher 5-year survival rates (12). The second most common subtype, cystic tumors, account 
for less than 5% of all pancreatic cancers (13). While many of these cystic lesions are benign, 
lesions with malignant potential include mucinous cystic neoplasms (MCN), serous 
cystadenomas, and intraductal papillary mucinous tumors (IPMT). MCNs are characterized by 
excessive mucin production while IPMNs resemble early stage PDAC lesions but form larger 
cystic structures (14,15). Apart from morphological differences, the location of the lesion within 
the pancreas can aid in diagnosis (12). For patients with exocrine cancer, both the cancer and 




Stage 0 (Tis, N0, M0)
Yes 17-23 Mos 10%
13%Stage IA (T1, N0, M0)
Stage IB (T2, N0, M0)
Stage IIA (T3, N0, M0)
6%
Stage IIB (T1-3, N1, M0)
Locally Advanced
Stage III Borderline <20 Mos
30% 3%
Stage III (T4, any N, M0) No 8-14 Mos
Metastatic Stage IV (any T, any N, M1) No 4-6 Mos 60% 1%
T = Primary tumor
Tis: Carcinoma in situ
T1: Tumor restricted to pancreas, <2cm
T2: Tumor restricted to pancreas, >2 cm
T3: Tumor extends beyond pancreas
T4: Tumor affects coeliac axis or superior mesenteric artery
N = Regional lymph node
N0: No regional lymph-node metastasis
N1: Regional lymph-node metastasis
M = Distant metastasis






surgical intervention may result in exocrine insufficiency, a condition marked by a deficiency in 
digestive enzymes produced in the exocrine pancreas (16,17). Treatment of these patients with 
pancreatic enzyme replacement therapy can offset unintentional weight loss caused by 
maldigestion and alleviate some symptoms of the disease (18).  
 Pancreatic cancer of the endocrine pancreas, whose biological function is to modulate 
glucose regulation, occurs infrequently and constitutes less than 5% of the instances of pancreatic 
cancer. Endocrine tumors, often referred to as neuroendocrine or islet cell tumors, are most often 
indolent but have malignant potential if left untreated. Endocrine tumor metastasis to the liver is 
the most common site of metastasis and the primary cause of death for these patients (19). 
Endocrine tumors are classified as functional, where the tumor produces excessive amounts of 
hormones; or nonfunctional, where the tumor does not secrete excess hormones. Individuals with 
functional neuroendocrine tumors present with symptoms reflective of the hypersecreted 
hormone. Functional tumors include insulinoma and glucagonomas, which secrete excessive 
amounts of insulin and glucagon, respectively. Unlike functional tumors, which present with 
symptoms specific to the hypersecreted hormone, nonfunctional tumors are less symptomatic and 
are frequently discovered incidentally or at more advanced stages (20). The distinction between 
functional and nonfunctional tumors is based on symptoms at the time of diagnosis as opposed to 
concrete hormonal expression differences, meaning that nonfunctional tumors can eventually 
trigger symptoms associated with functional endocrine tumors. Recently, treatment strategies for 
endocrine tumors have transformed from a "wait-and-see" approach to a more aggressive 
treatment approach (19). While still poor, 5-year survival is markedly higher for individuals with 
endocrine tumors compared to exocrine pancreatic tumors. The 5-year survival rates for exocrine 
tumors, largely biased by the high relative occurrence and poor outcome of PDAC, are 14%, 
12%, 7%, 5%, 3%, and 1% for stage IA, stage IB, stage IIA, stage IIB, stage III, and stage IV, 
respectively (7). In contrast, 5-year survival rates for patients with neuroendocrine tumors 
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following surgery are 61%, 52%, 41%, and 16% for stage I, stage II, stage III, and stage IV 
tumors, respectively (7). The 5-year survival of individuals with exocrine tumors that are eligible 
for surgical resection remains markedly lower than that of patients with endocrine tumors, except 
those diagnosed with the worst stage of endocrine cancer.  
1.1.3 Disease Etiology 
1.1.3.1 Risk Factors 
 Both environmental cues and genetic predispositions are associated with the development 
of pancreatic cancer. From a population standpoint, pancreatic cancer is most often diagnosed in 
individuals between 60-80 years of age, and rarely before the age of 40 (12). Men are more likely 
to develop pancreatic cancer, with rates for Caucasians being lower than other races (21). After 
controlling for enviromentental factors, studies have established in increased risk of developing 
pancreatic cancer associated with smoking, chronic pancreatitis, excessive alcohol consumption, 
type-2 diabetes, and obesity (22–28). These factors can induce pancreatic cancer through different 
mechanisms. Pancreatitis results in the release of growth factors, cytokines, and reactive oxygen 
species, while smoking, diabetes and obesity result in chronic inflammatory states (14,26). These 
environmental effects are often interconnected, such as heavy alcohol consumption promoting 
chronic pancreatitis (27,28). Among the controllable risk factors, smoking has the most profound 
effect on the population, and is estimated to result in a 2-fold increase in the rate of pancreatic 
cancer development and accounts for approximately 25% of all instances of PDAC (21). Efforts 
to identify the impact of dietary factors on PDAC incidence rates have been largely contested, 
with the most likely impact being through obesity and diabetes (21). However, there is some 
debate as to whether diabetes is in fact a cause of pancreatic cancer. Patients with new-onset type-
2 diabetes, as opposed to long time type-2 diabetic patients, have a higher risk of developing 
PDAC, suggesting the onset of diabetes may instead be a manifestation of PDAC (29). 
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 Genetic predispositions are estimated to cause around 10% of the instances pancreatic 
cancer (30,31). Individuals with 1, 2, and 3 first degree relatives with pancreatic cancer have a 
greater than 3-, 4-, and 14-fold increased risk of developing pancreatic cancer compared to 
individuals with no familial history of pancreatic cancer (26). Risk is further elevated when there 
is a history of early onset pancreatic cancer (age < 50 years) (32). BRCA1, BRCA2, PALB2, 
STK11, CDKN2A, PRSS1, and TP53 gene mutations are associated with elevated instances of 
PDAC (33–36). Among these, individuals with STK11 and CDKN2A mutations have the highest 
rate increase for developing PDAC compared to individuals without the gene mutations. 
Germline BRCA2 gene mutations contribute to the most instances of hereditary pancreatic cancer 
(32). Many of the genes mentioned above are frequently mutated in pancreatic cancer, and will be 
discussed further in regards to their role in cell signaling. While chronic pancreatitis is often 
induced by excessive alcohol consumption and thus characterized as an environmental risk factor, 
hereditary pancreatitis is associated with a 40% an increased risk of acquiring pancreatic cancer 
(21). It is likely that there are additional unknown genetic predispositions for pancreatic cancer.   
1.1.3.2 Common Signaling Pathways Linked to Pancreatic Cancer 
 While the exact biological mechanisms that drive of pancreatic cancer initiation and 
progression are not fully understood, recent studies have identified consistent molecular pathways 
that are likely involved. These mutations appear to regulate different stages of malignant 
progression, some appearing in early stage pancreatic intraepithelial neoplasia (PanIN) lesions 
while others manifest only in later stage PanIN lesions and malignancy (Figure 1). While 
malignant progression typically proceeds though PanIN lesions, other initiating lesions exist in 
the form of IPMNs and MCNs (15). Activating KRAS mutations are observed in many cancers, 
including pancreatic cancer (37). Gain-of-function KRAS mutations on chromosome p12 are 
estimated to occur in over 90% of pancreatic cancers and 36%, 44% and 87% of PanIN1, PanIN2, 
and PanIN3 lesions, respectively (15,38). While the substitution mutation of glycine for aspartate 
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at codon 12 is the most common mutation, other single point mutations at residues G12, G13, and 
Q61 have been observed (39,40). Mechanistically, substitutions at G12 and G13 produce steric 
interference between KRAS and GTPase activating proteins (GAPs), prolonging KRAS 
activation and enhancing downstream signaling (40,41). Under normal conditions, KRAS 
localizes to the plasma membrane and mediates a variety of biological processes, including 
proliferation, differentiation and survival (14,37). The prolonged KRAS activation in pancreatic 
cancer results in increased proliferation, suppression of apoptosis, alterations in the metabolism of 
the tumor microenvironment, and metastasis (40). While the exact KRAS-mediated pathways 
utilized during pancreatic cancer tumorigenesis are unknown, the mitogen-activated protein 
kinase (MAPK), phosphoinositide 3-kinase (PI3K) and ral guanine nucleotide exchange factor 
(RalGEFs) pathways have all been implicated. KRAS-mediated MAPK/ERK activation results in 
a proliferative, anti-apoptotic and invasive cellular phenotype in PDAC cell lines (14,42). 
Furthermore, in a murine model, the selective activation of the Raf-MEK-ERK pathway by 
oncogenic BrafV600E induced a more aggressive pancreatic cancer phenotype with more PanIN 
lesions than the KRASG12D murine model (43). Similarly, KRAS-mediated PI3K/AKT signaling 
regulates cell growth, motility and survival. PDAC is associated with increased signaling 
attributed to KRAS activity, decreased expression of PTEN, or amplification of AKT2 
(14,44,45). In murine models, expression of the oncogenic PIK3CAH1047R allele, which activates 
expression of p110αH1047R and PI3K signaling in the pancreas, resulted in PDAC tumors with 
nearly identical survival and metastasis rates as KRASG12D mutants (46). Additionally, blocking 
downstream PI3K signaling by inactivating PDK1 stopped the formations of PanIN and PDAC in 
KRASG12D mouse models(46). From a therapeutic standpoint, targeting downstream intermediates 
of these pathways have been more fruitful than KRAS inhibitors. Inhibition of downstream 
effectors of the MAPK or PI3K pathways, including MEKK, AKT2 and mTOR, results in growth 
inhibition, increased sensitivity to chemotherapy and reduced invasiveness in PDAC cell lines 
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and xenograft assays (26,45,47,48). While KRAS mutations appear early in tumorigenesis, they 
are frequently absent in PanIN lesions that ultimately progress to pancreatic cancer, and present 
in non-cancerous PanIN lesions, suggest that other signaling pathways are involved in the 
induction of pancreatic cancer, likely working in conjunction with KRAS signaling.  
 
 
Figure 1. PanIN to PDAC Transition is Associated with Genetic Mutations. The transition of 
the cellular morphology that occurs from the progression early PanIN lesions to full blown 
pancreatic cancer is accompanied with mutations of the KRAS oncogene and the P16, P53 and 
SMAD4 tumor suppressors. 
  
 In addition to KRAS oncogene mutations, three tumor suppressors are frequently 
inactivated in pancreatic cancer; these being CDKN2A, TP53 and SMAD4. Inactivation of the 
p16/INK4/CDKN2A tumor suppressor in pancreatic cancer occurs through homozygous deletion, 
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intragenic mutation, and hypermethylation of the promoter in 40%, 40% and 15% of instances, 
respectively (49). The resulting loss of p16 function occurs in around 90% of pancreatic cancers 
and is also observed in 30% of PanIN1 lesions, 55% of PanIN2 lesions, and 71% of PanIN3 
lesions (15,38). While this mutation occurs sporadically in pancreatic cancer, germline mutations 
of the p16/INK4/CDKN2A gene is associated with familial atypical mole-malignant melanoma 
(FAMMM) syndrome, a condition that is linked to a 13-fold increased risk of pancreatic cancer 
(14). Traditionally, the tumor suppressor gene p16/INK4/CDKN2A regulates cell cycle 
progression during G1/S transition of the cell cycle. Cancer derived loss of p16 function increases 
Rb phosphorylation via  the interaction of CDK4/6 with Cyclin D1, resulting in the release of 
E2F transcription factors and gene transcription required for S Phase (50). However, an additional 
role of inactivation of the p16/INK4/CDKN2A gene has been hypothesized. It is now known that 
p14ARF is located on the same gene locus, which functions to regulate p53-mediated cell cycle 
arrest through the stabilization of p53 (14,15,50). As the p16/INK4/CDKN2A locus encodes for 
two tumor suppressors, p16 and p14ARF, efforts to identify which gene plays a role in pancreatic 
tumorigenesis are ongoing. Inactivating mutations that target p16 or p16 and p14ARF, emphasize 
the importance of p16 as a tumor suppressor (33). Meanwhile, an analysis of pancreatic cancer 
mouse models established a role for both p16 and p19ARF,  the equivalent gene to p14ARF in 
humans,  in pancreatic cancer progression (38). Mutations in p16 may also be responsible for 
avoiding senescence induced by KRAS oncogene signaling (14,15,46). 
 P53 is mutated in pancreatic cancer, diminishing the ability of the transcription factor to 
regulate the G1/S and G2/M phases of cell-cycle progression and induce apoptosis. Uniquely, 
pancreatic cancer commonly diminishes p53 function by two mechanisms; p14ARF deficiency as a 
result of certain CDKN2A mutations or missense mutations in TP53  that encodes for the DNA-
binding domain (15,51). In the first mechanism, mutations of the p14ARF gene elevates expression 
of MDM2 and proteolysis of  p53 (14). Alternatively, mutations in p53 are estimated to occur in 
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over 70% of pancreatic cancers and in late stage PanIN lesions. The mutated protein forms 
heterooligomers with wild-type p53, resulting in impaired association with DNA and 
transcriptional activation (52–54). Unlike many cancers where these mechanisms are mutually 
exclusive, TP53 mutations and p14ARF deficiencies are both present in around 40% of pancreatic 
cancer patients (14). However, there are additional oncogenic, 'gain-of-function' properties that 
are observed only in the presence of mutated p53, suggesting additional functions for mutated  
p53 in pancreatic cancer progression. These properties result in chromosomal instability, the 
inhibition of DNA repair pathways, and more aggressive and drug resistant cell phenotypes (55). 
This aggressive phenotype is demonstrated by the observation that 65% of mice expressing 
mutated p53 developed metastases, while none of the p53-null mice did (56). 
 DPC4/SMAD4/MADH4 is the third tumor suppressor that is commonly mutated in 
pancreatic cancer. Like p53 mutations, loss of SMAD4 is seen late in pancreatic cancer 
progression, appearing in 31-41% of PanIN3 lesions and 50% of cancers (14,15). The loss of 
SMAD4 is thought to contribute to pancreatic cancer through TGFβ signaling. Under normal 
conditions, TGFβ binds cell surface receptors and initiates an intracellular kinase cascade 
resulting in the phosphorylation and translocation of SMAD4 to the nucleus, where SMAD4 
transcriptionally regulates apoptosis, proliferation and migration. While TGFβ exerts growth-
inhibitory and growth-promoting effects, it is thought that the loss of SMAD4 results in decreased 
growth inhibition in pancreatic cancer. Additionally, the loss of SMAD4 does not reduce the 
TGFβ-mediated promotion of EMT, shifting TGFβ to a tumor promoter (52,57). This is in 
accordance with the in vivo observation of reduced invasion upon TGFβ inhibition, elevated 
invasion and EMT upon addition of exogenous TGFβ, and elevated levels of TGFβ in PDAC 
cancer cells compared to normal cells and the effect (58–60). 
 Other signaling pathways and biological events have been also been implicated in 
pancreatic cancer, albeit not as frequently as those described above. The tumor suppressors 
11 
 
LKB1/STK11 and BRCA2 can be mutated in both sporadic and familial pancreatic cancer (61,62). 
Peutz-Jeghers syndrome, characterized by LKB1/STK11 gene mutation, is associated with a 
>40%-fold increase in PDAC instances (14). Whereas LKB1 promotes tumorigenesis through the 
regulation of mTOR, BRCA2 mutations impair DNA damage response pathways (63,64). BRCA2 
gene mutations are observed in around 17% of pancreatic cancers, and present in later staged 
lesions, suggesting a role in malignant transformation of precancerous lesions to full-blown 
PDAC (14,62). Other studies have implicated constitutive NF-kB signaling in pancreatic cancer 
based on the observation that inhibition of NF-kB inhibits tumorigenesis and increases sensitivity 
to anticancer agents (65–67). Similarly, both notch and sonic hedgehog developmental signaling 
pathways, which are absent in the normal adult pancreas, are activated in PanIN lesions and 
PDAC (68,69). Finally, both growth factors (EGF, IGF, VEGF) and their corresponding receptors 
have also been implicated in pancreatic cancer growth and proliferation (70–74). The disruption 
of growth factor receptor signaling has been shown to suppress both in vivo and in vitro tumor 
growth and enhance response to chemotherapy (74–78). 
1.3.3.3 Origin of Pancreatic Cancer Initiation 
 The definitive origin of the cells responsible for pancreatic cancer initiation remains 
unclear. Given the ductal-like morphology of the cancer, ductal cells were originally 
hypothesized to be the cellular origin of PDAC (79). This theory is supported by evidence linking 
the transformation of neoplastic ductal lesions (PanINs) to pancreatic cancer, including 
similarities in genetic alterations. On the genetic level, approximately 30% of patients with 
PanIN-1A lesions exhibit point mutations in the KRAS oncogene, a mutation that becomes more 
prominent as the lesions ultimately progress to PDAC, where the mutation is present in about 
90% of patients (80,81). Similarly, CDKN2A, TP53, and SMAD4 exhibit inactivating mutations in 
PanIN lesions and, to a larger extent, pancreatic cancer (40). While evidence linking the early 
genetic mutations in PanIN with those frequently observed in PDAC supports the theory of ductal 
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cell origin, this concept is difficult to prove, especially as expression of oncogenic KRAS 
specifically in ductal cells does not induce PanIN or PDAC in murine models (82). On the other 
hand, more recent data suggests that acinar/centroacinar cells can acquire features of ductal cells 
and progress to PDAC (83,84). Transgenic murine models with ectopic expression of TGFα or c-
myc demonstrate acinar cell acquisition of ductal cell features culminating in PDAC (84,85). 
Additionally, the insertion of activated KRAS into the open reading frame of Mist1, a 
transcription factor that is implicated in acinar organization, results in the development of 
aggressive pancreatic cancer in mice (86). Unlike ductal cells, the selective expression of 
oncogenic KRAS in acinar/centroacinar cells does induce PanINs and PDAC (83). Alternatively, 
subpopulations of cells that display characteristics analogous to stem cells have been 
hypothesized to act as cancer stem cells in pancreatic cancer. The subpopulation of pancreatic 
cancer cells that test positive for cell surface markers CD44+CD24+ESA+ represent <1% of 
pancreatic cancer cells (87,88). These cells display highly tumorigenic properties and are 
estimated to have greater than 100-fold higher tumorgenicity compared to cells that test negative 
for the surface markers (88). In a xenograft mouse model, tumors that developed from the 
CD44+CD24+ESA+ cells were indistinguishable from the parent tumor. Overall, the 
CD44+CD24+ESA+ cells displayed properties of self-renewal, the potential to produce 
differentiated cells, and resulted in the expression of sonic hedgehog signaling molecules, all 
properties common in cancer stem cells (88). Alternatively, CD133+CXCR4+ cells influence the 
metastatic phenotype of pancreatic cancer cells (89). These cells are predominantly localized at 
the invasive front of the tumor and the different surface markers confer survival advantages to the 
cells. CD133+ cells are more resistant to gemcitabine than CD133- cells, while the CXCR4+ 
marker identifies migratory cells. Liver metastases were unique in mice given CD133+CXCR4+ 
cells compared to CD133+CXCR4- cells (89). 
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1.1.4 Detection and Diagnosis of Pancreatic Cancer 
1.1.4.1 Clinical Approaches to Detect Pancreatic Cancer  
 Pancreatic cancer is difficult to detect due to ambiguous symptoms, as described 
previously. When individuals present with symptoms, possess genetic mutations that increase 
their probability of developing pancreatic cancer, or have a family history of pancreatic cancer, a 
physician may perform a physical examination to check for jaundice, physical masses or fluid 
buildup in the abdomen. Non-invasive and invasive imaging tests provide more information 
regarding the status of pancreatic cancer. Abdominal ultrasounds are typically used for initial 
examinations but are often followed up by other non-invasive strategies, such as computed 
tomography scans (CAT), magnetic resonance imaging (MRI), magnetic resonance 
cholangiopancreatography (MRCP) or positron emission tomography (PET) scans (90). 
Depending on the approach, these imaging techniques can identify the presence of cancer, locate 
metastatic sites, and differentiate between benign and metastatic masses. Invasive imaging tests, 
termed endoscopic ultrasounds (EUS) or endoscopic retrograde cholangiopancreatography 
(ERCP) tests allow for more detailed images, but can also be used to insert stents to compensate 
for obstructed ducts or obtain fine needle aspirate (FNA) biopsy samples (12). EUS is capable of 
detecting small pre-invasive lesions, making it well suited to identify lesions in high-risk 
individuals (32). A combination of multiple screening strategies may be used to improve the 
accuracy of cancer detection (91). The combination of EUS, multi-detector computed 
tomography (MD-CT), MRI and MRCP offers the best sensitivity for the detection of pancreatic 
cancer (90). Absolute certainty in identification is only achievable with a biopsy. In addition to 
FNA biopsies, brush biopsies and tissue biopsies can be used for disease diagnosis. In a brush 
biopsy, cells are collected during an ERCP test, whereas tissue biopsies are collected during 
laparoscopy. In addition to imaging tests and biopsy collections, a blood test can be performed to 
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assess the probability of pancreatic cancer. Blood work can assess levels of bilirubin, pancreatic 
enzymes, CA19-9, and CEA. While altered levels of enzymes or markers in the blood work do 
not conclusively determine if an individual has pancreatic cancer, they can determine the 
necessity of further evaluations (92). After identification of pancreatic cancer, genetic testing may 
be used to identify gene mutations. While screening is useful in prompting immediate family 
members to undergo genetic testing, genetic testing is underutilized by physicians (32).  
1.1.4.2 Gross and Microscopic Characteristics 
 Pancreatic cancer presents grossly as white-yellow firm masses, most often arising in the 
pancreatic head, but also infiltrating and metastasizing into surrounding tissues, including lymph 
nodes, spleen, peritoneal cavity, liver, and lungs (14,93). The tumor often has ill-defined edges 
and is surrounded by a dense fibrotic stroma and ECM proteins (79,94,95). The mean diameter of 
the tumor in the pancreatic head is between 2.5 and 3.5 cm, with larger tumors detected in the 
body or tail of the pancreas (12). At the microscopic level, the progression from low-grade 
(PanIN-1A or PanIN-1B) to high-grade (PanIN-3) lesions is accompanied by histological 
changes. Low-grade lesions are often flat and retain nuclear polarity, while high-grade lesions 
exhibit nuclear atypica, loss of nuclear polarity, and frequent mitoses (15).  The transition from 
PanIN-3 lesions to invasive carcinoma is marked by the invasion through the basement 
membrane (93). The presence of cancer is frequently associated with infiltrating small glands 
lined with mucin-containing cells, with the cancer surrounded by a desmoplastic reaction (93). 
Malignant glands can be distinguished from benign glands based off on variations in the gland 
architecture, location of the glands, variation in the size of nuclei, association with surrounding 
pancreatic parenchyma, and the presence of necrotic debris (96). PDAC is typically moderately or 
well differentiated, but there is often some variation in the degree of differentiation within the 
tumor (12,97). As glands become less differentiated, the lumen boundary and overall shape of the 
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duct becomes more irregular (96).  These glands commonly appear directly adjacent to muscular 
arteries or invade into perineural or vascular tissue.  
1.2 Mass Spectrometry 
1.2.1 Principles of Mass Spectrometry 
1.2.1.1 General Introduction to Mass Spectrometry  
Mass spectrometry (MS) is a powerful analytical approach to characterize analytes based 
off of the molecules’ mass-to-charge ratio (m/z) and the fragmentation pattern. The functionality 
of mass spectrometry relies on three primary components; the ion source, mass analyzer, and 
detector. As the mass spectrometer measures m/z values, an ion source is required to generate 
charged molecules during the ionization process. Charged ions are then separated by either an 
electric or magnetic field, known as the mass analyzer, prior to reaching the detector. Initial 
characterization of an analyte is commonly based on accurate mass from the MS, but further 
validation can be achieved by tandem mass spectrometry (MS/MS), in which the configuration of 
the mass spectrometer includes an initial ion selection step followed by fragmentation and 
analysis of fragments, also known as daughter ions. While an in-depth description of the 
underlying physics that drives the instrumentation is beyond the scope of this dissertation, a brief 
introduction to the common techniques used in the biomedical sciences and for this dissertation is 
provided.  
1.2.1.2 Ion Sources 
 The two most influential ionization techniques for the analysis of biological molecules, 
and thus the two ionization methods used in this dissertation, are electrospray ionization (ESI) 
and matrix-assisted laser desorption/ionization (MALDI). Both of these ionization techniques are 
regarded as soft ionization techniques, meaning they induce little molecular fragmentation, unlike 
the ionization techniques that preceded them. The concept of electrospray ionization was 
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introduced by Malcolm Dole in 1968 and developed and applied for the study of large biological 
molecules by John Fenn in the 1980s (98,99). The basic principle of ESI is that the solvent 
containing analytes is infused into a charged capillary resulting in a Taylor cone formation, which 
emits an aerosolized spray, ultimately resulting in charged droplets that travel through an electric 
field towards the mass analyzer. As the solvent evaporates, the charge density of the droplets 
increases until the point where the charge exceeds the Rayleigh limit and the droplet undergoes 
Rayleigh fission to create smaller charged ions (100). The presence of gas flow assists in the 
process of nebulization, directs the spray towards the mass spectrometer, and aids in solvent 
evaporation (101). The transition of analytes to the gas phase does not require exorbitant amount 
energy and can proceed with minimal fragmentation. One advantage of ESI is that it ionizes 
molecules in the liquid phase, allowing ESI to be in-line and coupled to conventional liquid 
chromatography, including reverse phase chromatography (102). Additionally, the ability of the 
ion source to generate multiply charged ions, and thereby smaller m/z values, results in ions that 
are more compatible with mass spectrometers, which are often set to detect m/z values less than 
2,000 Da. The presence of the same species with different charge states provides multiple 
opportunities to identify and fragment a molecule, which is particularly useful if the 
fragmentation produced by one charge state is not acceptable (103).  
 Franz Hillenkamp introduced MALDI as an ion source around the same time that John 
Fenn introduced ESI (104). In MALDI, the sample is mixed and cocrystalizes with a matrix that 
is present in large molar excess. Most matrices absorb UV light, which is fired in the form of a 
pulsed laser at the matrix crystal, causing the matrix to absorb energy from the laser, resulting in 
desorption of the matrix and the analyte (105). The matrix also acts as a proton donor or receptor, 
resulting in ionization for negative or positive ion mode, respectively (105). As the matrix 
absorbs the energy from the laser instead of the sample itself, MALDI is considered a soft 
ionization strategy and results in minimal analyte fragmentation. MALDI primarily produces 
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singly charged ions rendering mass spectra somewhat less complex than ESI spectra. However, 
multiply charged ions can be detected by altering the matrix or protocol for matrix application 
(106). MALDI is also more tolerant of contaminants, such as residual detergents, than ESI (107). 
While most studies rely on either ESI or MALDI ionization, the techniques can be quite 
complementary in nature. For proteomic analysis of complex samples, the use of MALDI in 
addition to ESI ionization resulted in 45% more protein identifications, including many that were 
identified based off of larger and more hydrophilic peptides, such as glycosylated peptides (108).  
1.2.1.3 Mass Analyzer 
 Once ionized, the mass analyzer functions to separate ions based off of their m/z. 
Importantly, the mass analyzer is responsible for the overall resolution, mass accuracy, mass 
range, and fragmentation profile that can be achieved (109). The general classes of mass 
analyzers are Quadrupole (Q), Time of Flight (TOF), Magnetic Sector, Electrostatic Sector, 
Quadrupole Ion Trap (QIT), and Ion Cyclotron Resonance (ICR). Each mass analyzer relies on 
specific physical properties to achieve ion resolution. Quadrupole mass analyzers consist of four 
parallel metal rods that are used to separate ions based on their trajectory in an electric field. One 
pair of rods is subjected to a direct voltage, whereas the other pair has an alternating 
radiofrequency (RF) potential. Depending on the voltage conditions, only ions with a certain m/z 
will be able to reach the detector (109). The quadrupole mass analyzer has been widely adopted 
as it is mechanically simple and offers advantages in terms of cost, size and speed (110). The 
TOF mass analyzer was popular in the 1960s but was surpassed due to limitations in sensitivity, 
resolving power, and speed. However, instrumental improvements have overcome these 
limitations resulting in a renewed interest in TOF (111). The principle behind TOF is that ions 
with the same kinetic energy but different masses will have a velocity that is inversely 
proportional to the square root of their m/z value (111). Thus, the time required to navigate the 
flight tube will be shorter for smaller ions based off of their greater velocity. The m/z of an ion 
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will be calculated based on the length of time it takes the ion to navigate the flight tube and reach 
the detector. Similar to the quadrupole analyzer, quadrupole ion trap mass analyzers can trap and 
accumulate ions using an electric field for the separation of ions based off of their m/z values. 
Unlike the quadrupole analyzer, the quadrupole ion trap is composed of a ring electrode and two 
end cap electrodes. Ions are trapped in the electric field and can be ejected by increasing the RF 
voltage (112). The quadrupole ion trap mass analyzers provide superior sensitivity and data 
acquisition speeds compared to other mass analyzers but are limited by reduced resolving power 
and higher mass defects (107). Ion cyclotron resonance and Orbitrap mass analyzers are 
becoming increasingly popular, due to their higher resolving power and mass accuracy. The FT-
ICR mass spectrometer uses ion optics to transfer ions into the magnetic field and the ICR cell, 
also known as a Penning trap. As the ions are orbiting, they are excited by an RF current to 
induce a current image, which can be processed by a Fourier transform (113).  
 Each mass analyzer offers different advantages that can be exploited depending on the 
nature and complexity of the experimental design. Additionally, certain analyzers seem to pair 
nicely with specific ion sources. The most common mass analyzers paired with a MALDI 
ionization source is the TOF mass analyzer (105). On the other hand, quadrupole mass analyzers 
have historically been interfaced with ESI sources, as quadrupoles are tolerant of high pressures, 
able to assess m/z values up to 3,000, and are considered low cost. More recently, quadrupole 
mass analyzers have been largely replaced by ion traps. FT-ICR mass analyzers can be coupled to 
both MALDI and ESI sources to improve resolution and mass defect errors. 
 As previously mentioned, tandem mass spectrometry is used to generate ion information 
beyond the m/z value. Collision-induced dissociation (CID) is one fragmentation technique, in 
which an ion is selected in the mass analyzer and fragmented through the collision of a gas in the 
collision cell. The triple-quadrupole mass analyzer is a common instrumental setup used to 
perform CID, in which a particular ion is isolated in the first quadrupole, fragmented in the 
19 
 
second quadrupole, and the fragments are analyzed in the third quadruple. Similarly, Q-Q-TOF 
instruments utilize the first quadrupole for precursor ion selection, the second quadrupole for 
CID, and the ToF for resolution of the product ions (107). In contrast, ion-trapping instruments, 
such as the QIT or FT-MS, operate in a tandem-in-time method, meaning that the fragmentation 
is performed in the same mass analyzer (114). In these instruments, selected ions are trapped and 
fragmented in the ion trap prior to the fragments being ejected onto the detector. The high 
MS/MS efficiencies of the ion trap instruments have made them a prominent analyzer for 
proteomic workflows. Other fragmentation techniques utilized in this dissertation include electron 
transfer dissociation (ETD) and high energy collision dissociation (HCD). For ETD, negatively 
charged reagent ions (fluoranthene radical anions) transfer electrons to the precursor cations 
causing them to fragment. For peptides, ETD fragmentation produces c and z type fragment ions 
of the peptide backbone (115,116). HCD fragmentation uses a beam-type CID mechanism, but 
operates at a higher energy than traditional CID. This generates informative low molecular weight 
ions that can be detected in the Orbitrap, which overcomes the one-third effect that is associated 
with CID in linear ion trap instruments (117).   
1.2.1.4 Mass Detector 
 In order for a signal to be generated from the ions, mass detectors rely on the process of 
secondary ion amplification or the generation of a current. An electron multiplier is one of the 
most common detectors and relies on a series of dynodes at increasing potential. As ions strike 
the dynode surface, secondary electrons are emitted and attract to the next dynode, which occurs 
in an iterative process to allow for signal amplification (105). Eventually, the emitted electrodes 
are collected by a metal anode. Scintillation counters are similar to the electron multipliers in that 
ions initially strike a dynode, initiating a cascade of electrons, but differ in that the electrons 
strike a phosphorus screen that emits photons that are detected by a photomultiplier (105). The 
quadrupole ion trap functions to trap ions and also to detect ions. As the potentials that are 
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applied to the electrodes of the ion trap are altered, ions reach an unstable trajectory and are 
scalned out of the ion trap and are monitored by an external detector (112). Charge detectors, 
which detect a current induced by a passing ion, are common in FT-MS instruments. In the FT-
ICR-MS, the m/z of an ion is determined by its ion cyclotron resonance frequency in the 
magnetic field. The m/z in the Orbitrap mass spectrometer is determined by its oscillation 
frequency in an electric field (118). This process generates an image current of an ion, which can 
be Fourier transformed to ultimately yield the m/z.   
1.2.2 Mass Spectrometry Applications in the Biomedical Sciences 
 Early applications for mass spectrometry were predominantly related to physics based 
research, but the introduction of MALDI and ESI ionization sources in the 1980s ushered in a 
new wave of biomedical research using mass spectrometry (119). These soft ionization sources 
enabled the analysis of large molecules instead of focusing on molecules less than 1kDa. The era 
of genomics enhanced the desire to assess broad “omic” studies of specimens in general, or for 
the study of diseases. As the mass spectrometer is able to simultaneously detect and characterize 
analytes in a single experiment as a function of their m/z and downstream fragmentation, the 
technique is well suited for "omics" research, in which thousands of analytes may be present. To 
this end, mass spectrometry has been instrumental in lipidomics, metabolomics, proteomics, and 
the global analysis of post-translational modifications (PTMs) (120–124). 
 Applications relating to general proteomic experiments will be outlined in this section, 
with a more in-depth review of glycoproteomics presented later in the dissertation. Proteomics is 
the global study of proteins and their modifications in a sample. A distinction can be drawn 
between classical proteomics, which aims to identify the entire proteome; and targeted 
proteomics, which assesses a defined subset of the proteome (i.e. glycoproteins) (103). In 
addition to protein identification, proteomic analysis can also be used to interrogate protein 
abundance in a quantitative fashion. The standard workflow typically involves sample 
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fractionation prior to analysis by mass spectrometry, which functions to allow the detection of 
lower abundance ions. This is required, especially for complex biological fluids, due to the high 
dynamic range of proteins in the sample. Proteomics is typically done at the peptide level 
(bottom-up proteomics), further complicating the sample complexity by producing multiple 
peptides for a single protein. The detection of peptides by the mass spectrometer is typically 
accomplished in positive ion mode, where the peptides are analyzed at a low pH where arginine, 
lysine and histidine amino acids are protonated (103). Fractionation and chromatography can be 
done at the protein level, through techniques such as SDS-PAGE, or at the peptide level using 
SPE cartridges. More commonly, chromatography can be applied in an on-line fashion by 
connecting chromatography instruments (i.e. HPLC) directly to mass spectrometers.  
 The detection of product ions only provides a list of m/z values, so fragmentation of each 
ion is required to determine the peptide sequence. Chromatographic separation prior to MS 
analysis allows concentration and resolution of peptides prior to mass spectrometery, resulting in 
more protein identifications. The selection of which ions to fragment can proceed through a 
variety of different mechanisms which ultimately play a role in the outcome of the experiment. 
The most common method is data-dependent acquisition (DDA) workflows, in which the most 
abundant ions throughout the chromatographic separation are selected for fragmentation (125). 
While commonly employed, DDA suffers in its ability to characterize low-abundance peptides in 
complex biological mixtures (125). To compensate for these limitations, several alterations to 
conventional DDA workflows can be applied (126). These include targeted LC-MS strategies, 
such as selected reaction monitoring (SRM) and parallel reaction monitoring (PRM). These 
targeted approaches function by acquiring MS/MS spectra for MS ions of interest, even when 
they are not the most abundant ions present (125). Alternatively, data-independent acquisition 




 While the ultimate goal of proteomics is to characterize the entire proteome of a sample, 
this remains a significant challenge. Recent successes rely upon advances in instrumentation and 
data processing strategies. During the last decade, mass spectrometers have made significant 
improvements in resolution, mass accuracy, sensitivity and scan speed (128). For shotgun 
proteomics, in which a peptide digest is processed by LC-MS/MS, peptide identification relies on 
database searching algorithms for protein identification. The software works to compare tandem 
mass spectra from the experimental data to that generated in an in silico protein digest, to 
determine what peptides are present in the sample, to make inferences about the proteins present. 
Many software packages are available to process complex shotgun proteomics data including 
ProteoIQ, Proteome Discover, Scaffold, and MaxQuant. Improvements in instrumentation and 
data processing software have resulted in a rapid growth of proteomics as a field, but 
improvements can still be made. The human proteome (~100,000 proteins) vastly exceeds the 
genome (~30,000 genes), even without considering the additional complexity provided by PTMs, 
mutations and truncations. Considering the added diversity, it is not unreasonable to expect the 
proteome to exceed 2,000,000 proteins (103,129). 
1.2.3 Mass Spectrometry Imaging 
 Imaging Mass Spectrometry (IMS) is recent addition to the field of mass spectrometry. 
This technique enables the simultaneous detection of analytes while retaining their spatial 
localization within tissue sections. General "omics" techniques reflect trends in analyte 
expression across the entire tissue, but may be biased by the presence of differing histology. To 
compensate for tissue heterogeneity, laser capture microdissection (LCM) is one approach used to 
selectively enrich specific cells of interest (130,131). However, the utility of LCM is limited in 
that the approach is time consuming and requires a high number of cells. Another approach to 
assess analyte distribution across a tissue section relies on voxelation followed by LC-MS, in 
which an individual analysis is done for each defined region, or voxel, of the tissue (132). While a 
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large number of analytes are detected, the spatial resolution of this approach is limited by the size 
of the voxels and length of time required, as sample preparation and data analysis must be 
performed on each voxel individually. To compensate for these limitations, IMS has been adapted 
for use with secondary ion mass spectrometry (SIMS), MALDI, and desorption electrospray 
ionization (DESI). Although SIMS-IMS is capable of achieving a higher overall spatial resolution 
(as small as 50 nm), the approach is not commonly used because of undesired fragmentation 
attributed to the high-energy ions used to promote ionization (133). Recent sample preparation 
strategies have improved the efficiency of SIMS ionization, which has a niche utility in imaging 
at the single cell level (134). DESI-IMS, in which ions are desorbed by targeting charged droplets 
and ions at the surface of the tissue, suffers from low spatial resolution and low sensitivity (133). 
MALDI-IMS is capable of achieving a relatively high spatial resolution, while inducing less 
fragmentation compared to SIMS, and thus represents the most popular ionization source for IMS 
analysis. Efforts to optimize the sample preparation are essential to MALDI-IMS experiments, as 
uneven distribution of matrix or the formation of large matrix crystals will negatively impact the 
experiment. Importantly, all IMS platforms generate parent ions that can be fragmented for 
further structural confirmation. As a platform, MALDI-IMS has been instrumental in the analysis 
of lipids, proteins, peptides, therapeutics, and metabolites (135–143). 
 All MALDI-IMS experiments require the same basic sample preparation steps prior to 
imaging, although variations to the general workflow can significantly impact the overall results 
or class of biological molecule that is detected. In the workflow schematic provided (Figure 2), 
solid connecting arrows represent conserved steps across all imaging experiments, while steps 
connected by dashed arrows can be utilized for selected experiments. Initially, tissues are 
sectioned and placed on a platform compatible with a MALDI adaptor, most commonly glass 
slides. A homogenous layer of matrix is then applied to the slide containing the sectioned tissue 
and allowed to crystallize. During the imaging process, a MALDI spectra is generated at specified 
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increments across the tissue section (termed spatial resolution). Software for data processing 
merges all of the individual spectra while maintaining their original location in the tissue section. 
Individual m/z values can be selected and visualized by the relative intensity for the ion across the 
entire tissue section. This approach is specifically useful in discovery phase research, where 
undefined ions are only observed in a specific compartment of a tissue, but are not commonly 
observed in global omics research due to ion suppression from more abundant species. While the 
general approach applies to all MALDI-IMS experiments, efforts to optimize sample preparation 
have been performed to enhance sensitivity performance for certain molecular targets. Initial 
MALDI-IMS workflows utilized fresh/frozen tissue sections, but the adaptation of 
immunohistochemical workflows has enabled MALDI-IMS analysis of formalin-fixed paraffin-
embedded (FFPE) tissue blocks and tissue microarrays (144). Depending on the target of the 
imaging experiments, different washing procedures can be employed. While MALDI-IMS of 
lipids does not require washing of the slide, washing with ammonium formate or ammonium 
acetate can improve the overall ionization efficiency and number of ions observed (145). To 
analyze proteins or peptides by MALDI-IMS, lipids should be removed by washing the slide in 
organic solvents to mitigate ion suppression (144,146). Following the wash, in situ enzymatic 
digestion can be performed by the application of an enzyme (i.e. trypsin) followed by MALDI-
IMS. Both the method of matrix application and type of matrix used can significantly affect the 
type of molecules detected and the overall quality of the experiment. Automated spray stations 
and microdroplet inkjet printers are among the most common instruments used for matrix 
application, but suffer from solvent-induced analyte delocalization and the formation of large 
matrix crystals (138,147). On the other hand, matrix application by sublimation produces a 
homogeneous layer matrix with reduced sizes of matrix crystals (136). Different matrix 
compositions can improve analysis of specific classes of molecules in MALDI-IMS, largely 
reflective of traditional MALDI-MS. Both 2,5-dihydroxybenzoic acid (DHB) and α-cyano-4-
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hydroxycinnamic acid (CHCA) are commonly applied matrices for MALDI-IMS of lipids, but 
are primarily used for the detection of PCs and SMs in positive ion mode. 1,5-
Diaminonaphthalene (DAN) matrix was demonstrated to be efficient in positive and negative ion 
mode, enabling the detection of lipids that are primarily detected in negative ion mode, such as 
sulfatides, ceramides and gangliosides (136).  
 
Figure 2. MALDI-IMS Workflow Schematic. Universal (Solid Arrows) or optional (dashed 
arrows) steps can be optimized to achive better MALDI-IMS results. Optimal conditions are often 




1.2.4 Mass Spectrometers in the Dissertations 
1.2.4.1 Bruker SolariX FTICR 
 A majority of the MALDI MS and MALDI-IMS experiments in this dissertation were 
carried out on Bruker SolariX 7 Tesla FTICR mass spectrometer. The instrument possesses both 
an ESI and MALDI ion source. After ionization in the MALDI source by a smartbeam-II laser, 
ions are focused into an ion beam using DC and RF voltages. At this stage, ions pass through a 
vacuum stage and are decelerated. Ions then traverse to the quadrupole, in which a specific m/z 
window can be defined to only allow ions within that range to pass through to the hexapole. If 
desired, specific ions can be fragmented in the collision cell. Ions are then focused by optical 
lenses prior to entering the magnetic field of the ICR cell, which is under ultrahigh vacuum 
conditions. The infinity cell, which exists at the center of the 7T magnet, consists of three sets of 
electrodes that are used for ion trapping, excitation and detection. The magnetic field traps ions 
and induces cyclotron motion, but a small electrical field is required to prevent ions from 
escaping the ICR cell. The trapped ions are then excited by a RF frequency sweep, which 
increases the radius of selected ions and enables detection by the detection plate (148). 
1.2.4.2 Thermo Orbitrap Elite  
 The Thermo Scientific Orbitrap Elite mass spectrometer is considered a hybrid mass 
spectrometer that couples a linear ion trap with an Orbitrap mass analyzer. The linear ion trap on 
the front-end is the Thermo Scientific Velos Pro mass spectrometer. This functionality provides 
excellent sensitivity and data acquisition speed associated with ion trap mass analyzers, and is 
capable of trapping, isolating and fragmenting ions (149). The linear ion trap possesses an 
independent MS detector, so that the ions can be detected in the ion trap or proceed to the 
Orbitrap for further analysis. The transition to the Orbitrap requires ions to move from the RF-
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only octopole into the curved linear trap (C-trap). As the ions go from a gas-free environment to 
the gas-filled C-trap, ions lose their kinetic energy by colliding with the nitrogen collision gas. 
Ions are transferred to the Orbitrap by ramping off RF voltages applied to the C-trap and applying 
extracting voltages onto the Orbitrap electrodes. As described in Thermo literature, the Orbitrap 
analyzer consists of a central spindle-shaped electrode surrounded by bell-shaped outer 
electrodes. Injected ions begin axial oscillations around the central electrode of the Orbitrap, and 
applied voltages prevent collision with the electrode. An image current is detected by two split 
halves of the outer electrode of the Orbitrap, which can ultimately determine the frequency of 
axial oscillation and m/z ratio of ions. The Orbitrap mass analyzer enables the detection of 
analytes with high mass accuracy, resolution and expands the dynamic range that can be detected 
(149). The combination of two divergent mass analyzers enables peptides to be measured at sub-
ppm mass accuracy which significantly improves bottom-up protein identification. The Orbitrap 
Elite is setup to allow CID, HCD, and ETD fragmentation of selected precursor ions (116). For 
HCD fragmentation, ions enter the HCD cell from the C-trap and the fragment spectra are 
detected in the Orbitrap analyzer. The ETD source is located on the back of the Orbitrap Elite 
mass spectrometer and can fragment peptide ions in the linear ion trap by the transfer of electrons 
from negatively charged reagent ions. 
1.3 Glycosylation 
1.3.1 Broad Overview of Glycosylation 
1.3.1.1 The Complexity of Protein Glycosylation 
 Glycosylation refers to the addition of monosaccharide or oligosaccharide chains, 
commonly referred to as glycans, onto biomolecules such as proteins, lipids, proteoglycans and 
glycophosphatidylinositol (GPI) anchored proteins. Recently, free, unbound glycans have been 
discovered and implicated as important signaling molecules (150). It is estimated that over 50% 
28 
 
of human proteins are glycosylated, making it the most common and complex post-translational 
modifications. There are nine monosaccharide units from which glycans are constructed, but 
additional diversity can be achieved by further modification of those monosaccharides (150). A 
general classification system groups monosaccharides based on their molecular weight. Hexose 
(Hex) monosaccharides consist of glucose (Glu), galactose (Gal) and mannose (Man) residues. N-
acetylhexosamine (HexNAc) monosaccharides, which differ from Hex monosaccharides by the 
addition of an acetyl functional group, consist of both N-acetylglucosamine (GlcNAc) and N-
acetylgalactosamine (GalNAc). The remaining monosaccharides include fucose (dHex, fuc), N-
acetylneuraminic acid (NeuAc), glucuronic acid (GlcA) and xylose (Xyl). Figure 3 provides a 
schematic of monosaccharides compositions as they will appear throughout the rest of this 
dissertation. While most of these monosaccharides are present throughout all species and across 
all glycoconjugates, some monosaccharides display a specificity to certain biological species or 
types of glycoconjugates. In contrast to plants, in which complex N-glycans contain xylose 
residues, these residues are only observed in humans on proteoglycans (150,151). In addition to 
variation in the type of monosaccharides found, species wide differences in glycosylation also 
appear as differences in glycosidic bond linkages. For example, plant N-glycans express non-
human glycan linkages, such as α1,3-linked core fucose residues (151). While limited in the 
number of monosaccharides, glycosylation is quite complex. Unlike transcription and translation, 
the process of glycosylation is not template encoded but depends on a variety of cellular factors. 
Substrate availability, developmental stage, nutrient availability, pH and enzyme localization all 
alter the observed cellular glycoforms, and allow for the glycome to respond to subtle biological 
changes (152). Glycosyltransferases and glycosidases, which add and remove monosaccharides 
from glycans, are responsible for the structure of the glycoform. It is estimated that around 5% of 
the genome encodes enzymes that are involved in cellular glycosylation in some fashion (150). 
Multiple enzymes can reside in the same region of the cell and compete over the same substrate, 
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resulting in a complex array of glycoforms (152). However, glycan synthesis is not completely 
random, as glycosyltransferases exhibit some degree of specificity for the protein, glycopeptide 
and growing glycan structure (152). Glycosidases promote trimming of the glycan, both during or 
after synthesis, but are equally responsible in yielding glycan structures. As these enzymes 
function sequentially, the absence of a single glycosyltransferase that acts early in glycan 
synthesis can result in pronounced differences in all observed glycoforms (153,154).  
 
Figure 3. Molecular Weight of Monosaccharides. 
 
 Glycosylation, like all post-translational modifications, renders the proteome more 
complex than the transcriptome would suggest. Given the seemingly stochastic nature of glycan 
synthesis, it is not surprising that glycosylation is associated with an enormous degree of 
heterogeneity. Heterogeneity in protein glycosylation can be further classified as 
microheterogeneity and macroheterogeneity. In the field of glycobiology, microheterogeneity 
refers to the observation that multiple glycoform compositions are present at an individual 
glycosylation sites. Furthermore, glycan branching results in divergent glycans with the same 
monosaccharide composition (155). It is estimated that the human serum N-glycome consists of 
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around 300 to 500 glycan compositions, representing close to 5000 structures (156). 
Macroheterogeneity of glycosylation refers to the rate of glycan occupancy on an individual site 
of glycosylation. Even with the complex nature of cellular glycan processing, many proteins 
display consistent glycosylation patterns across independent samples, suggesting an important 
role of glycosylation in cellular function.  
1.3.1.2 Physiological and Pathological Roles of Glycosylation  
 Glycosylation is integral to cell survival, demonstrated by role of glycoconjugates in cell 
viability and embryonic development. While specific changes in glycosylation are well 
documented, the global elimination of a single class of glycan results in cell death (157). More 
subtle modifications of the glycan biosynthetic pathway have variable impacts on cell viability, 
depending on what stage of glycosylation is impacted. For N-glycan synthesis specifically, 
termination of N-glycan synthesis prior to the formation of hybrid and complex glycans is 
embryonic lethal, while modification of terminal glycan structures elicits more limited 
abnormalities (153). The role glycosylation plays in embryonic development is emphasized by 
the detection of glycans which are expressed embryonically but are absent in adult tissues (152). 
Even the process of fertilization is mediated by glycan epitopes on the sperm interacting with 
selectins on the ECM of the oocyte (158).  
The biological role of glycosylation is not limited to the developmental stages of cells. 
Glycosylation regulates normal biological activity through direct and indirect effects. Direct 
effects refer to the interaction of the glycan with various glycan binding proteins (GBPs), 
including lectins, GAG-binding proteins and antibodies (152). Biologically, direct interactions are 
important in the cells interaction with cells, the ECM and other molecules. While all GBPs use 
direct effects to modulate biological function, the mechanisms for binding vary between the types 
of GBPs. For instance, lectins recognize terminal glycan epitopes and fit them into shallow 
binding pockets, while GAG-binding proteins use electrostatic interactions between the anionic 
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GAG chains and cationic amino acids (150). While direct effects typically lack specificity 
between similar glycoforms, the interaction can sometimes be highly specific. For example, P-
selectin exclusively recognizes and binds to P-selectin glycoprotein ligand-1 (PSGL1) when 
SLeX is expressed on a core 2  O-glycan, but not on a core 1 O-glycan (159). While direct effects 
depend on the glycan itself, indirect effects of protein glycosylation refer to effects that are 
caused by the physiochemical properties of the glycan or alterations in the properties of the 
protein resulting from the addition of bulky hydrophilic sugar group. These indirect effects impart 
broad regulatory functions on both secreted and membrane proteins. Glycosylation of secreted 
proteins reduces nonspecific interactions, protects the protein from proteases and antibodies, and 
improves the solubility of the secreted proteins (160). These indirect effects may or may not 
depend on the composition of the glycan. Terminal sialic acid residues are important for reducing 
nonspecific interactions due to their negative charge, while the general presence of bulky, 
hydrophilic groups can shield sites from protease digestion (160). In addition to these effects, 
indirect effects of membrane protein glycosylation ensure proper folding of the protein, enable 
ECM localization and maintain the tissue structure and integrity (150). The fact that all cells are 
coated with an external layer of glycoconjugates, highlights the importance of glycosylation in 
molecular recognition and signaling. In fact, glycosylation can mediate downstream signaling by 
directly modulating functionality or cell surface receptor expression. For example, both 
glycosylated and deglycosylated beta-human chorionic gonadotropin exhibit similar receptor 
binding affinity, but only the glycosylated hormone can stimulate adenylate cyclase (150). 
Glycosylation of epidermal growth factor receptors (EGRFs) has been directly linked to elevated 
signaling due to reduced receptor turnover and prolonged exposure on the membrane (161). 
 Glycosylation plays important roles in regulating the immune system and inflammatory 
responses. In the immune system, the presence of protein glycoforms can be used to define self 
glycans but also impacts the efficacy of immunoglobulins. Human ABO blood groups are 
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determined by the status of specific glycosyltransferases possessed by an individual, resulting in 
specific oligosaccharide moieties on proteins and lipids (162). For this reason, when blood is not 
appropriately matched during transfusions, antibodies recognize foreign glycan antigens and elicit 
an immune response. Autoimmune diseases, such as lupus or rheumatoid arthritis, arise due to the 
aberrant immune response triggered by self-glycans (157). In mice, the absence alpha-
mannosidase-II (αM-II) mimics the systemic lupus erythematosus phenotype. Functionally, the 
absence of αM-II  results in incomplete N-glycan branching and an increase in hybrid-type N-
glycans with a terminal mannose, which results in an immune response and inflammation (163). 
The glycosylation patterns of immunoglobulins also plays a role in regulating the efficacy of the 
mounted immune response. The absence of fucose or sialic acid residues on IgG enhances the 
antibody dependent cell mediated cytotoxicity (ADCC) as a function of higher-affinity binding to 
FCγRs (164). IgG glycosylation can elicit pro- or anti-inflammatory effects. Patients with 
rheumatoid arthritis frequently present with reduced galactosylation levels of serum IgG, even 
prior to the onset of RA, suggesting that the pro-inflammatory effect of aberrant glycosylation 
ultimately drives rheumatoid arthritis (164). Given the role glycosylation plays in regulating basic 
immune response functions, it is unsurprising that defective immune cell function is the most 
common phenotype in mice that survive deletion of specific glycosyltransferases (157). The 
regulator role of immunoglobulin glycosylation on inflammation is not the only mechanism by 
which inflammation is linked to glycosylation. Cytokines generated in response to pathogen-
associated molecular patterns (PAMPs) or damage-associated molecular pattern molecules 
(DAMPs), interact with glycoprotein receptors and lectins during leukocyte homing to inflamed 
tissues. Glycan fragments released during the process of leukocyte degradation of ECM 
glycoconjugates signal for more leukocyte chemotaxis and activation, resulting in further 
inflammation (157).  
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 In addition to normal biological functions, abnormal glycosylation has been observed in 
nearly every disease.  Diseases may be caused by the presence of unique glycans, elevated 
expression of glycans, or the absence of glycans in a biological system. In cardiovascular disease, 
evidence suggests that glycosaminoglycans (GAGs) on proteoglycans are responsible for 
initiating early stages of atherogenesis (165). After initiation, monocyte entry into the 
subendothelial regions of blood vessels relies upon the interaction of SLeX on PSGL-1 with 
endothelium selectins. This observation was verified in vivo by the reduction of fatty streaks in 
mouse models that are deficient in P- or E-selectins compared to control mice (166,167). In 
contrast, the absence of specific glycans can result in disease. One such example is inclusion cell 
disease, a lysosomal storage disease that is characterized by the buildup of substances in the 
lysosome. This buildup is caused by the absence of enzymes in the lysosome due to the absence 
of mannose-6-phosphate, which targets enzymes to the lysosome (153).  
 Host-pathogen interactions are often mediated by the interaction of pathogens with 
specific glycan patterns on the host cell. The functionality of the influenza virus depends on two 
glycoproteins, hemagglutinin and neuraminidase. Hemagglutinin binds to sialic acids on the host-
cell glycoproteins and glycolipids to initiate viral infection. Following viral replication, 
neuraminidase cleaves the sialic acid to allow the virus to release from the host-cell and continue 
to infect more cells (168). Similarly, cholera toxin binds sialylated glycolipids, primarily GM1, 
present on the intestinal epithelia (169). Occasionally, the absence of specific glycoforms can 
result in pathogen invasion. The absence of terminal α-GlcNAc residues on mucin core 2 O-
glycans results in Helicobactor pylori colonization (170). Apart from the direct host-pathogen 
interaction, glycans on the viral glycoprotein coats can aid in pathogenesis. In human 
immunodeficiency virus (HIV), N-glycosylation on the envelope glycoprotein (Env) provides 
resistance to antibody neutralization and enhances infectivity (171). Alternatively, pathogens can 
adapt to mimic host glycan structures in an effort to evade the hosts immune system (172). 
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 Given the broad nature of glycosylation in diseases, it is understandable that 
glycosylation is frequently exploited for therapeutic purposes. Rational vaccine design has 
benefited from an increased knowledge of aberrant glycosylation in diseases and improved 
synthetic approaches for glycopeptide synthesis. Traditionally, carbohydrate antigens initiate low-
affinity, short-lived IgM responses, but fail to induce a T-cell response (173). However, by 
combining carbohydrate antigens to a specific carrier protein, T-cell responses can be initiated. 
This approach has been applied in the generation of anticancer vaccines, which aim to eliminate 
preexisting cancer cells (172). Using this rationale, Muc1 glycopeptides were determined to 
initiate immune responses and antibody-dependent cellular cytotoxicity (ADCC) more efficiently 
than non-glycosylated Muc1 peptides (174,175). Neu5Gc-bearing gangliosides have been 
successful targets in immunotherapy based on the antigenicity of the non-self Neu5Gc 
monosaccharide (172). Host-pathogen interactions are another area where knowledge of 
glycosylation can be used to improve therapeutic outcomes. As the initial stage of pathogen 
infection often involves the pathogen interaction with specific glycan sequences on the target 
cells, the disruption of this interaction is associated with improved therapeutic effects. The use of 
free glycans that mimic the pathogen interaction sequence has been reported to inhibit infection 
by various pathogens (172). Free glycans, along with the presence of immunoglobulins, are the 
suggested reasons that breastfed are on average healthier than formula fed infants (176,177). In 
addition to disrupting the initial interaction between the host and pathogen, the glycosylation 
related mechanisms can also be exploited to inhibit the release of the pathogen from cells. An 
example of this is the influenza virus, which requires neuraminidase activity to release from the 
cell surface of infected cells. Two current treatments for the influenza virus, zanamivir and 
oseltamivir, function by inhibiting neuraminidase activity and thereby preventing the release and 
further propagation of the virus (178,179). Unique glycosylation patterns on viral coats are also 
being exploited for rational vaccine design. The HIV coat protein is heavily glycosylated, but 
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with oligomannose-type glycans that are rare in cell surface and secreted glycoproteins (180). 
Antibodies that recognize various glycan-peptide epitopes on the HIV coat protein are projected 
to be useful in developing HIV vaccinations. A therapeutic approach for treating patients with 
glycosylation-based genetic disorders is to provide exogenous monosaccharides. Patients 
diagnosed with leukocyte adhesion deficiency II (LAD II), a disease associated with a loss of 
SLeX-mediated leukocyte rolling, display improved immune function following treatment with 
exogenous L-fucose (181). Conversely, lysosomal storage diseases, characterized by defective 
enzyme activity of lysosomal enzymes, can be treated by enzyme replacement therapy. For 
instance, both Fabry disease and Mucopolysacchridosis I, can be treated by the administration of 
recombinant enzymes α-galactosidase A and α-L-iduronidase, respectively (182,183).  
 Biotherapeutic glycoproteins represent a robust market for pharmaceutical companies. 
The presence of specific glycoforms on glycoprotein therapeutics can modulate immune 
response, impact therapeutic pharmacokinetics, and therapeutic functionality (184). Therapeutic 
glycoproteins are often expressed in nonhuman cell lines and are therefore subject to non-human  
epitopes and linkages. Efforts to humanize glycans are being investigated through the use of cell 
glycosylation mutants and transgenically altered cell lines. By using cell lines with specific 
glycosylation machinery, scientists can exert some control over the ultimate glycoforms on 
therapeutic glycoproteins, which play important roles in therapeutic efficacy. Erythropoietin is a 
prime example of this, where deglycosylated erythropoietin exhibits similar in vitro activity 
compared to glycosylated erythropoietin, but the in vivo activity is reduced by about 90%. The 
reduced in vivo activity was found to be a function of rapid renal clearance of the deglycosylated 
erythropoietin (150). Similarly, proper glycosylation of antibodies also increases the circulatory 
lifetime (185).The ability to regulate the sites and structures of glycoforms is a focal point in 
glycoprotein therapeutic research.  
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1.3.1.3 Mechanisms Involved in Protein Glycosylation 
 The addition of N-glycans to proteins occurs co-translationally in the endoplasmic 
reticulum and is followed by further glycan processing in the Golgi. During protein synthesis, an 
amino acid sequence targets proteins to the secretory pathway resulting in their co-translational 
transportation to the ER, where a signal-recognition particle (SRP) binds the receptor in the ER 
membrane, promoting the protein complex to enter the ER through the translocon (186). The en 
bloc addition of N-glycans is essential for secretory and membrane protein folding. Two lectin-
like chaperones in the ER, calnexin (CNX) and calreticulin (CRT), bind glucose residues on the 
nascent glycan to ensure proper folding and prevent aggregation of the protein (187). Ultimately, 
glycosidase trimming releases properly folded proteins from the CNX/CRT complex. Misfolded 
proteins are reglucosylated by UDP-Glc:glycoprotein glucosyltransferase (UGGT), which can 
then interact with CNX/CRT or be transported to the cytosol and degraded by ER-associated 
degradation (150). Properly folded proteins are packaged in COPII-coated vesicles and then 
transported to the Golgi where further glycan processing occurs. 
 N-glycan synthesis begins with the transfer GlcNAc-P from UDP-GlcNAc to the lipid-
like precursor, dolichol phosphate, to form dolichol pyrophosphate N-acetylglucosamine (Dol-P-
P-GlcNAc). Dol-P-P-GlcNAc is further extended on the cytoplasmic face of the ER membrane by 
the sequential addition of one more GlcNAc and five mannose residues. A "flippase" is then used 
to flip the N-glycan precursor to the lumen of the ER, although the mechanism is not completely 
understood. In the ER lumen, the glycan is further extended by the addition of four mannose 
residues and three glucose residues, completing the synthesis of the mature N-glycan precursor, 
Glc3Man9GlcNAc2-P-P-Dol. The transfer of activated sugars to the growing N-glycan is 
mediated by the ALG genes, which encode unique glycosyltransferases that carry out specific 
transfers of sugar residues at defined stages of glycan synthesis (188,189). The completed 
precursor (Glc3Man9GlcNAc2-P-P-Dol) is then transferred to an asparagine residue in the N-
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glycan consensus sequence by an oligosaccharyltransferase (OST) complex. The N-glycan 
consensus sequence is N-X-S/T, where X is anything other than proline. After protein 
glycosylation, the glycan is further trimmed in the ER by α-glucosidases I and II and α-
mannosidase I (Figure 4a). Trimming resumes in the cis-Golgi, where glycans can be processed 
to Man5GlcNAc2, which serves as the precursor to complex and hybrid glycan structures. 
Glycans that are not processed or incompletely processed by α1-2 mannosidases in the cis-Golgi 
cannot be further modified and are detected as high-mannose glycans (Man5-9GlcNAc2) (Figure 
4b). In the medial-Golgi, Man5GlcNAc2 is acted upon by N-acetylglucosaminyltransferase I 
(GlcNAcT-I) and α-mannosidase II to form GlcNAcMan3GlcNAc2. Decoration of the GlcNAc 
residue at this stage results in the formation of hybrid N-glycans (Figure 4c). Alternatively, the 
transfer of an additional GlcNAc by GlcNAcT-II generates the base of complex N-linked glycans. 
Triantennary and tetraantennary complex glycans utilize GlcNAcT-IV and GlcNAcT-V to add 
additional branches, while GlcNAcT-III transfers a bisecting GlcNAc residue onto the complex 
glycan (Figure 4d). Finally, in the trans-Golgi, further maturation may take place to provide 
additional glycan diversity. Among the most common additions are the transfer of β-linked 
galactose residues to the non-reducing end, the addition of α1,6-linked fucose residues to the 
GlcNAc directly bound to the asparagine (termed core fucosylation), and the addition of sialic 
acids and fucose residues on branched LacNAc chains.  
 Secreted and membrane proteins are frequently O-glycosylated with mucin-type O-
glycans, which can appear as linear or branched arrangements of glycans with an O-GalNAc at 
the reducing end. While this type of glycosylation is termed mucin-type, it is also present on 
proteins that are not part of the mucin family. In fact, it is estimated that over 80% of proteins that 
are processed through the secretory pathway are O-glycosylated (190). Unlike with N-
glycosylation, O-glycosylation does not appear to occur on conserved consensus sequences, but 
does target serine or threonine amino acids. The synthesis of mucin-type O-glycans is initiated in 
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the golgi by the transfer of GalNAc from UDP-GalNAc to a Ser/Thr in an α-linked manner by the 
polypeptide GalNAc-transferase (ppGalNAcTs) family of enzymes, forming the Tn antigen 
(152). The Tn antigen is further modified to form core 1-4 structures, and less frequently core 5-8 
structures. The core 1 structure (T antigen) is synthesized by the transfer of Gal from UDP-Gal to 
Tn by the enzyme Core 1 β3-galactosyltransferase (C1GalT1, T-synthase) in the cis and medial 
Golgi. Interestingly, this enzyme is associated with a molecular chaperone Cosmc, the only 
known glycosyltransferase chaperone. Cosmc functions to insure proper folding of T-synthase in 
the rough ER (191). Alternatively, Core 3 N-acetylglucosaminylfransferase (C3GnT) transfers a 
GlcNAc from UDP-GlcNAc in a β1,3 fashion to form Core 3 structures. The family of Core 2 
GlcNAc Transferases (C2GnT) or a subset of the family, the C2/4GnT enzyme, add a branched 
β1,6-linked GlcNAc to Core 1 and Core 3 glycans respectively, generating Core 2 and Core 4 O-
glycans. The core can be further extended to generate biologically relevant glycan moieties, such 
as blood group antigens (ABO), Lewis antigens, and large extended structures.  
 
Figure 4. N-Glycan Processing. The glycan precursor is transferred onto proteins in the ER and 
upon trimming of glucose residues, ensures proper folding (a). The glycoprotein is then 
transferred to the Golgi, where high mannose glycans are formed in the cis-Golgi (b), hybrid and 





 Nuclear and cytoplasmic proteins may also be glycosylated to include O-GlcNAc, O-Glc 
or O-Fuc modifications. O-GlcNAc is an especially dynamic modification that can crosstalk with 
phosphorylation to regulate signal transduction (152). O-GlcNAc cycling by O-GlcNAc 
transferase (OGT) and O-GlcNAcase (OGA) can rapidly add or remove the modification from 
protein substrates to respond quickly to biological signals (192). Ultimately, the process of O-
GlcNAc glycosylation allows for the timely regulation of cell cycle progression, response to 
stressors, and cell survival (192). 
1.3.1.4 Glycosylation in Cancer 
 The first example of aberrant glycosylation in cancer was discovered in the 1950s by the 
observation that peptides were larger in transformed cells compared to untransformed cells. It is 
now known that this increase in peptide molecular weight is linked to elevated levels of β1,6 
branched N-glycans. Around the same time, plant lectins demonstrated enhanced binding to 
tumor cells compared to non-tumor cells (193,194). In the 1970s and 1980s, following the 
discovery of monoclonal antibodies, researchers began to immunize mice against tumor cell 
extracts to generate antibodies. A majority of the antibodies generated act directly against a 
glycan antigen or glycopeptide epitopes, including B72.3, CA19-9, CA15-3, and CA-125 (195–
199). Since these original experiments, alterations in glycosylation are now recognized to be a 
hallmark of cancer.  
 Cell surface changes in glycosylation can be categorized as oncofetal antigens, neo-
antigens, and normal antigens. Oncofetal antigens are glycan epitopes that are expressed during 
embryonic development, are absent in normal adult tissue, but reappear in the presence of tumor 
tissue. In contrast, neo-antigens are novel glycan structures that are not present in embryonic or 
adult tissues. Oncofetal antigens and neo-antigens primarily exist in the form of truncated O-
glycans (152). Both structures make ideal disease markers as they are tumor specific and rarely 
detected in patients with benign disease. Tn, sialyl-Tn and T antigens have been classified as pan-
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carcinoma antigens based off of their presence in most cancers. In fact, T and Tn antigens have 
been observed in around 90% of carcinomas, while the two antigens are rarely co-expressed in 
benign diseases (200). As these truncated antigens are often co-expressed in tumors, comparing 
the ratio of Tn to T antigen can provide prognostic information regarding cancer progression 
(201). Normal antigens are glycans that are present in normal physiological situations but have 
altered levels of expression that correlate with a disease. Normal antigens most often vary in their 
terminal and extended structures. Unlike oncofetal and neo-antigens, alterations in normal 
antigens exist on N-linked glycans in addition to O-linked glycans. While the form of aberrant 
glycosylation varies across different forms of cancer, the general trends of elevated β1,6 GlcNAc 
branching, decreased β1,4 bisecting GlcNAc, increased cell surface sialylation, elevated core 
fucosylation, elevated expression of Lewis antigens, and alterations in ABO structures are 
commonly detected (158,198,202–206). An example of system dependent variation in glycan 
expression is the deregulation of ABO structures in cancer. ABO structures are not observed in 
healthy colon tissues but are present in tumor colon tissue. In contrast, lung cancer tissues exhibit 
mismatched ABO structures compared to the normal tissue (206–208). Another example of the 
differential effect of glycosylation is the role of bisecting GlcNAc in reducing tumor volume and 
metastasis in most cancers, but promoting liver metastasis in melanoma and leukemia cell lines 
(209). The identification of aberrantly expressed glycans can often be linked to the 
glycosyltransferases that are responsible for their synthesis (210,211).  
 The mechanisms employed by glycosylation to regulate tumor initiation to metastatic 
progression are still under investigation. Truncated O-glycans are detected early during malignant 
progression and are thus hypothesized to be important to the early stages of tumor development 
(198,212–214). Other modifications, such N-glycan branching, present later during the 
tumorigenic process and are mainly linked to the later stages of tumor growth and metastasis. 
While it has long been suggested that interactions of branched glycans with GBPs promotes 
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metastasis, a recent manuscript has hypothesized N-glycan branching may also alter the half-life 
and conformation of cell surface receptors (215). Changes in terminal monosaccharide residues 
can impact the functional role of the glycan. Many tumors, including those of the pancreas, 
express elevated levels of sialyl Lewis antigens, which have terminal sialic acid residues. These 
antigens play important roles in metastasis through their interaction with selectins. E-selectins 
enable tumor cells in the vasculature system to adhere and infiltrate distant sites, while P-selectins 
interact with the cancer cell and protect it from the immune system (152). It is through this 
process that cimetidine and heparin, which have been reported to block the interaction of sialyl 
Lewis antigens with selectins, are thought to improve cancer-related disease survival (152,198). 
Elevations of α2,6 sialylation, specifically on integrins, have also been implicated in metastasis 
(216,217).  
1.3.2 Glycomics 
1.3.2.1 General Introduction into Glycomic Analysis 
 As glycosylation plays a pivotal in many diseases, numerous studies have attempted to 
characterize broad disease-associated alterations in the glycome. A complete survey of the entire 
glycome should determine the molecular composition of the glycan, the structure and branching 
pattern, and the anomeric linkages of each monosaccharide (218). These studies attempt to 
identify broad changes in glycosylation, which are ultimately representative of the partial or 
global proteome (219). While different approaches are commonly used to study the glycome, the 
general procedure typically involves [1] glycan release, [2] labeling, [3] 
enrichment/chromatography, and [4] detection and characterization. 
1.3.2.2 Release of Glycans 
 Prior to analysis of the glycome, glycans must be released from the protein by enzymatic 
or chemical methods. Enzymatic release of glycans is primarily reserved for N-linked glycans due 
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to the availability of enzymes. Endoglycosidases are used for glycan release, while 
exoglycosidases can be used for structural analysis of released glycans. Endoglycosidases release 
the entire glycan, or a defined subset of the glycan, from the protein at the reducing end. For 
example, PNGaseF severs the bond between the asparagine amino acid and the glycan (220). 
PNGaseF is capable of releasing high-mannose, complex and hybrid glycans, with the only 
limitation being those with an α1,3-linked core fucose. However, the core α1,3 fucose linkage is 
not present in mammals, so the limitation is not a factor in the digestion of human samples. 
Endoglycosidase H (Endo H), an enzyme that cleaves between the two core GlcNAc residues on 
an N-glycan, can be used to digest high-mannose and hybrid glycans (220,221). Non-fucosylated 
glycans released by PNGaseF and EndoH will vary by the mass of a GlcNAc residue. Other 
endoglycosidases (i.e. EndoM, EndoF1, EndoF2, EndoF3) release classes of N-glycans 
depending on fucosylation and amount of branching (221). There are few commercially available 
enzymes that can release O-linked glycans, and none can universally release all classes of O-
linked glycans (220). For instance, endo-α-N-acetylgalactosaminiadase, is only capable of 
releasing core 1 O-glycans (222). Thus, studies that profile the O-glycome rely on chemical 
methods for glycan release, primarily β-elimination and hydrazinolysis (223). The original 
protocol for reductive β-elimination utilizes basic sodium hydroxide conditions to cleave O-
glycans under moderate temperatures, followed by the reduction of the terminal monosaccharide 
to an alditol (224). A faster release of O-glycans can be achieved by using dimethylamine instead 
of sodium hydroxide (225). Reductive β-elimination is not amenable to certain glycan detection 
strategies, as glycans cannot be labeled with a fluorophore or chromophore, as will be discussed 
in the glycan derivatization section. Approaches to release O-glycans by nonreductive β-
elimination have been explored, but are subject to glycan degradation at the reducing end, 
referred to as "peeling" (226–228). Hydrazinolysis represents another nonreducing glycan release 
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strategy that can be applied to both N-and O-glycans (223). However, selectivity for O-glycan 
release can be achieved under lower temperatures (229).  
1.3.2.3 Glycan Derivatization 
 Derivatization of native glycans is almost universally performed prior to glycan analysis. 
While native glycans can be profiled by modern instrumental methods, derivatization functions to 
[1] allow glycans be detected by alternative approaches, [2] stabilize monosaccharide residues 
that are labile under native conditions, [3] improve detection sensitivity, and/or [4] provide more 
informative structural information following tandem mass spectrometry (230). The most common 
N-glycans derivatization strategies can be classified into the broad categories of reductive 
amination, Michael addition, hydrazide labeling, permethylation, and the selective modification 
of terminal monosaccharides. In reductive amination, the reducing end of the glycan is labeled by 
a condensation reaction with a primary amine, resulting in a Schiff base that is then reduced to 
yield a secondary amine (230). Reductive amination is commonly used in glycomic analysis is to 
incorporate fluorescent tags on the reducing end of glycans, thereby allowing detection by a 
fluorescence detector after chromatographic separation. This strategy is compatible with a wide 
variety of labels, including 2-aminobenzamide (2-AB), 2-aminobenzoic acid (2-AA) and 2-
aminopyridine (2-PA). Efforts to monitor the process of 2-AB and 2-AA labeling demonstrate a 
high labeling efficiency and negligible loss of sialic acid (231). However, glycans released by 
reductive β-elimination are incompatible with derivatization by reductive amination as the glycan 
is already reduced during glycan release. Michael addition labels the reducing end of the glycan, 
but under alkaline conditions reducing the loss of sialic acids. 1-Phenyl-3-methyl-5-pyrazolone 
(PMP) is the most common labeling reagent added through Michael addition, but no fluorescent 
labels are known (230). In an effort to improve throughput, a one-pot method to release and label 
O-glycans by β-elimination has been developed (232). Hydrazide labeling at the reducing end of 
the glycan results in a permanent positive charge on the glycan. Other labeling strategies are 
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directed at the non-reducing end or terminal monosaccharides. Permethylation replaces hydroxyl, 
amine and carboxyl groups with methyl groups, generating a more hydrophobic glycan, which 
can dramatically improve downstream chromatography and analysis (233). During the first step 
of this procedure, alcohol groups on the glycan are converted into alcoholate ions by sodium 
hydroxide in DMSO. A methyl group from methyl iodide is then substituted onto the alcoholate 
ions (220). In one adaptation of the method, the processes of O-glycan release and permethylation 
are combined (234). Other derivatization approaches selective modify the monosaccharides that 
complicate downstream analysis, specifically sialic acids. P-toluidine can incorporate onto the 
sialic acid residues on glycoprotein and the derivatized glycans can then be released with 
PNGaseF (235). Other approaches offer the ability to differentially modify sialic acids based off 
of their linkages. Methyl esterification results in the lactonization of α2,3-linked sialic acids and 
the formation of methyl esters on α2,6-linked sialic acids (219,236). A more recent study 
examined methanol, ethanol, 2-propanol, and 1-butanol as alkyl donors. Both methanol and 
ethanol performed well in initial testing, but ethanol [ethyl esterification] was concluded to 
exhibit more selectivity between α2,3- and α2,6-linked sialic acids (237). The modification of 
sialic acids enhances the stability of sialic acid residues, while enabling detection in positive ion 
mode. 
1.3.2.4 Glycan Enrichment/Chromatography 
 The glycan enrichment/chromatography step serves two primary roles in the analysis of 
the glycome. The first function is the removal of salts and labeling reagents, which are often 
present in significant excess over the glycans. Solid phase extraction (SPE) approaches reduce the 
amount of labeling reagents present after glycan derivatization, especially for reductive amination 
or hydrazide labeling approaches (230). Liquid-liquid extraction is used to remove additives from 
permethylated glycans (238). The second function of chromatographic separation of native or 
derivatized glycans is to separate the glycans prior to detection, thereby reducing suppression of 
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lower abundance glycans or enabling structural isomers to be distinguished (239,240). Efficient 
chromatographic separation often relies upon on-line chromatography interfaced with the method 
of detection. Native glycans are hydrophilic and are not efficiently retained on reverse phase (RP) 
columns, but derivatization often increases the hydrophobicity of glycans and enables the use of 
RP chromatography for separation (239,241,242). In addition to RPLC, the hydrophilic properties 
of native glycans and some derivatized glycans encourages the use of hydrophilic interaction 
chromatography (HILIC), where there is a direct correlation between retention time and the size 
and polarity of the glycan (241,243). Ultimately, chromatography steps that employ RPLC are 
advantageous as labs that are currently equipped for bottom-up proteomics can process glycans 
with minimal alterations to the existing workflows already in place. Porous graphitized carbon 
(PGC) resin can enrich glycans in both on-line and SPE workflows, with enrichment following 
the same principles as HILIC enrichment (239,240,244). Thin layer chromatography (TLC) and 
gel electrophoresis (GE) can be used in place of LC to chromatographically resolve glycans 
(245). The emphasis placed on chromatographic separation of glycans has resulted in novel 
modalities developed specifically to study glycosylation, such as the GlycanPac AXH-1 
analytical column, which can separate glycans based on charge, size and polarity (243). While the 
interaction is similar to HILIC chromatography, the charge state of the glycan does not play a role 
in HILIC enrichment. 
1.3.2.5 Glycan Detection and Characterization 
 Traditional glycomic approaches rely upon chromatographic retention in comparison to 
reference glycan libraries from standard samples (239). For this approach, glycans are labeled 
with a fluorophore or chromophore, which not only stabilizes the glycan but also serves to enable 
detection by fluorescent or UV detectors following chromatography (223). In addition to 
retention time, glycan structures can be validated by sequential glycosidase digestions (219,246). 
After exoglycosidase digestion, a change in the retention time denotes the presence of the enzyme 
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substrate that is targeted by the exoglycosidase. While useful, this approach is limited by the 
number of commercially available enzymes. Complete structural assignment may be unobtainable 
as enzymes, such as those to specifically digest bisecting GlcNAc residues, are unavailable (246).  
 More recently, glycomic analysis has benefitted from advances in the field of mass 
spectrometry, as mass spectrometry is more sensitive and consumes less sample. Importantly, 
studies have shown that the signal derived from neutral and permethylated glycans increases with 
glycan abundance (233,247). MALDI-MS is a fast and convenient way to profile the glycome. 
Both neutral and acidic native glycans can be profiled by MALDI but the presence of both types 
in a single sample complicates analysis (231). In positive ion mode, neutral glycans are 
predominantly detected as [M + Na]+ ions, but [M + H]+ and [M + K]+ are also observed (220). 
However, MALDI-MS in positive ion mode is the not ideal for detecting sialylated glycans, as 
sialic acid residues are often labile and released by in-source decay due to the energy of the laser 
and vacuum conditions in the ion source (248,249). The use of ion sources with higher-pressure 
conditions reduces the dissociation of sialic acids. Negative ion mode is primarily used for the 
detection of sialylated glycans, which are detected as [M - H]- ions, as opposed to [M + Na]+ and 
[M - nH + (n + 1Na)]+ ions in positive ion mode (247). Sialylated glycans profiled in negative ion 
mode do not suffer from sialic acid loss to the extent observed in positive ion mode. The choice 
of MALDI matrix has a pronounced effect on the signal observed for the detection of native 
glycans. Both DHB and CHCA can be used to survey glycans in positive ion mode, with CHCA 
promoting more sialic acid dissociation (250). Furthermore, the combination of matrices has been 
demonstrated to improve glycan analysis over individual matrices. DHB/CHCA and DHB/SA 
combinations were shown to effectively increase ionization efficiency of glycans and improve 
shot-to-shot reproducibility (251). Additionally, DHB/SA enables detection of both glycans and 
deglycosylated proteins in a single experiment. In addition to MALDI, ESI, typically preceded by 
chromatographic separation, is also widely used for glycomic analysis. However, ESI generates a 
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weaker signal compared to peptides and proteins, in part due to limited surface activity in ESI 
droplets caused by the hydrophilicity of the glycans (230,233). Using ESI, quantitation of N-
glycans can be achieved using multiple-reaction monitoring (MRM) in the mass spectrometer 
(252). 
 It is often beneficial to derivatize glycans prior to analysis by mass spectrometry. The 
increased hydrophobicity of glycans as a result of permethylation increases the ionization 
efficiency and results in higher signal and increased stability. As permethylation functions by 
substituting methyl groups for hydrogen groups on hydroxyl, amine, and carboxyl groups, 
permethylated glycans do not differ by a consistent mass difference compared to the native 
glycans. Instead, a larger glycan will have a relatively larger shift in molecular weight, due to 
increased substitutions sites on the glycan. When derivatization only occurs at the reducing end of 
the glycan, the resulting mass shift will not vary with the size of the glycan. An example of this is 
the 2-AB label, which is commonly used for fluorescence detection, but is also compatible with 
MALDI and ESI (231). The labeling of labile and acidic residues can also consolidate the polarity 
used for glycan detection. Labeling by permethylation or p-toluidine enables sialylated glycans to 
be detected in positive ion mode (230,235). 
 The initial assignment of the glycans present in a sample is often done by mass accuracy 
or retention time, but an additional structural validation is sometimes required (253). As 
previously mentioned, sequential exoglycosidase digestion represents a traditional approach to 
study monosaccharide linkages. This technique is often employed prior to chromatography, but 
can be implemented prior to mass spectrometry as well (219,246). Given the limitations in 
throughput and enzyme availability, mechanisms to structurally differentiate glycan isomers by 
mass spectrometer have been investigated. Fragmentation in a mass spectrometer represents a less 
time consuming and easier technical approach to characterizing the composition and linkages of a 
glycan. Initial fragmentation techniques relied on spontaneous post-source decay, taking 
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advantage of the poor stability of glycans, albeit usually at a poor resolution (218,247). While 
useful for verifying the glycan composition, this approach was unable to produce information 
relevant for defining the structure. More recently, CID is more commonly utilized. It is important 
to understand information produced by specific ions when evaluating the efficiency of 
fragmentation for structural elucidation of glycans. The original nomenclature for glycan product 
ions, established by Domon & Costello, defined two series of fragment ions; a, b and c, and x, y, 
and z (254). The first series of ions (a, b, and c) contain the non-reducing terminus, while the 
second series (x, y, and z) contain the reducing terminus (Figure 5). The b, c, y and z ions are 
generated from fragmentation across the glycosidic bonds, while a and x ions are generated from 
cross-ring cleavages (254). Defining anomeric linkages by fragmentation requires the generation 
of a and x ions. Unfortunately, when selected for fragmentation by low energy CID in positive 
ion mode, [M + H]+ and [M + Na]+ ions primarily fragment across the glycosidic bonds, with the 
sodium adduct providing more linkage-informative cross-ring cleavages. Ramping up the 
fragmentation energies promotes more cross-ring cleavages (255). While not ideal, fragmentation 
across glycosidic bonds can sometimes provide structural information based off of characteristic 
diagnostic ions, such as those generated from the presence of a bisecting GlcNAc residue or core 
fucose (247,255). Efforts to improve the fragmentation efficiency and formation of cross-ring 
cleavages have focused on the using sample additives, different MALDI matrices, and glycan 
derivatization. The addition of alkali metal additives into the glycan sample enhance 
fragmentation efficiencies (Li>Na>K>Rb>Cs) and activation energies (256). For MALDI-MS 
analysis, the choice of matrix significantly impacts the glycan fragmentation pattern. CHCA is 
characterized as a “hot” matrix and primarily promotes cleavages at the glycosidic bonds, 
predominantly forming b and y type ions (218). In contrast, DHB provides a more informative 
fragmentation pattern, promoting glycosidic and cross-ring cleavages. The glycan structural 
information can be further enhanced by glycan derivatization. CID in negative ion mode is quite 
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productive in structurally defining glycans. Fragmentation of glycans in negative ion mode 
promotes more cross-ring cleavage and diagnostic ions that denote branching patterns, the 
presence of bisecting GlcNAc residues, and the location of fucose residues. As with positive ion 
mode, fragmentation can be enhanced  by the addition of anions, such as chloride, nitrate, and 
phosphate salts (246). 
 
Figure 5. Glycan Fragmentation Series. Fragmentation of glycans results in different series that 
either contain the reducing end (x, y, and z ions) or do not contain the reducing end (a, b, and c 
ions). The types of ions generated often depend on the fragmentation strategy used. 
 
1.3.3 Glycoproteomics  
1.3.3.1 General Introduction into Glycoprotein Analysis 
 Given the dynamic role of glycosylation in biological and pathological functions, 
glycoproteomics has become extremely relevant in the initial phase of biomarker discovery 
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research. Protein glycosylation is highly specific, both in regards to the site of glycosylation and 
the oligosaccharide structures. However, disease related changes in glycoproteins can manifest as 
one or multiple of the following characteristics; [1] alterations in the site or frequency of 
glycosylation, [2] overall changes in protein abundance, or [3] changes in structure of the 
oligosaccharides at a specific site. Thus, an uncoupled analysis of the glycome and proteome 
results in a significant void of information by not linking the proteins to their attached glycans. 
General glycomic analysis results in a loss of information about the modified protein and specific 
sites of glycosylation, while proteomic analysis ignores the site and structure of oligosaccharide 
modifications. Glycoproteomics aims to rectify these limitations by characterizing and 
quantifying the protein and glycan attachments for each glycoprotein in the sample. 
Glycoproteomic research is typically directed at secreted proteins detected in bodily fluids (i.e. 
saliva, cysts, serum, secretions from cells) or membrane proteins (i.e. tissue sections or cell 
membrane fractions). Generally, secreted glycoproteins represent ideal biomarkers for the non-
invasive detection of diseases, while membrane glycoproteins provide information on the cellular 
mechanisms that drive the disease (257). 
1.3.3.2 Glycoprotein Enrichment 
1.3.3.2.1 General Enrichment Overview 
 While recent analytical advances have improved the analysis of the glycoproteome, 
significant limitations in mass spectrometry-based glycoproteomics persist due to the inherent 
complexity of glycosylation. This complexity is attributed to poor digestion efficiency, the 
presence of non-glycosylated peptides, glycan heterogeneity, and the physiochemical properties 
of the glycan modification. A majority of glycoproteomic research relies upon bottom-up 
proteomic analysis of glycopeptides or previously glycosylated peptides, due to the limitations of 
top-down mass spectrometry (129,258). Trypsin is the most common enzyme used for 
glycoprotein digestion, but often produces prohibitively large glycopeptides due to limited 
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digestion sites and missed cleavages when the glycan is in close proximity to the cleavage site 
(259,260). Thus, the use of other enzymes with complementary cleavage sites can improve the 
number of glycoproteins detected (261). While it is estimated that >50% of human proteins are 
glycosylated, only 2-5% of peptides are glycopeptides, thus there is a significant need to enrich 
glycopeptides from the total peptide mixture (262). Another complication for glycoproteomics is 
the issue of protein dynamic range. Serum proteomics for low abundance biomarkers often 
necessitates multi-dimensional separation strategies to overcome the large dynamic range of 
serum proteins, which is approximately 10^12 (263). It is estimated that 22 of the most abundant 
plasma proteins constitute 99% of the total protein mass, including some (i.e. albumin) which are 
non-glycosylated (150,221,264). As these proteins provide little clinically relevant information, 
depletion often improves the total number of identified proteins (63). Even though the dynamic 
range is not as robust in tissue sections, enrichment strategies are still required (258). 
Macroheterogeneity and microheterogeneity further enhance the complexity of glycoprotein 
analysis (221,265). In conjunction with dynamic range issues, micro- and macroheterogeneity 
result in a low abundance of identical glycopeptides, especially compared to peptides with no 
posttranslational modifications. Finally, the hydrophilicity of glycans reduces the ionization 
efficiency of the peptides when analyzed by mass spectrometry. Taken together, the low 
abundance, complexity and low ionization efficiency of glycopeptides necessitate glycopeptide 
enrichment prior to mass spectrometry. While enrichment can be performed at the protein level, 
enrichment at the peptide level is beneficial as some glycans are masked by the protein tertiary 
structure (257). Enrichment of glycoproteins can be performed at the protein and peptide level 
and can be classified into three broad categories; affinity enrichment, covalent interactions, and 





1.3.3.2.2 Affinity Enrichment 
 Affinity enrichment approaches rely on lectins or antibodies that recognize specific 
glycan epitopes or monosaccharide linkages. Under both strategies, glycoproteins that interact 
with the lectin or antibody are retained, while other molecules are removed by washing. Lectins 
are carbohydrate-binding proteins that recognize specific oligosaccharide epitopes with various 
degrees of specificity. Lectin enrichment offers the capability to do both broad, or targeted 
glycoprotein enrichment, depending on which lectins are used. Broad specificity lectins, such as 
concanavalin A (ConA) or wheat germ agglutinin (WGA) display a broad specificity for common 
glycoforms. Other lectins interact with specific monosaccharides at defined linkages, such as 
sambucus nigra lectin (SNA), which interacts preferentially with α2,6-linked sialic acids (267). 
Even though not all anomeric linkages can be differentiated using lectins, the combination of 
lectins and sequential exoglycosidase digestion can provide relevant structural information based 
off of changes in glycoconjugate binding (268). A general redundancy exists in glycoprotein/ 
glycopeptide identification when comparing enrichment with different lectins, as glycoforms 
interact with multiple lectins (269). After enrichment, bound glycoconjugates are eluted by 
adding sugars with high affinity for the lectin to outcompete glycoconjugate binding. This 
reversible binding mechanism enables downstream analysis of intact glycoconjugates (270). The 
scope of glycoprotein analysis can be broadened by using multiple lectins simultaneously 
(MLAC) or sequentially (SLAC) to enrich glycoconjugates with broad glycosylation motifs 
(271). These approaches are used to provide a more global glycoconjugate enrichment or to 
enrich structures the do not interact with a single lectin. Total enrichment efficiency can be 
improved by incorporating nonionic detergents (221). While some glycoprotein enrichment 
approaches require the removal of abundant, non-glycosylated proteins (i.e. albumin), a 
comparison of lectin enrichment before and after depletion demonstrated little utility (269). 
Several limitations of lectin enrichment include variation due to poor standardization of lectins 
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from different commercial sources, poor reproducibility across large cohorts of samples, and low 
binding efficiency (269). When applied to global glycoproteomics, lectin enrichment may result 
in experimental bias due to variation in lectin-glycan binding affinity across glycoforms. In 
addition to glycoconjugate enrichment, the use of lectins in a microarray format can identify 
which lectins will be useful in an experimental study. Using this technique, proteins are 
fluorescently labeled and allowed to interact with immobilized lectin spots. Lectins that display 
altered binding between two conditions, such as tumor and non-tumor, represent promising 
targets to enrich aberrantly glycosylated proteins (221). This is especially useful as over 160 
lectins have been identified and at least 60 are sold commercially (267). Commercially available 
lectins are available in pure, resin-bound, biotinylated and fluorescently-labeled forms (269). 
 Alternatively, antibodies targeted against glycan antigens can be used for glycoprotein 
enrichment. However, this approach is limited as glycans are poor antigens, resulting in few 
antiglycan antibodies with high affinity and specificity (272). Antiglycan antibodies have been 
utilized to enrich glycoproteins with O-GlcNAc, O-GalNAc, SLeX, CA19-9, and polysialic acid 
epitopes (221,273). However, the ability to generate antibodies requires the presence of multiple 
monosaccharides or the combination of a monosaccharide with a peptide. This has limited the 
success of generating antibodies specific to truncated glycoforms (274,275). Most antiglycan 
antibodies recognize terminal residues, but the underlying glycoform and class of glycan can play 
a role in binding affinity (150). 
1.3.3.2.3 Covalent Interactions  
 Glycoconjugate enrichment strategies that rely on covalent bond formation improve the 
specificity of glycoconjugate enrichment by increasing the efficiency of non-glycoconjugate 
removal (276). These approaches enrich glycoconjugates by forming covalent bonds between the 
glycan moiety and a functionalized solid support. In the most established method, hydrazide 
chemistry, protein-bound carbohydrate cis-diol groups are oxidized to aldehydes, which then 
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react with the hydrazide resin to form hydrazone linkages. In the initial protocol, non-
glycosylated proteins were removed by stringent washing, and bound glycoproteins were digested 
with trypsin to release non-glycosylated peptides from the glycoproteins. The bound 
glycopeptides were then removed by incubation with PNGaseF and analyzed by LC-MS/MS 
(277). More recently, this approach has been adapted for enrichment at the peptide level, which 
reduces sample complexity and exposes concealed N-glycopeptides to the hydrazide resin 
(262,278). Interestingly, there is poor overlap between protein identification when hydrazide is 
performed at the peptide level compared to the protein level (279). At the peptide level, the 
overall specificity of hydrazide-mediated enrichment of glycopeptides is improved (221,262). On 
the other hand, enrichment at the glycoprotein level is associated with a larger number of 
glycoprotein identifications (63,279). To date, hydrazide enrichment has been broadly adapted for 
glycoconjugate enrichment of cell lysates, fluids, and tissues (63,258,261,262,279–283). 
PNGaseF is used to release glycopeptides from the resin, resulting in asparagine deamidation, 
which can be used to identify the site of glycosylation. Misidentification caused by chemical 
deamidation, or deamidation not attributed to PNGaseF, can be reduced by performing the 
digestion in 18O water, which results in a mass shift of 3Da (129,284,285). Furthermore, the use 
of higher resolution mass spectrometers and optimized search parameters can increase 
glycopeptide identification and reduce misidentification to around 1%. Unlike lectin enrichment, 
traditional hydrazide enrichment does not exhibit preference towards specific glycoforms, making 
it an ideal approach for global glycoprotein analysis. In one adaptation of the standard protocol, 
the use of mild oxidizing conditions can specifically enrich glycopeptides that contain a sialic 
acid (286). In this approach, acid hydrolysis is used to release the glycopeptide by cleaving the 
glycosidic bond between the sialic acid and the rest of the glycoform, enabling intact 
glycopeptide analysis (276). Given the importance of hydrazide enrichment in glycoprotein 
research, efforts to improve enrichment by altering wash conditions, enzymatic digestion, pre-
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enrichment depletion, and membrane protein solubility have been investigated (63,261). Of note, 
the depletion of common proteins, and the use of detergents to solubilize membrane proteins, 
improved glycoprotein identifications. Incorporation of isotopically labeled compounds enables 
quantitative glycoprotein analysis (277). The primary limitation of hydrazide enrichment is that 
glycopeptides are released by PNGaseF, resulting in a complete loss of information about the 
structure of glycans on specific peptides. However, the deglycosylated peptides exhibit more 
efficient retention to RP columns and improved sensitivity in mass spectrometers, making 
glycoprotein identification easier than intact glycopeptides.  
 Boronic acid chemistry is another glycoprotein enrichment strategy that utilizes covalent 
binding (270). This enrichment strategy has been used for the enrichment of carbohydrates, 
nucleosides, glycolipids, RNA and glycoproteins. In boronic acid chemistry, basic conditions 
result in covalent ester bonds formation between the boronic acid and cis-diols on the glycans. 
These bonds are reversibly hydrolyzed under neutral or acidic conditions, rendering intact 
glycopeptide analysis possible (221,287).  Like general hydrazide enrichment strategies, boronic 
acid enrichment is unbiased in terms of enriching specific glycoforms.  
 Glycoproteins can be enriched using the concept of "bioorthagonal click chemistry", a 
term coined by Carolyn Bertozzi, which refers to the incorporation of non-native molecules into 
biological systems without the impairment of biological processes (288). Importantly, the 
reaction involves the incorporation of a monosaccharide analog with an azide functional group, 
and a subsequent interaction with an exogenous probe that reacts with the analog through click 
chemistry, allowing for detection and enrichment of the target (289). The utility of the azide 
functional group lies in its small size, biological stability, and absence in native biological 
systems. These traits allow the azide-labeled monosaccharide analogs to incorporate into 
glycoconjugates using the cell’s natural biosynthetic machinery, without modifying the 
underlying protein structure or function (289,290). Acetylation of the sugar analog increases the 
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lipophilicity and allows the monosaccharide to passively diffuse through the plasma membrane, 
which can then be deacetylated by nonspecific esterases (291). Once incorporated, the sugar 
analogue can be assessed by reactions that involve azide-alkyne cycloaddition or Staudinger 
ligation. Global changes in glycosylation can be accessed by a variety of analytical approaches, 
including flow cytometry, confocal microscopy, and gel electrophoresis (292,293). For mass 
spectrometry-based proteomic applications, glycoproteins can be enriched using alkyne resin, 
which reacts with the azide functional group forming a 1,4 disubstituted 1,2,3-triazole linkage 
(294). The use of alkyne-agarose resin, as opposed to biotin-alkyne reduces the number of 
enrichment steps and results in higher glycoprotein specificity (294,295). Metabolic labeling of 
glycans was initially optimized for in vitro labeling glycans, but has more recently been applied 
to in vivo models (296–300). Multiple sugar analogs have been used to enrich glycoproteins with 
various monosaccharides compositions. For instance, tetraacetylated N-azidoacetyl-D-
mannosamine (ManNAz) incorporates into glycoproteins in place of sialic acids. The 
incorporation of ManNAz onto sialic acid containing glycoproteins was validated by Western blot 
analysis before and after sialidase treatment (301). Tetraacetylated N-azidoacetylglucosamine 
(GlcNAz) can be utilized to survey O-GlcNAc-modified proteins (192,298). While the efficiency 
of incorporation is low, treatment with O-GlcNAcase inhibitors has been reported to improve O-
GlcNAz incorporation. Tetraacetylated N-azidoactylgalactosamine (GalNAz) was originally 
reported to incorporate in place of GalNAc monosaccharides, but can also incorporate in place of 
O-GlcNAc modifications following the conversion of UDP-GalNAz to UDP-GlcNAz by UDP-
galactose 4'epimerase (GALE) (192,297). Interestingly, GalNAz is more efficient at labeling sites 
of O-GlcNAc modifications than GlcNAz, which is attributed to the rate-limiting UDP-GlcNAc 
pyrophosphorylase step in the GlcNAc salvage pathway (192). Peracetylated 6-azidofucose 
(6AzFuc) is converted intracellularly to GDP-FucAz prior to incorporating in place of fucose 
(302). Conversely, treatment directly with GDP-FucAz improves the incorporation efficiency by 
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bypassing the fucose salvage pathway (289). For all analogs, the incorporation efficiency varies 
amongst different cell lines (290). During the click chemistry enrichment process, covalently 
bound glycoproteins are separated from non-glycosylated proteins following extensive washing 
steps. After the removal of non-glycosylated proteins, glycoproteins are digested with trypsin 
enabling protein identification by LC-MS/MS. Glycopeptides remain bound to the click resin, but 
can be assessed following PNGaseF digestion. Unfortunately, given the nature of peptide release, 
all information regarding the exact structure of the glycoform is lost.  
 1.3.3.2.4 Physiochemical Enrichment  
 Glycans substantially alter the physiochemical properties of the underlying peptide. 
Unlike non-glycosylated peptides, glycopeptides are poorly retained on the C18 stationary phase, 
due to their increased hydrophilicity (221). This causes most glycopeptides to elute early during 
chromatography, with little resolution of unique glycopeptides. Even glycopeptides with different 
glycoforms are not adequately resolved on RP columns, with the exception being those that differ 
in their levels of sialylation (303). However, RP-HPLC-MS remains integral to glycoproteomic 
workflows involving the analysis of deglycosylated peptides. Alternatively, RP-LC can be used in 
conjunction with other chromatographic approaches that are able to resolve glycopeptides (303–
305). These other chromatographic approaches are better suited to enrich and resolve 
glycopeptides. 
 Hydrophilic interaction chromatography (HILIC) is used to enrich all glycopeptides, 
irrespective of the glycan structure. HILIC enrichment is based off of the increased peptide 
hydrophilicity due to the bound glycan. Glycopeptides are retained on the hydrophilic stationary 
phase, and are eluted with an increasingly aqueous buffer (267). While mechanistically similar to 
normal phase (NP) chromatography, analyte retention on HILIC columns is based on the 
association of the analyte with a water layer surrounding the polar stationary phase, instead of the 
stationary phase itself (306). Multiple materials are amenable to HILIC enrichment of 
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glycopeptides, including zwitterionic (ZIC), amide-based (TSKgel Amide-80), and carbohydrate-
based materials (cotton wool, sepharose) (307). ZIC-HILIC enrichment involves polar and ionic 
interactions, while cotton HILIC materials utilize hydrogen bonding (308). In a comparison 
between HILIC materials, ZIC-HILIC provides higher selectivity and efficiency in glycopeptide 
enrichment. The use of both materials in tandem further improves glycopeptide selectivity 
(303,308). Unlike RP-LC, HILIC-LC is able to resolve glycopeptides that vary only in the 
composition of neutral monosaccharide residues (303). When applied in a SPE format, HILIC 
material is able to enrich glycopeptides and remove detergents, prior to downstream LC-MS 
applications (309). A drawback of HILIC enrichment is the relatively poor enrichment specificity 
compared to other enrichment strategies. Hydrophilic non-glycosylated peptides are often 
retained during HILIC enrichment, while more hydrophobic glycosylated peptides are lost (310). 
To improve the specificity of glycopeptide enrichment, TFA can be added as an ion-pairing 
reagent, which acts to decrease the hydrophilicity of non-glycosylated peptides, while not 
affecting the hydroxyl groups of the glycan on glycopeptides. The net effect of using ion-pairing 
agents is to further separate the hydrophilicity of glycopeptides from non-glycosylated peptides 
(306,308). 
 Physiochemical enrichment strategies can be applied to enrich selected glycopeptides. 
Glycopeptides with sialic acids can be enriched with TiO2 through the interaction of negatively 
charged carboxylic acid and hydroxyl groups of sialic acids with Ti4+ (311). TiO2 also enriches 
phosphopeptides, so the specificity of glycopeptide enrichment is improved by pretreating with 
phosphatases (267,311). Larsen et al. compared glycopeptide enrichment pre- and post-
neuraminidase treatment to demonstrate the importance of sialic acid in TiO2 enrichment (311).  
 New approaches to enrich glycopeptides are continually being evaluated. Takakura et al. 
demonstrated the ability to selectively precipitate glycopeptides over non-glycosylated peptides in 
acetone (312). Preliminary unpublished evidence demonstrates the utility of strong anion 
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exchange (SAX) for glycopeptide enrichment, with initial results showing improved enrichment 
compared to HILIC. Finally, Alvarez-Manilla et al. used an in-silico analysis of all human 
peptides to propose size exclusion chromatography as an enrichment strategy for glycopeptides, 
based on the added molecular weight imparted on the peptide by the glycan. In their analysis of 
digested peptides, 90% of peptides are smaller than 2000 Da, while nearly all glycopeptides are 
larger than that threshold (313). 
 1.3.3.2.5 Selection of Enrichment Strategies and Combinatorial Approaches 
 The determination of an ideal enrichment strategy depends on the ultimate goal of the 
study. Most published studies of the glycoproteome focus primarily on the N-glycoproteome as 
opposed to the O-glycoproteome due to [1] reduced protease shielding from fewer sites of 
glycosylation, [2] predictable N-glycan consensus sequences, [3] a common core structure of N-
glycans, [4] and a larger size of N-glycans resulting in more pronounced physiochemical changes 
(257). For cancer studies, the appropriate enrichment strategy is determined by preceding data 
implicating differential glycosylation; including differential lectin staining, altered glycosylation-
related gene expressions, or changes observed at the glycan level. This preexisting data may 
dictate whether it is beneficial to enrich specific glycoforms as opposed to all glycoproteins. 
Efforts directed at identifying both the glycoform and underlying peptide backbone typically 
gravitate towards the use of lectins or physiochemical enrichment strategies, due to the reversible 
mechanism of glycoconjugate release. However, these approaches do not provide the specificity 
of covalent-mediated glycopeptides enrichment. In a comparison of enrichment methods in the 
cell secretome, Li et al. reported a higher selectivity of glycopeptides with hydrazide enrichment 
(80% specificity) compared to ZIC-HILIC enrichment (30% specificity) (314). 
 Combinations of enrichment strategies can enhance the specificity of glycoconjugate 
enrichment and the total number of identified glycoproteins. Combinations can use similar 
enrichment approaches, such as the combination of multiple lectins, or different enrichment 
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strategies. There is often little overlap in the glycopeptides and glycoproteins identified using 
different enrichment strategies, resulting in more glycoprotein identifications (282,314). For 
instance, a comparison of hydrazide and lectin enrichment approaches for blood serum revealed 
only a 42% overlap in common glycoproteins (282). The differential enrichment can be explained 
in part by the specificity of lectins and antibodies for a subset of glycan structures compared to 
the non-selective hydrazide approach.  
1.3.3.3 Mass Spectrometry Strategies for Glycoprotein Identification 
1.3.3.3.1 Ionization Strategies 
 Following glycoconjugate enrichment, the selection of the proper ionization source and 
fragmentation parameters can dramatically improve glycoprotein identification and reduce 
analytical complexity (271). As previously referenced, glycosylated peptides are not ionized as 
efficiently as their deglycosylated counterparts. Multiple studies have compared the utility of ESI 
and MALDI for intact glycopeptides. MALDI-TOF instruments operating in linear mode result in 
broad peaks that contain information on the average carbohydrate content at the glycosylation site 
(249,315). The removal of glycans or further digestion of the underlying peptide is required to 
obtain more informative information (315). When performed in reflectron mode, MALDI-TOF is 
able to profile glycopeptides with isotopic resolution (249). Studies have shown that the overall 
signal strength of glycopeptides when assessed by MALDI-TOF correlates with the relative 
abundance, regardless of the peptide backbone (316). Unfortunately, in-source decay of the 
oligosaccharide frequently occurs during MALDI ionization, specifically at sialic acid and fucose 
residues, rendering the use of derivation approaches essential. The use of MALDI-FTICR instead 
of MALDI-TOF improves the glycopeptides resolution and aids in the retention of sialic acids 
(249). ESI is the more common ionization approach for intact glycopeptides analysis. As ESI is a 
more gentile ionization strategy than MALDI, fragmentation is less common (315). Additional 
advantages are that ESI ionization is more efficient than MALDI, can process glycopeptide 
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mixtures quickly following chromatographic separation, and can be used to trigger MSn scans 
(317). One disadvantage for ESI is that the ionization results in multiply charged analytes, 
rendering the spectra more difficult to process manually. Irungu et al. found that the two 
ionization sources are quite complementary, with ESI-MS/MS generating the most complete 
information on the glycan moieties and MALDI-MS/MS providing high confidence peptide 
assignments (317). 
1.3.3.3.2 Fragmentation for Glycopeptide Identification 
 The need to characterize both the glycan and underlying peptide backbone complicates 
mass spectrometry approaches for glycopeptides. CID fragmentation is insufficient to fragment 
both the glycan and peptide. Complete fragmentation of the glycan moiety is achieved at lower 
collision energies that leave the underlying peptide backbone largely intact (267,318,319). The 
peptide-glycan bond is also cleaved at lower collision energies diminishing information about the 
site of glycosylation (320). At higher collision energies, only peptide backbone b and y 
fragmentation series are observed. Thus, other fragmentation approaches have been investigated 
for intact glycopeptide analysis. Electron-activated dissociation methods, such as ETD and ECD, 
fragment the peptide backbone into c and z fragments, while retaining the glycan on the original 
site of glycosylation. Therefore, peptide sequencing can be performed using the c and z type 
fragmentation series, while the glycan is still bound to the glycosylation site (320). Conversely, 
HCD primarily fragments the glycan, generating oxonium ions specific to monosaccharides.  
Importantly, HCD in the C-trap and detection in the Orbitrap is not limited by the low mass cutoff 
associated with ion trap mass spectrometers, and is thus able to overcome the 1/3 cut-off rule to 
enable the detection of low molecular weight oxonium ions. While fragmentation of the 
underlying peptide is generally inefficient, HCD does generate a characteristic y1 ion that is 
representative of the peptide + GlcNAc (221,267). HCD fragmentation and subsequent detection 
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in the orbitrap, is also compatible with tandem mass tag (TMT) labeling for quantitative mass 
spectrometry analysis (319). 
 Due to the inadequacies of single ionization approaches in determining the site of 
glycosylation and the structure of both the glycan and peptide, multiple ionization approaches 
have been used in succession for the analysis of glycopeptides. One such strategy utilizes the 
Thermo Orbitrap Elite mass spectrometer to combine HCD and ETD in a product dependent 
manner (HCD-pd-ETD) (Figure 6). Using this approach, abundant precursor ions are selected for 
HCD fragmentation. HCD fragmentation of glycopeptides results in the generation of diagnostic 
oxonium ions, which are then detected by the mass spectrometer and trigger ETD fragmentation 
of the original precursor ion (320). Information gathered by the HCD and ETD fragmentation can 
be combined to provide relevant information on both the glycan and underlying peptide. This 
approach improves the duty cycle of the mass spectrometer in comparison to alternating HCD and 
ETD (HCD-alt-ETD), by initiating ETD fragmentation only on glycopeptides. In a comparison of 
HCD-pd-ETD to HCD-alt-ETD, Yin et al. demonstrated that HCD-pd-ETD was more useful in 
identifying low abundance glycopeptides, while HCD-alt-ETD predominantly identified high 
intensity glycopeptides (321). However, both approaches identified fewer total proteins than 
analysis of deglycosylated peptides. Additionally, only 16 out of 151 glycoproteins were 
identified by all three strategies (321). Improvements in analytical instrumentation continue to 
improve glycopeptides analysis. The Orbitrap Fusion outperforms the Orbitrap Elite by enabling 
data acquisition on the highest charged precursors, which have the most robust fragmentation by 
ETD, as opposed to the most intense ions. In contrast to HCD-pd-ETD, HCD-pd-CID can better 
elucidate the glycan structure (322).  The new trihybrid Orbitrap configuration allows CID to also 
be incorporated into the HCD-pd-ETD workflow. This HCD-pd-CID/ETD fragmentation 
workflow reduces glycan assignment errors, provides an additional validation step, and can 
















































































































































1.3.4 Glycoproteins and Glycans Antigens as Biomarkers 
1.3.4.1 Glycoprotein Cancer Biomarkers 
 The detection of cancer at early stages of tumor progression is advantageous from a 
therapeutic treatment standpoint, resulting in improved treatment efforts and survival statistics 
(161). Disease markers, often referred to as biomarkers, can be utilized to indicate normal 
biological functions, disease processes, or response to therapy (323). The detection of one subset 
of biomarkers, tumor markers, which arise from either the tumor or the host, indicate the presence 
of a tumor (324). Ideal tumor markers should have very high performance in terms of sensitivity, 
specificity and predictive value, originate from specific organs instead of being ubiquitously 
expressed, and correlate with disease prognosis; including the tumor stage, volume, and 
likelihood of recurrence (325,326). For early stage cancer diagnosis, markers should ideally 
present prior to malignancy. Disease markers have been classified as proteins, glycoproteins, 
glycan antigens, hormones, hormone receptors, enzymes, genetic mutations or aberrations, and 
RNA (324,326). However, when looking at protein-based biomarkers, nearly all FDA approved 
biomarkers for cancer are glycoproteins or individual glycan antigens (160). Biomarkers 
experiments directed at identifying glycoconjugates are popular due to [1] the success for these 
molecules as biomarkers, [2] the prevalence of these molecules in biological fluids, and [3] the 
role that glycosylation plays in tumor progression. Clinically, these markers can be detected in a 
variety of complex biological matrices, including serum, plasma, urine and tissue. While research 
has been directed at identifying new tumor markers, very few prospective markers progress to 
clinical application. The poor transition from biomarker discovery to clinical assay can be 
explained by a variety of factors, including technical limitations, sample complexity, and 
experimental design. Techniques utilized to identify disease markers, including mass 
spectrometry based "omics" strategies, are not easily implemented in clinical labs (324). 
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Additionally, biomarker assays directed at individual proteins suffer from the broad dynamic 
range of protein expression, with biomarkers often expressed at very low levels compared to 
abundant serum proteins (325). Changes in glycosylation resulting from malignancy are also 
difficult to detect and obscured by more abundant glycoforms (160,327). Among other reasons, 
prospective biomarkers rarely transition to clinical biomarkers because research scientists do not 
have the knowledge or experience needed to navigate the regulatory requirements necessary to 
advance the biomarker to a clinical assay. To adjust for these limitations, the National Research 
Council Early Detection Research Network (EDRN) has laid out a series of phases for biomarker 
development (324). Narimatsu demonstrates the workflow by taking a small number of potential 
disease markers identified in tissue, assessing their presence and serum, and then developing a 
simplified assay to assess the most promising biomarker on a large number of serum samples in a 
high-throughput fashion (327). While it is ideal for biomarkers to work with non-invasive 
biological fluids, tissues are frequently used to identify initial disease marker candidates. In 
comparison to serum, tissues have a reduced protein dynamic range and a direct relationship with 
the origin of the biomarker. As described above, these initial targets can be validated in fluids 
(328). Clinical diagnosis may require the use of tissue/biopsy cores, but biofluid analysis is 
preferable, as the process of obtaining the biopsy is invasive and risky.  
 While biomarkers can be difficult to identify in initial biomarker discovery approaches, 
targeting specific molecules with known identities is a more effective strategy. Mass 
spectrometry represents a powerful approach for initial serum/tissue biomarker investigations, but 
is often too complicated, expensive, and time-consuming to be utilized in clinical labs. The most 
common assays used in the clinic to measure biomarkers are immunohistochemistry (IHC) for 
tissue sections, or immunoassays for biological fluid samples. Assays to measure glycoprotein 
biomarkers in fluids can be compartmentalized into 3 categories; [1] the use of monoclonal 
antibodies directed against the protein, [2] the use of antibodies or lectins to measure the level of 
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an antigen/glycan motif, and [3] a combination of the previous approaches to quantify both the 
protein and associated glycoforms (325). An example of each category of biomarker is described 
in the text below by prostate-specific antigen (PSA), CA19-9, and alpha fetoprotein (AFP), 
respectively. The use of monoclonal antibodies to determine protein expression primarily relies 
on enzyme-linked immunosorbant assays (ELISA) (326). Similarly, enzyme-linked lectin assays 
(ELLA) or monoclonal antibodies directed against glycan antigens are used to measure total 
glycan antigen levels. The combination of protein and glycoform quantification can be achieved 
by either capturing all glycoproteins with immobilized lectins and then assessing the abundance 
of a specific protein with antibodies, or using an antibody to capture a specific protein and then 
detecting the abundance of the glycoform with lectins (325,327).  
1.3.4.2 Selected Glycoprotein Biomarkers 
1.3.4.2.1 Prostate-Specific Antigen (PSA) 
 PSA is a protein secreted from the prostate that is detected in the blood at small amounts 
in healthy males. However, PSA is often elevated in males with benign prostate hyperplasia 
(BPH), prostatitis and prostate cancer (161). While PSA measurements can distinguish healthy 
patients from diseased patients, elevations in PSA do not distinguish between benign and 
malignant conditions (160). Overall, the utility of PSA screening for prostate cancer is highly 
controversial, due to limited conceived benefits, the risks of therapeutic intervention upon 
detection of prostate cancer, and uncertainties regarding the screening strategy (329). These 
factors have lead to the argument that PSA screening has resulted in overdiagnosis and 
overtreatment of prostate cancer (330). Recent evidence suggests that factoring in site-specific 
glycoform composition may improve the PSA screen in distinguishing malignant prostate cancer 
from benign conditions. PSA glycans from patients with BPH consist predominantly of complex 
biantennary glycans with various degrees of core fucosylation and sialylation. In contrast, PSA 
glycoforms from patients with prostate cancer exhibit elevated multiantennary complex 
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glycoforms with altered sialylation, fucosylation, and LacdiNAc groups (160,161,331). Thus, 
utilizing absolute PSA levels can identify diseased patients and subsequent analysis of the 
glycosylation patterns can distinguish malignant from benign conditions.  
1.3.4.2.3 Carbohydrate Antigen 19-9 (CA19-9) 
 CA19-9 (sialyl Lewis A, SLeA), a glycan motif initially identified by Koprowski et al. in 
a colorectal cancer cell line, is currently the only FDA approved blood test for the management of 
pancreatic cancer (332,333). It is now recognized that the CA19-9 antigen is present on 
glycoproteins and glycolipids (334,335). CA19-9 is composed of four monosaccharides, 
consisting of a Gal and GlcNAc residue with a terminal α2,3-linked sialic acid on the galactose 
and an α1,4-linked fucose on the GlcNAc. In contrast, SLeX differs in regards to the fucose 
linkage. The synthesis of both structures are mediated by α2,3 sialyltransferases and α1,3/4 
fucosyltransferases, with various degrees of specificity between SLeA and SLeX synthesis (336). 
CA19-9 is thought to play an important role in disease metastasis through the interaction of the 
antigen with endothelium E-selectin (337). This claim is evidenced by the abolished interaction of 
cancer cells with E-selectin following [1] treatment with antibodies against SLeA, [2] the 
exogenous addition of mucins containing CA19-9 to compete for E-selectin binding, and [3] 
inhibition of CA19-9 expression (338–340).  
 While CA19-9 is used as a blood test for pancreatic cancer, the antigen is not used 
clinically to diagnose pancreatic cancer. Low sensitivity and specificity of CA19-9 in the 
prediction of pancreatic cancer are exacerbated by the low prevalence of pancreatic cancer, 
rendering CA19-9 ineffective as an early stage diagnostic biomarker (333). The specificity of 
CA19-9 is hindered by diseases other than pancreatic cancer, many of which are benign, that 
express elevated CA19-9 levels; including biliary obstruction, thyroiditis, diabetes, and chronic 
pancreatitis (341–343). The sensitivity of CA19-9 as a pancreatic cancer biomarker is limited by 
the fact that between 5-15% of the population do not express fucosyltransferase 3 and are 
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therefore incapable of expressing CA19-9 (333,343). Efforts to investigate CA19-9 as a screening 
marker in asymptomatic individuals yield a dismal predicative value positive of .5-.9%, due to a 
large percent of false positive identifications (344,345). The clinical utility of CA19-9 for the 
diagnosis of symptomatic patients is also low (346). 
 While not an ideal diagnostic marker, pre-operative and post-operative serum CA19-9 
levels can be useful in assessing cancer stage, resectability, prognosis, response to chemotherapy 
and postoperative recurrence. A study by Kim et al. demonstrated a rise in mean pre-operative 
serum CA19-9 levels at each cancer stage, starting at 40.05 U/mL for stage IA patients, and rising 
to 3239 U/mL for stage IV patients (344). Pre-operative CA19-9 serum levels were found to be 
lower in patients with localized tumors compared to patients with advanced or metastasized 
tumors (347). Therefore, it is unsurprising that patients with normal pre-operative CA19-9 levels 
have a higher 5-year disease specific survival (DSS) than patients with elevated CA19-9 levels, 
even when comparing patients with similarly staged tumors (348). Furthermore a decline in 
CA19-9 serum levels following treatment is associated with longer overall survival (346).  
1.3.4.2.3 Alpha Fetoprotein (AFP) 
 AFP is a glycoprotein with a mass of around 70 kDa with one N-glycosylation site, 
typically occupied by a complex biantennary N-glycan (160). AFP expression is abundant in the 
human fetus, but levels decrease rapidly during fetal development and after birth (326). 
Therefore, the detection of AFP in adults is used as a marker for hepatocellular carcinoma (HCC). 
However, elevated levels of AFP are also observed in benign liver diseases, limiting the use of 
AFP in distinguishing malignant from benign conditions. An additional limitation of AFP as a 
biomarker of HCC is the low sensitivity for early stage cancer (349). Efforts to improve the utility 
of AFP have focused on differential glycosylation of AFP, where α1,6 core fucosylated AFP 
outperforms AFP alone as a biomarker for HCC (350–352). AFP can be fractionated into three 
groups using lens culinaris agglutinin (LCA) lectin to provide information of the underlying 
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cause of AFP elevation; these being AFP-L1, AFP-L2, and AFP-L3. AFP-L3 elevation is linked 
to malignancy, while AFP-L1 and AFP-L2 are linked to non-malignant liver disease and yolk sac 
tumors, respectively (160). Other studies have suggested that AFP sialylation can distinguish 
malignant from benign liver diseases, providing another avenue to enhance biomarker specificity 
(161). The use of AFP as a biomarker is the best example of how proteomic and glycomic data 
can be combined to diagnose a cancer.  
1.4 Aberrant Glycosylation in Pancreatic Cancer 
1.4.1 Biological Factors that Promote Aberrant Glycosylation in Pancreatic Cancer 
 Pancreatic cancer, like many other cancers, has been characterized as a glycolytic tumor 
based off a reliance on glycolysis for energy production, as opposed to oxidative phosphorylation, 
which enables rapid energy production in the hypoxic tumor microenvironment (353,354). 
Anaerobic glucose metabolism in pancreatic cancer relies on an upregulation of glucose 
transporters (GLUTs) and glycolytic enzymes including hexokinase II (HK2), 
phosphofructokinase I and II (PFK1, PFK2), and pyruvate kinase (PKM2) (354). Even 
surrounding, well oxygenated PDAC cells can utilize lactate produced during glycolysis to 
promote cell proliferation, as the surrounding cells express elevated levels of the lactate uptake 
enzyme, monocarboxylate transporter I (MCT1) (353). Pancreatic cancer cells also exhibit a 
glutamine addiction, in which glutamine can be metabolized to glutamate by glutaminases (GLS1 
and GLS2) as a major source of energy. In fact, cells cultured in the glutamine-deficient media 
exhibit decreased cell viability and proliferation (353). The metabolism of glucose and glutamine 
both converge upon the hexosamine biosynthetic pathway (HBP) and increase the presence of 
monosaccharides that can ultimately be incorporated into glycans. The need for glycolytic energy 
production in pancreatic cancer is perpetuated by the dense stroma and ECM accumulation 
resulting in a desmoplastic region that surrounds the cancer promotes hypoxia (355). For cancer 
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in general, more pronounced hypoxic conditions have been linked to metastatic spread, resistance 
to therapy, and poor prognosis. These trends that hold true in pancreatic cancer, as there is a 
correlation between hypoxia and reduced survival (355). In addition to promoting glycolysis, 
hypoxia transcriptionally upregulates glycosyltransferase and sugar transporter expression in 
cancer cells through the hypoxia-inducible factors (HIFs) (356). Hypoxia has been directly linked 
to increased glutamine-fructose-6 phosphate aminotransferase I and II (GFPT1 and GFPT2) 
expression in cell lines (353). Additionally, hypoxia plays a role in cancer invasion and metastasis 
by promoting the expression of the selectin analogs, SLeA and SLeX, in malignant cells by 
upregulating fucosyltransferase (FUT7) and sialyltransferase (ST3Gal1) expression (357). Sialin 
expression, a transporter for NeuGc and NeuAc, is also induced by hypoxia, providing one 
potential mechanism of the incorporation of non-human NeuGc in malignant cells (211,358). 
GBPs, such as Galectin-1, are also observed to be elevated in hypoxic tissues. 
 In addition to altering the glycan biosynthetic machinery, the hypoxic environment in the 
tumor provides a selective pressure that favors the growth of the most aggressive cells that are 
capable of surviving in conditions with limited oxygen and nutrients (355). These conditions 
promote the expansion of cells with mutations in oncogenes and tumor suppressors, such as 
KRAS and TP53 mutations, respectively (359,360). These mutations are also interconnected with 
the HBP. Mutated KRAS increases GLUT1, HK1, HK2, PFK1, and lactate dehydrogenase A 
(LDHA) expression, all of which impact glycosylation by directing glycolytic intermediates to 
the HBP (40). Extinction of mutated KRAS in cell or xenograft models results in downregulation 
of a variety of metabolic processes and inhibited tumor grown. The inhibitory effect was directly 
attributed to diminished glycosylation, as the knockdown of GFPT1 exhibited the same effects on 
tumor growth (361). In addition to O-glycosylation, activating mutations of RAS oncogenes have 
also been associated with N-glycan branching.  
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 Given the broad scope of aberrant glycosylation in PDAC, efforts have been directed at 
identifying the source of aberrant glycosyltransferases that play a role in tumor progression. 
Specific alterations of glycans structures can, but do not always, coincide with alterations in the 
expression of glycosyltransferases (210,217). CA19-9 expression is the most well defined marker 
for pancreatic cancer, so efforts have been directed at identifying the enzymes culpable for the 
elevated expression of the antigen. Sialyltransferases and fucosyltransferases responsible for 
sialyl Lewis structure synthesis have been reported to be elevated in pancreatic cancer, including 
α2,3-sialyltransferases, ST3Gal III, ST3Gal IV, and ST3Gal VI (336). Ectopic expression of 
ST3Gal III and ST3Gal IV has been linked to an increase in expression of sialyl Lewis antigens 
and a reduction of α2,6-linked sialic acids, resulting in increased cell motility, reduced adhesion, 
and increased metastasis in mouse models (336,362,363).  
1.4.2 Protein and Glycoprotein Alterations in Pancreatic Cancer 
 Early efforts to identify proteins that are aberrantly expressed in pancreatic cancer 
performed comparative studies on whole tissue sections with cancerous and non-diseased regions. 
Pancreatic cancer cells are often surrounded by stromal cells, which are capable of occupying up 
to 90% of the total tumor volume, so the overall conclusions did not definitively identify 
differences between tumor and non-tumor tissue. However, these experiments did provide some 
mechanisms for cancer progression. There is a disease-related variation in proteins responsible 
for tumor growth, migration, invasiveness, metastasis and ECM interactions, highlighting the 
importance of the cancer cell interactions with the stroma and ECM during tumor progression 
(364,365). Proteins involved in cytoskeletal or ECM regulation, such as annexin A2, cathepsin B, 
cathepsin D, fascin, gelsolin, and plectin-1, were upregulated in the tumor tissue, providing 
mechanisms for tumor cells to degrade of the ECM and enter the bloodstream (365–367). Overall, 
these studies identified a larger number of proteins elevated in the tumor compared to the 
matched non-tumor tissues, but elevated expression could not be directly linked to the stromal or 
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epithelial cells (365,366,368). Digestive enzymes, including amylases, peptidases, lipases and 
elastases, were the main category of proteins that were downregulated in the tumor tissue 
(366,369). From these initial experiments, proteins of interest were selected for further analysis. 
Pan et al. evaluated gelsolin concentration as a potential biomarker for pancreatic cancer by SRM 
analysis, and determined that serum levels of gelsolin to have an AUC = .89 for distinguishing 
PDAC from pancreatitis and control serum (370). In another study, Bausch et al. found that IHC 
staining of plectin-1 was able to identify late-stage PanIN lesions and metastatic sites (367). In 
addition to proteins that regulate cytoskeletal or ECM regulation, proteins that play a role in cell-
cell and cell-matrix interaction were also elevated in PDAC and late stage PanIN lesions; 
including galectin-1, galectin-3, integrin β1, actinin-4, laminin β1, and vimentin 
(365,366,368,371). The identification of altered proteins in PanIN lesions and full-blown PDAC 
implicates these proteins in early stages of tumor progression, through their role in cell motility 
and cell interaction (368,371). Similar studies tabbed versican and lumican as PDAC-elevated 
proteins that promote metastasis, with plasma levels of lumican achieving an AUC = .94 for 
differentiating PDAC from control serum by SRM analysis (370). In order to mitigate the role of 
stromal proteins in the analysis, laser capture microdissection (LCM) was used to isolate 
pancreatic cancer cells. Downstream proteomics identified S100A6 and annexin III to be elevated 
in tumor cells, while trypsin and LDH were elevated in non-tumor cells (372). The analysis of 
serum and biofluids has identified protein families that are consistently observed in pancreatic 
cancer. Mucin and CEACAM proteins are predominantly expressed in cancer specimen. 
Additionally, both proteins have been recognized to act as CA19-9 carriers. Research has 
identified MUC1, MUC2, MUC4, MUC5 and MUC16 as proteins that can be used for the 
diagnosis or prognosis of diseased pancreas tissue (15,373–375). These proteins have been linked 
to tumor progression, altered adhesion, and the promotion of perineural invasion. MUC4 
stabilizes HER2 expression on the cell surface, which promotes downstream signaling through 
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FAK and p42/44 (375). MUC1 interacts with Siglec-4a to promote perineural invasion (374). 
Numerous integrins are upregulated in PDAC including α1, α2, α4, α6, and β1 subunits 
(363,376). 
 While initial proteomic experiments were important from a disease marker perspective, 
the data were also useful in elucidating potential driving mechanisms for pancreatic cancer. These 
studies largely conclude that among all proteins, glycoproteins are overexpressed (364). Gene 
ontology annotation of the human pancreas N-glycoproteome demonstrates that a majority of 
pancreas glycoproteins are involved in cell organization, immune response, adhesion and 
mobility. The deregulation of these processes may be directly related to the tumorigenic process 
(377). In addition to alterations in glycoprotein expression, the overall level or structure of 
glycosylation is altered in pancreatic cancer. Numerous potential disease markers have been 
identified that differ only in glycosylation and not protein abundance. The ratio of glycosylated 
RNase1 to total RNAase1 has been tested clinically as a serum biomarker for pancreatic cancer 
(378). The comparison of non-diseased and diseased ductal fluids revealed kininogen-1 and 
biglycan to exhibit elevated levels of glycosylation while maintaining a similar protein level 
(283). Alternatively, fibrillin exhibited elevations in protein expression but a reduction in glycan 
occupancy. The same study found that occupancy rates of different glycopeptides from the same 
protein varied significantly and independently, allowing unique sites to be concurrently elevated 
and diminished in diseased samples compared to non-diseased samples. For example, 
apolipoprotein B-100 had two glycosylation sites that exhibited elevated occupancy and three 
sites that had reduced occupancy in diseased samples (283).  
 Unfortunately, there is a large degree of similarity between the pancreatic cancer and 
pancreatitis proteome, especially when comparing PDAC to severe chronic pancreatitis, which 
exhibited more dysregulation of the proteome than mild pancreatitis. Among highlighted proteins 
identified in the earlier global proteome analysis, cathepsin D, integrin β1, plasminogen, versican 
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and lumican are all over-expressed in both PDAC and pancreatitis compared to control samples 
(379,380). Factoring information about the protein expression level and associated glycoforms 
can distinguish malignant from benign conditions. At the protein level, the trend of elevated 
glycoproteins in PDAC was also observed in pancreatitis. However, efforts to identify 
glycoproteins that can distinguish PDAC from both benign and non-diseased samples following 
glycoprotein enrichment have been fruitful. Ingenuity pathway analysis (IPA) of elevated 
glycoproteins unique to PDAC in patient ductal fluids emphasized the role of the proteins in 
endothelial and tumor cell movement and interaction. Mucin and CEACAM proteins were 
represented among the proteins that were only elevated in tumor (283). A similar study identified 
members of the REG protein family, phospholipase A2 and elastase 2B to be present in only 
ductal fluid from patients with cancer or premalignant lesions (381). Other proteins were elevated 
in tumor compared to pancreatitis specimen, including versican, biglycan, haptoglobin, annexin 
A2, IGFBP-2 and apolipoprotein E (283,364,382). In addition to assessing glycoprotein 
expression levels, studies have also assessed glycoform structure and occupancy on those 
proteins. Nie et al. used AAL lectin to enrich fucosylated glycoproteins in an effort to identify 
individual serum glycoprotein discriminators to distinguish serum from patients with PDAC, no 
disease, diabetes, pancreatitis, obstructive jaundice, and benign cysts (343). Using LC-MS/MS for 
initial glycoprotein identification followed by ELISAs and lectin ELISAs for validation, 
numerous glycoproteins were determined to perform better than CA19-9 in disease 
discrimination. Importantly haptoglobin, lumican, α-1-antichymotrypsin and α-1-antitrypsin were 
able to distinguish pancreatic cancer from benign diseases more effectively than CA19-9 (343). 
Finally, a biomarker panel of proteins consisting of α-1-antichymotrypsin, thrombospondin-1, and 
haptoglobin showed improved utility and an increased AUC for distinguishing PDAC from 
cancer (AUC = .95), diabetes (AUC = .89), cyst (AUC = .82), and pancreatitis (AUC = .90) 
(343). As the expression of these proteins was not highly correlative with CA19-9, adding CA19-
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9 into the biomarker panel improved the AUC values. Other assays also showed improved 
biomarker performance by combining protein and CA19-9 expression (383). Lectin enrichment of 
α2,6-linked sialic acids from serum samples revealed elevated levels of disialylated biantennary 
glycans (Hex5HexNAc4NeuAc2) on α-1-antitrypsin in PDAC, but decreased levels of the 
glycoform in pancreatitis (318). Overall, both conditions had elevated levels of α-1-antitrypsin, so 
only the glycoform difference can be used to distinguish benign from malignant conditions. The 
same glycoform was found to be elevated on transferrin in pancreatitis over PDAC (318). Protein 
expression and glycoform occupancy do not always correlate. While haptoglobin was elevated in 
pancreatic cancer serum, glycoform differences were only observed in pancreatitis (318,382). 
Given the divergence between the proteome and the glycome, the combination can be used to 
enhance the utility of biomarkers. Li et al. evaluated a multiplexed bead assay directed at 
quantifying specific proteins and the corresponding levels of α2,6-linked sialic acid in order to 
distinguish PDAC from pancreatitis and control serum. This study concluded that serum levels of 
amyloid P were significantly lower in PDAC than non-diseased serum, while the glycoforms on 
α-1-β glycoprotein vary significantly between PDAC and pancreatitis (384). The functional role 
of dysregulated protein glycosylation has also been investigated. Integrins have also been 
implicated in PDAC progression through their modulatory effects on adhesion and invasion. 
Integrins frequently exhibit higher levels of sialylation, which alters their binding to the ECM and 
regulates tumor cell migration (336,363).  
1.4.3 Pancreatic Cancer Glycomics 
 Most experiments assessing glycosylation changes in pancreatic cancer have utilized 
serum samples. While noninvasive to obtain, serum glycoproteins often originate in areas other 
than the malignant site, reducing the probability of cancer identification based off of global 
glycosylation changes (327). Broad changes in PDAC serum glycosylation have been assessed by 
interaction with specific lectins and have identified a notable increase in terminal α-fucosylation 
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in serum from PDAC patients compared to non-diseased and benign controls (343). Additional 
lectin array data has identified a variety of other glycan patterns that are elevated in PDAC, 
including the CA19-9 antigen, complex/branched glycans, O-GlcNAc modifications, β-GalNAc 
residues, and α2,6-linked sialic acids (373). However, limited studies have assessed individual 
glycoform variations in pancreatic cancer. A broad glycomic analysis of N-glycans from serum 
and ductal fluids found that only serum glycans could distinguish diseased from non-diseased 
patients, and that the glycans could also provide information on metastatic progression (381,385). 
Serum from PDAC patients exhibited an overall higher amount of glycosylation, specifically in 
regards to elevated branching, fucosylation, and sialylation. On the other hand, the level of high-
mannose and hybrid glycans did not differ in PDAC serum compared to control serum (385). 
Elevated levels of LacdiNAc groups have also been observed in pancreatic cancer (331). 
Glycomic analysis of ductal fluid was marred by glycoform heterogeneity but did identify driver 
glycans that could cluster glycans into specific groups, which could then be used for diagnostic 
classification. However, this study was done on an extremely limited sample set, so it remains to 
be seen how this clustering method performs over larger sample sizes (381). 
1.5 Broad Overview 
 To summarize, the dismal outcomes of pancreatic cancer necessitate in-depth research to 
identify early stage disease markers and evaluate mechanisms involved in disease progression. 
Aberrant glycosylation, a hallmark of cancer, has been linked to pancreatic cancer through the 
regulation of glycosylation synthetic machinery and elevated expression of CA19-9. Apart from 
potential roles of CA19-9 and sialylated glycoconjugates in adhesion and metastasis, the role that 
aberrant glycosylation plays in the tumorigenic process is undefined. Cancer-related trends in 
glycosylation have been observed, but knowledge of individual glycoforms that are encompassed 
within these trends is absent. Efforts to study pancreatic cancer glycosylation are further hindered 
by the low prevalence of pancreatic cancer, which limits the number of samples available to study 
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While alterations of glycoforms can be used to identify the presence of a disease, it is perhaps of 
more use to identify aberrantly expressed glycoproteins that are indicative of pancreatic cancer, 
both in terms of protein abundance and glycoform occupancy on the protein. Linking aberrantly 
expressed glycoforms, including the CA19-9 antigen, to the underlying protein in pancreatic 
cancer offers the potential to identify pancreatic cancer biomarkers. Both glycomic and 
glycoproteomic experiments initiated in tissue specimen can be further assessed in biological 
fluids as non-invasive disease markers. While glycomic and glycoproteomic research related to 
pancreatic cancer is lacking, the advent of novel methodologies to improve throughput, reduce 
sample handling, and overcome limitations in detection, can advance our understanding of the 
pancreatic cancer glycoproteome and identify putative disease markers for further validation. The 
relevance of technologies such as MALDI-IMS, glycan derivatization, click chemistry, and intact 
glycopeptide analysis will be outlined in this dissertation in relation to pancreatic cancer 




Chapter 2: Hypothesis 
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 The overarching goal of this research project is directed at developing and applying novel 
mass spectrometry-based technologies for the identification of glycan and glycoprotein disease 
markers for pancreatic cancer. The methods developed and adapted towards this goal include: [1] 
the development of a MALDI-IMS approach to identify N-glycoforms with retention of their 
spatial distribution across tissue sections, [2] adaptation of a novel N-glycan derivatization 
strategy that stabilizes sialic acid residues and differentiates their linkages based on an induced 
mass difference, [3] azido-sugar metabolic labeling of sialic acids followed by protein enrichment 
and identification by LC-MS/MS, and [4] intact analysis of glycopeptides using a product-
dependent fragmentation strategy. The importance of applying these novel technologies for 
pancreatic cancer is based on the fact that pancreatic cancer consistently ranks among the most 
deadly cancers, due to delayed diagnosis, rapid disease progression, and limited therapeutic 
efficacy. The only curative treatment for pancreatic cancer is disease resection, and this option is 
available to only a small subset of patients whose disease is not locally invasive or metastasized 
at the time of diagnosis. Identification of early stage disease markers for pancreatic cancer offers 
the potential to improve clinical outcome by increasing the number of patients who can undergo 
disease resection.  
 Glycoproteins and the glycoforms present on those proteins represent a promising avenue 
for early detection biomarker discovery research, given the established evidence linking aberrant 
glycosylation to pancreatic cancer. In addition to elevated levels of CA19-9 in pancreatic cancer, 
evidence has also shown that pancreatic cancer is associated with alterations in glycosylation 
biosynthetic machinery, broad structural changes in N-linked glycans, and robust changes in 
glycoprotein expression levels. However, the low prevalence of disease and even lower number 
of clinical specimen available, have hindered the ability to identify disease markers. Furthermore, 
techniques directed at studying glycobiology are both labor and time intensive, and require large 
amounts of sample material. While glycobiology research has lagged behind proteomics and 
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genomics in recent years, new analytical technologies offer the potential to produce profound 
improvements in the sector. Therefore, I hypothesize that the application of analytical techniques 
that characterize the glycome of the tumor and adjacent regions, and a subsequent analysis of the 
dysregulated glycoproteome, will identify molecular events associated with the development and 
progression of pancreatic cancer. A premise of this hypothesis is that these alterations in 
pancreatic cancer glycosylation are conserved across multiple patients. This hypothesis is tested 
by the following specific aims: 
 
Aim 1: Develop a method to simultaneously indentify and localize N-glycans on tissue sections, 
while maintaining information related to relative abundance 
 
Approach 
A novel method to spatially profile N-linked glycans on biologically relevant tissue 
sections will be developed for MALDI-IMS to enable the identification, abundance and 
localization of N-linked glycans in tissue sections. While most MALDI-IMS approaches utilize 
fresh/frozen tissue sections, the method will be optimized to include formalin-fixed paraffin-
embedded (FFPE) tissue blocks. Initial characterization will rely on mass accuracy of released 
glycans, but secondary characterization strategies, including glycan fragmentation and 
derivatization, will confirm glycan compositions. Once optimized, this method will be used to 
identify diagnostic and prognostic glycan alterations directly in the clinical tissue blocks. 
Towards this end, the use of tissue microarrays (TMAs) will improve assay throughput and 







 The intent of Aim 1 is to improve glycobiology methodologies relating to the study of N-
glycan localization. In 2012, the U.S. National Research Council laid out a series of goals to 
advance the field of glycobiology research; one being to develop imaging methods to assess 
glycan localization (386). The current method for localizing N-glycans in tissue sections relies on 
staining with broad affinity lectins or antibodies specific to one glycan antigen. Therefore, a 
global profiling of N-glycans using traditional approaches requires serial staining of multiple 
slides, requiring the use of excessive materials (i.e. tissue slices, lectins, and antibodies), and still 
does not definitively identify the glycan composition. MALDI-IMS is a developing technique that 
has been used to study the biological localization of drugs, lipids, metabolites and proteins in 
tissue slices. MALDI-IMS following enzymatic digestion has already demonstrated promise in 
the field of bottom-up protein imaging. By adapting a similar workflow, we aim improve 
throughput and dimensionality of N-glycan imaging by globally profiling all N-glycans in a 
single experiment. PNGaseF will be applied to tissue sections prior to imaging to release glycans 
at the N-glycan consensus sequence. Following analysis, each slide will be stained with 
hematoxylin and eosin and processed by a pathologist to enable a comparison of glycan 
localization with histology. Tissue embedding in FFPE blocks is considered the gold standard for 
sample preservation, so adapting the imaging method to enable FFPE tissue analysis will expand 
the scope of studies (387). An additional benefit of optimizing the method for FFPE tissues is the 
ability to use FFPE cores housed in a TMA blocks to look at a large number of samples in a 
single imaging run.  
 
Aim 2: Use higher-throughput MALDI imaging approaches to identify N-glycan biomarker 





 The developed MALDI-IMS platform will be applied to the study of pancreatic cancer by 
profiling N-glycans from pancreas tissues and TMA blocks containing patient matched tumor and 
non-tumor tissue cores. Initial disease markers for pancreatic cancer will be discovered by higher-
throughput N-glycan profiling of 6 TMAs with tissue cores from 76 patients. Data will be 
processed by supervised machine learning algorithms to identify panels of N-linked glycans that 
are capable of distinguishing tumor from non-tumor cores. The utility of individual glycan and 
glycan panels can be validated in high resolution imaging experiments of entire pancreatic cancer 
tissue blocks. Given the heterogeneous nature of tumors and the presence of a significant 
percentage of the population that is unable to express CA19-9 antigen, we expect biomarker 
panels to improve the overall disease marker utility. 
 
Rationale 
 The goal of our work in Aim 2 is to assess the ability of N-glycans to serve as disease 
markers for pancreatic cancer, a facet ignored by most glycosylation-centered pancreatic cancer 
studies. The observation of specific glycoproteins has been used to detect early stage pancreatic 
lesions, suggesting that aberrant glycans may have a similar role. Additionally, the development 
of a glycan disease-marker panel can improve the sensitivity and specificity of disease markers 
compared to CA19-9. To identify individual glycans and glycan panels that can be used as 
biomarkers for pancreatic cancer, we aim to utilize the method developed in Aim 1 to perform 
discovery phase experiments in TMAs and tissue sections. Tissues are ideal for discovery phase 
disease marker studies due to reduced sample complexity compared to serum, as molecules are 
obtained directly from the organ of interest and are present in higher levels. An added benefit of 
MALDI-IMS is the ability of the technique to link glycan structures with histology. Pancreatic 
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cancer is a very complex disease that requires input from cancer cells and surrounding stromal 
cells, an interaction that would be missed by traditional biochemical approaches (95).  
 
Aim 3: Link aberrant glycosylation to modified proteins and develop an integrative 




Additional disease markers will be identified by leveraging information relevant to 
individual protein expression and glycoform occupancy/heterogeneity. Due to the inherent 
complications of glycoprotein analysis, novel methods will be adapted to the study of the 
pancreatic cancer glycoproteome. In one approach, putative carriers of the CA19-9 antigen will 
be assessed using a targeted glycoprotein enrichment procedure specific for sialic acids. In this 
approach, cells with known CA19-9 expression levels will be treated with an azide-labeled sialic 
acid analog. Alterations at the protein level may identify common trends associated with CA19-9 
expression, and selected proteins can be further evaluated as CA19-9 carriers. Additionally, this 
approach will catalogue sialylated glycoproteins in pancreatic cancer. In another approach, an 
intact glycopeptide enrichment step followed by a product-dependent fragmentation of selected 
glycopeptides will be used to simultaneously characterize both glycan compositions and peptide 
sequences. This experimental workflow will be developed with protein standards and then 
attempted on complex biological mixtures (i.e. tissue, serum, cell lysates). Glycoconjugate 
enrichment will be performed at the peptide level though unbiased enrichment strategies that rely 






The ultimate goal of Aim 3 is to identify aberrations in both glycans and their 
corresponding glycoproteins that can be used as disease markers for pancreatic cancer in a 
clinical setting. While it is doubtful that MALDI-IMS will be used clinically for biomarker 
classification, derivative experiments based off of identified glycan or glycoproteins can be 
assessed by immunohistochemistry, ELISA, lectin-ELISA, or MRM analysis. Clinically, secreted 
glycoproteins are successful non-invasive biomarkers for a variety of diseases, including 
hepatocellular carcinoma, prostate cancer, colon cancer and breast cancer (271). However, these 
glycoproteins are often elevated in benign diseases, resulting in false diagnosis and additional 
screens. Recent evidence has suggested that monitoring site-specific protein glycosylation can 
improve the biomarker, an example being elevated core fucosylated glycoforms of AFP in 
hepatocellular carcinoma compared to benign liver diseases (352). In pancreatic cancer, certain 
glycoproteins have displayed improved sensitivity and specificity over CA19-9 in distinguishing 
between pancreatic cancer, normal pancreas tissue, and other diseases (i.e. pancreatitis or 
pancreatic cysts). However, these trends are observed in small subsets of data, but require further 
validation in larger trials (343). Targeted approaches, focusing on glycosylation motifs will be 
used to assess specific aberrations at the glycoprotein level. However, the click chemistry 
approach utilized in this aim does not retain glycans on the protein. Mapping specific changes in 
glycosylation unique to pancreatic cancer may require glycoproteins to be isolated in order to 
reduce sample complexity, prior to glycoproteomic analysis. The workflow for intact 










 MALDI-IMS can simultaneously map the molecular distribution and relative abundance 
of hundreds of analytes on a single tissue section. Furthermore, the distribution can be directly 
linked to cellular histology on serial tissue sections. While MALDI-IMS has not been applied to 
the study of glycosylation, the technique has been used to profile the distribution of lipids, 
metabolites, drugs, proteins and peptides within tissue sections. Given that MALDI-MS is a 
powerful technique to study N-glycosylation, albeit usually following glycan derivatization and 
enrichment, the application of PNGaseF to tissue sections should release glycans and enable 
analysis by MALDI-IMS. Glycosylation is a dynamic PTM that is dysregulated in response to 
malignant transformation and promotes cancer progression and metastasis. Mapping 
glycosylation in correlation with disease histology could identify cancer related glycans and 
implicate glycosylation-related processes in disease progression. In comparison to other classes of 
molecules, defining the underlying monosaccharide composition of N-linked glycans is relatively 
straightforward, as N-glycans possess a common core structure and elongation proceeds through 
a limited number of well characterized processes. Current approaches to define glycan 
localization are limited to broad affinity lectins and a small number of antibodies directed against 
glycan antigens, both of which enable the localization of structural classes of glycans but not 
identification of individual structures. Furthermore, glycans bound to proteins should be 
accessible in FFPE tissue blocks. As FFPE fixation represents the gold standard of tissue 
preservation, adaptation of an imaging approach to profile N-glycans on these sections is 
extremely relevant. From a biomarker discovery standpoint, individual tissue cores from different 
patients can be profiled simultaneously in a higher-throughput TMA based format. A targeted 
MALDI-IMS approach to localize N-linked glycans in relation to histopathology can serve as a 
platform for identifying novel disease related targets for biomarker and therapeutic applications.   
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3.2 MALDI-IMS Workflow For N-Glycan Imaging 
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 A new Matrix Assisted Laser Desorption Ionization Imaging Mass Spectrometry 
(MALDI-IMS) method to spatially profile the location and distribution of multiple N-linked 
glycan species in tissues is described. Application of an endoglycosidase, peptide N-glycosidase 
F (PNGaseF), directly on tissues followed by incubation releases N-linked glycan species 
amenable to detection by MALDI-IMS. The method has been designed to simultaneously profile 
the multiple glycan species released from intracellular organelle and cell surface glycoproteins, 
while maintaining histopathology compatible preparation workflows. A recombinant PNGaseF 
enzyme was sprayed uniformly across mouse brain tissue slides, incubated for two hours, then 
sprayed with 2,5- dihydroxybenzoic acid matrix for MALDI-IMS analysis. Using this basic 
approach, global snapshots of major cellular N-linked glycoforms were detected, including their 
tissue localization and distribution, structure and relative abundance. Off-tissue extraction and 
modification of glycans from similarly processed tissues and further mass spectrometry or HPLC 
analysis was done to assign structural designations. MALDI-IMS has primarily been utilized to 
spatially profile proteins, lipids, drug and small molecule metabolites in tissues, but it has not 
been previously applied to N-linked glycan analysis. The translatable MALDI-IMS glycan 
profiling workflow described herein can readily be applied to any tissue type of interest. From a 
clinical diagnostics perspective, the ability to differentially profile N-glycans and correlate their 
molecular expression to histopathological changes can offer new approaches to identifying novel 
disease related targets for biomarker and therapeutic applications. 
3.2.2 Introduction 
 The majority of proteomic and metabolomic analytical techniques require the macro- or 
microdissection and subsequent extraction of analytes from the target tissue. This process leads to 
loss of the spatial distribution and associated histopathology of the tissue. A novel but maturing 
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technology, MALDI imaging mass spectrometry (MALDI-IMS), has been used to generate two- 
and three-dimensional molecular maps of hundreds of analytes directly from the surface of a 
tissue section, allowing the display of the relative abundance and spatial distribution of individual 
analytes (388–392). The distribution of the analytes are also readily linkable to molecular 
histology and pathology data from the same tissues (393,394). To date, most applications of 
MALDI-IMS have focused on profiling of proteins, lipids and drug metabolites in tissues, but the 
technique has not yet been defined for analysis of complex carbohydrates, typified by N-linked 
glycans (138,143,395–399). Glycosylation is a major post-translational modification to proteins 
critical in regulating protein folding and vesicular transport, cell-cell communication and 
adhesion, immune recognition and other extracellular functions (150,400,401). N-linked glycans 
are specifically attached to asparagine residues in proteins via a conserved amino acid motif of N-
X-S/T, where X represents any amino acid except proline, and represent a diverse but 
biosynthetically definable group of carbohydrate structures ranging generally from m/z = 1000 - 
5000 in size (150). Because MALDI-TOF analysis is one of the most robust and well established 
methods for profiling multiple species of N-linked glycans, imaging of glycans directly on tissue 
by MALDI-IMS should be feasible (402,403). 
 Using a recombinant source of peptide N-glycosidase F, which allowed an abundant 
supply of enzyme for optimization, and adaptation of a molecular spraying method developed for 
on-tissue protease digestions, a method workflow for MALDI-IMS of released N- glycans has 
been developed that maintains their spatial distribution in frozen tissue specimens (395,404). 
Combinations of permethylation derivatization, 2-aminobenzoate-modified normal phase HPLC 
separations, glycan standards, and existing structural database resources were used to confirm 
glycan release and initial structural determinations (238,405,406). Examples of the method 
development and verification workflows for robust on-tissue N-linked glycan profiling by 
MALDI-IMS are presented for mouse brain and human kidney tissues. 
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3.2.3 Materials and Methods 
3.2.3.1 Materials 
 The glycan standard A2 and sialidase S were obtained from ProZyme (Hayward, CA). 
Asialofetuin glycoprotein, 2,5-dihydroxybenzioc acid (DHB), trifluoroacetic acid, sodium 
hydroxide, dimethyl sulfoxide (DMSO), and iodomethane were obtained from Sigma-Aldrich (St. 
Louis, MO). HPLC grade methanol, ethanol and water were obtained from Fisher Scientific. ITO 
slides were purchased from Bruker Daltonics (Billerica, MA) for MALDI-IMS experiments. 
3.2.3.2 Tissue Specimen 
 Mouse brains were excised from four euthanized C57BL/6 mice and snap frozen. Mice 
were housed in an Institutional Animal Care and Use Committee-approved small animal facility 
at MUSC, and brains were harvested as part of approved projects. Whole excised brains were 
placed in plastic weigh boats and rapidly frozen at the vapor phase interface of a liquid nitrogen 
containing dewar. A human kidney tissue was obtained from an Institutional Review Board 
approved study from the Mayo Clinic (Jacksonville, FL) evaluating the molecular changes 
associated with matched patient non-tumor and clear cell renal cell carcinoma tissues. A slice of 
kidney from a non-tumor region was selected for use in this current study. No personal identifier 
information was provided to the laboratory investigators. This particular tissue section represents 
a distal section of kidney where there was no evidence of tumor. Coronal sections of mouse 
brains (10 microns) and the human kidney (10 microns) were prepared using a Thermo Microm 
HM550 cryostat and stored at −80°C. For each section analyzed, a serial section was collected for 
histological analysis and staining with hematoxylin and eosin (H&E). 
3.2.3.3 Recombinant Peptide N-Glycosidase F Expression 
 The entire Peptide N-Glycosidase F (PNGase F) gene (P21163.2) from the genome of 
Flavobacterium meningosepticum was cloned, expressed and purified into the T7 expression 
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vectors pET 29-b (Novagen) and  pQE-T7 (Qiagen). This insertion results in the addition of the 
sequence for an in frame histidine tag at the C-terminal end of the PNGase F gene sequence. The 
recombinant PNGase F HIS-tagged construct (rPNGase F) was transformed into bacterial strain 
BL21 Star (DE3) that carries the gene for the T7 RNA polymerase under control of the lacUV5 
promoter and allows for high level isopropyl-beta-D-thiogalactopyranoside (IPTG) inducible 
expression of gene products from T7 expression vectors such as pET and pQE. Bacterial 
transformation and cell culture growth conditions were done following manufacturers protocol 
(Invitrogen). Cells were harvested by centrifugation and cell pellets were washed with 1X 
phosphate buffered saline (PBS) containing protease inhibitors (SigmaFast EDTA-free). Total 
cellular protein lysates were made using an Avestin C5 high pressure homogenizer. FPLC 
purification methods for the rPNGase F histidine tagged protein used Ni-NTA  (Qiagen) and 
IMAC HisTrap HP (GE Healthcare) columns. Bacterial cell lysate from IPTG induced cultures 
was loaded onto to the column in binding buffer; 50 mM NaHPO4, 1M NaCl (pH 7.0) and bound 
histidine tagged rPNGasE F was washed and eluted using an imidazole step gradient (250mM to 
800mM imidazole) in binding buffer. Purified enzyme was dialyzed and stored in PBS buffer at a 
concentration of 1mg/mL, analogous to concentrations found in commercial sources of this 
enzyme. 
3.2.3.4 MALDI Imaging Mass Spectrometry 
 Sectioned mouse brain tissue samples were mounted on ITO coated slides, and desiccated 
at room temperature for 20 minutes. A sequential ethanol wash was done in 70% ethanol for two 
minutes, two times, and one wash in 100% ethanol for two minutes, then a final desiccation at 
room temperature for 10 minutes. An ImagePrep spray station (Bruker Daltonics) was used to 
coat the slide with a 0.2mL solution containing 20μL of 1mg/mL PNGaseF stock in water. This 
solution was sprayed by the ImagePrep using settings originally optimized for spraying of trypsin 
that result in minimal volumes and retention of spatial distribution (395,403). If sialidase was 
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used, 0.1 units of enzyme were diluted in 200μL water and sprayed following PNGaseF 
application using the same ImagePrep settings. Control tissue slices were blocked with a glass 
slide during the spraying process. Following application of glycosidase, slides were then 
incubated at 37°C for 2hrs in a humidified chamber, then dried in a desiccator prior to matrix 
application. 2,5-Dihydroxybenzoic acid (DHB) matrix at a concentration of 0.2M in 50% MeOH 
1% TFA was sprayed on to the slide using the ImagePrep for positive ion mode analysis. Spectra 
were acquired across the entire tissue section on a SolariX 70 dual source 7T FTICR mass 
spectrometer (Bruker Daltonics) to detect the N-glycans (m/z = 690–5000) with a SmartBeam II 
laser operating at 1000 Hz, a laser spot size of 25µm and a raster width of 125µm unless 
otherwise indicated. For each laser spot, 1000 spectra were averaged. Images of differentially 
expressed glycans were generated to view the expression pattern of each analyte of interest using 
FlexImaging 3.0 software (Bruker Daltonics). Following MS analysis, data were loaded into 
FlexImaging Software focusing on the range m/z = 1200–4500 and reduced to 0.98 ICR 
Reduction Noise Threshold. Glycans were identified by selecting peaks that appeared in an 
average mass spectrum from the tissue that received PNGaseF application but did not appear in 
the control tissue. Observed glycans were searched against the glycan database provided by the 
Consortium for Functional Glycomics and known glycans that exist in mouse brain (407). 
3.2.3.5 Permethylation and Normal Phase HPLC of Tissue Extracted N-Glycans 
 PNGaseF sprayed mouse brain tissue slides were incubated for 2hr at 37°C; 50μL water 
was applied on top of the tissue and incubated for 20 minutes to extract the released native N- 
glycans. The water was removed from the tissue, then concentrated under vacuum by 
centrifugation. Permethylation was performed as described, and glycans analyzed by MALDI 
(238). Masses detected in the permethylation experiments were searched against the 
permethylated glycan database provided by the Consortium for Functional Glycomics (407). 
Alternatively, concentrated glycans were labeled with 2-aminobenzamide (2-AB) for subsequent 
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normal phase HPLC analysis (405,406). Glycan identification was made through sequential 
exoglycosidase digestions as previously described (406). 
 PNGaseF (0.02mg) sprayed mouse brain tissue slides were incubated for 2hrs at 37°C; 
50uL water was applied on top of the tissue and incubated for 20 minutes to remove the released 
glycans. The water was removed and concentrated under vacuum by centrifugation. 
Permethylation was performed by dissolving the dried glycans in 0.2μL H2O, 22μL iodomethane 
and 50μL dimethylsulfoxide and applied over a sodium hydroxide microspin column as described 
(238). The permethylated glycans were dissolved in 5μL 50% MeOH/water and spotted with 
DHB (10mg in 1mL 50% MeOH). N-glycans were detected by averaging 10 MALDI scans at 25 
μm laser width, averaging 1000 shots in each acquired scan between m/z = 690-5000. Masses 
detected in the permethylation experiments were loaded into DataAnalysis 4.0 and searched 
against the permethylated glycan database provided by the Consortium for Functional Glycomics 
(407). 
 Tissue extracted PNGaseF released N-glycans (as above) were prepared for rapid glycan 
sequencing using previously optimized procedures (405,406).  Briefly, the concentrated N-
glycans were labeled with 2-aminobenzamide (2-AB) for subsequent normal phase HPLC 
analysis (406).  Glycan identification was made through sequential exoglycosidase digestion as 
previously described by Guile et al., as well as bovine kidney fucosidase (406).  The resulting 
peaks, separated by time of appearance, correspond to specific glycan structures on the basis of 
glucose unit values (data not shown).  All HPLC analyses were performed using a Waters 
Alliance HPLC System and quantified using the Millennium Chromatography Manager (Waters 
Corporation, Milford, MA).  Glycan structures were identified by the calculation of the glucose 
unit value, as previously described, as well as through the comparison to known standards and 
sequential exoglycosidase digestion22,23 (405,406). 
94 
 
3.2.3.6 Analysis of Asialofetuin and Glycan Standards in Mouse Brain Tissues 
 A frozen mouse brain was cored with a disposable 1.5mm tissue coring tool. A quartile of 
a different brain from a littermate, which contained the same region of tissue cored in the other 
sample, was homogenized in a glass Dounce homogenizer in 0.5mL water. The goal was to 
maintain a highly viscous preparation, which was then supplemented with 0.02mL of water 
containing 1mg purified asialofetuin glycoprotein standard. This solution was added back to the 
cored brain, and refrozen at -80°C. This brain was subsequently prepped for MALDI imaging as 
described for other brain samples.  
3.2.4 Results 
 A workflow for on-tissue analysis of PNGaseF released N-glycans was developed, as 
summarized in Figure 7. Initial experiments were done to verify that PNGaseF is active on mouse 
brain tissues following application by an ImagePrep sprayer, and that the products of the reaction 
are N-glycans. Two frozen mouse brain tissue slices (10 micron) were mounted on ITO-coated 
glass slides and dehydrated in sequential ethanol washes. One brain slice was covered by a glass 
slide to serve as an experimental control, and the other section was sprayed with 20μg PNGaseF. 
The tissues were incubated for 2hr at 37°C in a humidified chamber. After drying, DHB matrix 
was applied to the entire slide and MALDI-IMS imaging done for each brain slice. The spectra 
from the PNGaseF sprayed brain slice revealed multiple novel ions peaks that are consistent with 
release of N-glycans (Figure 8a). Additionally, these ions displayed regional localization 
following PNGaseF spray (Figure 8b, 2d, 2f, 2h) but were not detected in the absence of 
PNGaseF spray (Figure 8c, 2e, 2g). These obvious patterns of differential glycan expression 
distributions associated with brain substructure is a novel finding, and a representative overlay 





Figure 7. MALDI-IMS of N-Linked Glycans Workflow. A summary schematic of the on-




Figure 8. Application of PNGaseF Results in Enzyme-Mediated Generation of Ions. The 
PNGase F workflow was applied to one mouse brain while the other mouse brain was prepared 
with an identical workflow without PNGase F. (a). The upper spectrum is from the brain slice 
incubated with PNGase F and the lower spectrum is from the non-PNGase F control brain slice. 
Example masses that were detected following PNGase F treatment are shown for three ion peaks 
that also displayed regional expression distributions in the mouse brain. The m/z = 2421.5 
(b and c), m/z = 2745.5 (d and e) and m/z = 2786.5 (f and g) were only detected after PNGase F 
digestion (panels b,d,f,h). An overlay of these three peaks in the PNGase F digested brain slice is 






Figure 9. Addition of a Glycoprotein Standard Following PNGaseF Digestion and MALDI-
IMS. Asialofetuin was incubated with PNGase F and the native glycans were analyzed by FT-
MS. Hex5HexNAc4 + Na (m/z = 1663.5) and Hex6HexNAc5 + Na (m/z = 2028.7) were detected. 
Asialofetuin was incorporated into a mouse brain and the PNGase F imaging method was 
performed. The two inset images show the same N-glycans at m/z = 1663.5 and m/z = 2028.7 m/z 
detected on-tissue following PNGase F digestion.  
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 Purified glycoprotein and glycan standards were added to mouse brain tissues prior to 
PNGaseF digestion and matrix application, to further verify the on-tissue PNGaseF activity and 
the ability to detect native N-glycans on tissue. A common purified glycoprotein standard, 
asialofetuin, was mixed with brain tissue homogenate and added back to the brain for refreezing 
and MALDI-MS imaging analysis of the tissue. Focusing on two known N- linked glycans of 
asialofetuin, Hex5HexNAc4 + Na (m/z = 1663.5) and Hex6HexNAc5 + Na (m/z = 2028.7), these 
glycans were detected following in-solution digest of asialofetuin alone (Figure 9). Following on-
tissue PNGaseF digestion, these same glycans were readily detected in the supplemented brain 
tissue following PNGaseF digestion (inset of Figure 9), but not in the tissue without the enzyme 
sprayed (data not shown). Furthermore, addition of a glycan A2 standard (m/z = 2223.8, 
Hex5HexNAc4NeuAc2) directly on mouse brain tissues revealed multiple glycan ion peaks that 
differed in loss of sialic acids (−1 NeuAc, m/ z = 1954.7; −2 NeuAc, m/z = 1663.5) (Figure 10), a 
common occurrence in MALDI analysis of sialylated glycan structures, and multiple sodium ion 
adducts (247). The corresponding MALDI imaging distribution of the standard glycan peaks are 
shown for each ion in Figure 10. Analysis of these standards further verified detection of N-
linked glycans by MALDI-IMS. 
 Two off-tissue approaches were used to further verify the release of N-glycans and begin 
to identify specific glycan structures associated with on-tissue native glycan peaks. Brain tissues 
were digested with PNGaseF on-slide as already described. Released glycans were extracted from 
the on-slide digestion in water. On-slide extracted glycans were treated with 2-aminobenzoate 
(2AB) for subsequent normal-phase HPLC analysis, or permethylated for further MALDI 
analysis and comparison to structure and reference spectra databases (405–407). Reference 
spectra for these extracted glycans following permethylation and MALDI profiling and normal 
phase HPLC separation of 2AB glycans are presented in Figure 11 and Figure 12. Structural 
identification of the permethylated N-glycans were assigned by searching for the same ion in the 
99 
 
MALDI structural databases and reference spectra of mouse brain glycans provided by the 
Consortium for Functional Glycomics (407). A majority of the permethylated glycans extracted 
from the tissues were the same masses as the glycans listed in the Consortium for Functional 
Glycomics mouse brain tissue spectral libraries. 
 
Figure 10. Analysis of A2 Standard on Tissue Sections. An A2 Standard 
(Hex5HexNAc4NeuAc2; 0.1 µg) was spotted directly on a ground steel plate (a.), or 0.1 µg/µL 
standard was spotted onto a mouse brain tissue slice prior to matrix application (b‐g). The 
MALDI mass spectrum demonstrates the spectral complexity of non‐derivatized native sialic acid 
N‐glycans due to loss of sialic acid residues and different numbers of sodium adducts. 
Representative images correspond to the ions detected in the mass spectrum localized to the tissue 
area where they were spotted (b‐g). The glycan composition and number of sodium adducts per 
analyte are indicated above each image panel. The colored stars in the spectra correspond to the 




Figure 11. Linkage of Permethylated Glycan Masses with Native Tissue Glycan Ion 
Distribution. The N-glycan imaging method was applied to a mouse brain for tissue imaging and 
an off tissue permethylation was performed for glycan verification. (a.) Permethylated glycans 
Hex5dHex3HexNAc5 + Na (m/z = 2837.6), Hex4dHex2HexNAc5 + Na (m/z = 2459.3), and 
Hex3dHex1HexNAc5 +2Na (m/z = 2081.1) were identified and the corresponding glycans 
displayed specific localization in the tissue image (b). M/z = 2306.1 corresponds to 
Hex5dHex3HexNAc5 + 2Na (red), m/z = 1996.1 corresponds to Hex4dHex2HexNAc5 + Na 
(green), and m/z = 1710.9 corresponds to Hex3dHex1HexNAc5 + 2Na (blue). A raster distance 





Figure 12. HPLC Analysis of 2-AB Labeled N-Glycans. Mouse brain tissues (10 um slices) 
were digested on‐slide with PNGaseF, extracted with water then concentrated for derivation with 
2‐aminobenzoate (2AB) and separated by normal phase HPLC. Sialidase digestion was done in 
solution with the 2AB modified glycans, prior to HPLC separation. The structure key for 






Figure 13. Mouse Brain N-Glycan Imaging Panel. 28 N-glycans were observed in both the 






Figure 14. N-Glycan Permethylation Spectra. Permethylation analysis of the same glycan 
extract as done with the HPLC analysis, with MALDI spectra split into two overlapping mass 
ranges: (top panel) m/z = 1550‐2900; (bottom panel) m/z = 2700‐4550.  
104 
 
 These permethylated masses and structures were used to correlate back to the expected 
native mass/structure of the glycan. As an example, an overlay of Hex5dHex3HexNAc5 + Na, 
Hex4dHex2HexNAc5 + Na, and Hex3dHex1HexNAc5 + Na demonstrates the spatial pattern of 
expression for these specific glycans by MALDI-IMS linked to the corresponding extracted 
permethylated peaks (Figure 11). A reference panel of 28 glycan structures was generated that 
lists structural composition (Figure 13), expected and observed masses of the permethylated 
glycans (Figure 14), and the masses of their corresponding native glycan masses for cross-
referencing permethylated glycan spectra and native tissue glycan masses. Additionally, the 
majority of the identities of the off-tissue native glycan species reacted with 2AB and separated 
by normal phase HPLC are also common to those listed in Figure 13. The majority of the detected 
masses were within 0.5 mass units of the predicted masses. The few discrepancies of more than 
0.5 mass units generally occurred with native glycans of larger mass (>2500) and were associated 
with complex overlapping ion signals in those specific tissue regions.  
 Many larger glycans are branch-chained with terminal sialic acid residues, thus a 
comparison was done for detection of on-tissue glycans released by PNGaseF digestion alone 
versus a combination of PNGaseF and sialidase. If larger sialylated structures were present, then 
sialidase digestion would result in new glycan peaks detected in the spectra relative to PNGaseF 
alone. As shown in Figure 15, the on-tissue analysis indicated an increase in the levels of larger 
mass native glycan ions (m/z > 2500) detected in the double digest of PNGaseF and sialidase 
(Figure 15a–c). These structures are consistent with the sialidase products of glycans that 
contained tri- and tetra branched chains with multiple N-acetylglucosamine-galactose (LacNAc) 
dimers (408). A representative overlay image of three of these structures detected only in the 
combined sialidase/PNGaseF digest is shown in Figure 16d. Sialidase digestion of 2AB modified 
glycans also demonstrated shifts in the detection of smaller glycan species following normal 
phase HPLC separation (Figure 12). 
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 The methods developed for mouse brain tissues were applied to a frozen slice of human 
kidney containing both medulla and cortex regions. As shown in Figure 17, representative N- 
glycans released by on-tissue PNGaseF digestion can be detected that are specific to either cortex 
or medulla regions. Compared to the mouse brains analyzed, the total number of glycan species 
was slightly reduced in the human kidney sections. Beyond these kidney tissues and mouse brain 
tissues, we have found it is necessary to optimize the length of incubation and amount of 
PNGaseF digestion conditions for each tissue type being tested. Overall, these baseline conditions 






Figure 15. Mass Spectra of N-Glycans Released with PNGaseF and Sialidase. Three serial 
sections from a mouse brain were prepared and either (a) untreated, (b) digestion with PNGaseF, 
or (c) a combination of PNGaseF and Sialidase S. Recombinant PNGaseF (20 mU) alone or in 
combination with 100 mU Sialidase S (Prozyme) were applied using a Bruker ImagePrep prior to 






Figure 16. Novel Glycans Observed After Sialidase Release. MALDI-MSI results of the 
average spectra shown in Figure 15, where a representative overlay image of the unique glycans 
detected with the sialidase and PNGaseF combination is shown for m/z values of 2673.5 (blue), 
2694.2 (orange) and 3364.7 (green). A raster distance of 125 microns was used per MALDI laser 




Figure 17. N-Glycan MALDI-IMS of a Normal Human Kidney Tissue Section. Three serial 
sections from a human kidney were prepared and either untreated (data not shown), digested with 
PNGaseF, or analyzed by H&E staining. Cortex and medulla regions were confirmed by a 
pathologist. Recombinant PNGaseF (20 mU) was applied using a Bruker ImagePrep followed by 
a 2 hr incubation at 37° C. Following MALDI-MSI, m/z values that are specific to PNGaseF 
treated tissue are observed. Shown are the results for an m/z value of 2767.7 (a) localized in the 
cortex, while the m/z values of 2139.4 (b) and 1973.2 (c) are localized primarily in the medulla 
when compared to the H&E stain (d). An overlay of the three m/z values is provided (e). A raster 





 We describe a new mass spectrometry-based glycan imaging approach in combination 
with on-tissue PNGaseF digestion to spatially profile released N-linked glycans in their local 
microenvironment. The method has been designed to facilitate the tissue analysis of the cell 
surface glycans in frozen tissues while maintaining histopathology compatible preparation 
workflows. While MALDI-IMS has primarily been utilized to spatially profile proteins, lipids, 
drug and small molecule metabolites in tissues, it has not been previously applied to N-linked 
glycan analysis. Coronal slices of mouse brain tissues were ideal for method development 
because of the robust glycan signal and the existence of an N-glycan catalogue, provided by the 
Consortium for Functional Glycomics, that documents known N-glycans present in mouse brain 
tissue (407). Therefore the off-tissue extraction of glycans from PNGaseF digested brain slices 
for permethylation and mass spectrometry profiling or normal phase HPLC analyses could be 
readily compared to on-tissue glycan species, in particular for assigning glycan structure and 
composition. The Consortium of Functional Glycomics reference spectra library of permethylated 
N-glycan species from mouse brains as detected by MALDI lists over 40 identified structures. 
We estimate that 30 or more N- glycan species can be detected on-tissue in mouse brains by our 
current MALDI-IMS workflows, including the 28 structures listed in the panels of Figure 13. 
This number varies depending on the location of the tissue cut within the brain and the number of 
sub-regions present. MALDI-IMS detection of brain substructure regions of protein, small 
molecule metabolites and lipid distributions in brain substructure regions is well documented, so 
detection of specific N-linked glycan isoform distribution is not surprising, and represents to our 
knowledge the first demonstration of this (396,409–411). The specific distribution of N-glycans 
in the medulla and cortex regions of the human kidney tissue (Figure 17) also demonstrates sub-
organ structure specificity of glycan species expression. 
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 MALDI mass spectrometry is a common detection method for analysis of complex 
carbohydrates, including routine analysis of N-linked glycans released from glycoproteins by 
PNGaseF. From a practical perspective, our approach used a recombinant PNGaseF enzyme 
engineered for increased stability and activity. In addition, the amount of commercially available 
preparations of PNGaseF that would be required to perform the described experiments would not 
be economically feasible for most laboratories. The recombinant enzyme is also not formulated 
with detergents and additives that are common components of commercial enzyme, many of 
which can interfere with MALDI ionization. However, glycan analysis by MALDI is notoriously 
complicated by problems with glycan dissociation and sodium adduct additions. It is common to 
observe the loss of sialic acid when native glycans are analyzed by MALDI MS, hence the need 
for modifications like permethylation or 2-aminobenzoate that stabilize and help ionize sialic acid 
containing glycans (247). Most common chemical modification methods require organic solvents 
and the need to separate reaction products, thus these are not feasible for on-tissue derivatization 
and retention of spatial distributions. The MALDI-IMS profiling of the A2 glycan standard on- 
tissue was similarly affected, with the number of Na ions and loss of sialic acid being a factor for 
an effective prediction of structure. In addition to those glycans listed in Figure 13 that we have 
cross-referenced for structure identification, there are multiple PNGaseF-released ions detected 
that have not been correlated to reported structures. Many of these are larger species m/z > 3500, 
and like those glycan ions assigned structures, all will ultimately require confirmatory structural 
characterization involving tandem MS identifications off tissue (412,413). Use of MALDI alone 
may be difficult to structurally identify very high mass poly-lactosamino-glycan species on-
tissue, but some of these higher mass glycans are potentially profilable by MALDI-IMS (408). 
Differential exoglycosidase digestion strategies more amenable to native glycan identification on-
tissue and preservation of spatial distribution, analogous to that described for sialidase (Figure 
15), are ongoing. Preliminary experiments in negative ion mode using other matrices have 
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yielded promising results, and we expect this could be a partial solution for more effective 
detection of native sialylated glycan species. 
 Overall, we present a functional MALDI-IMS workflow for on-tissue analysis and 
distribution of N-glycan species, and there remains room for continued improvement of the assay 
and analysis workflow. We only report the use of one type of MALDI matrix, data was only 
collected in positive ion mode, and only fresh frozen tissues were used. Except for those glycans 
directly compared with reference standards, the structural assignments are correlative to existing 
databases and subject to known limitations of MALDI analysis. Further verification of these 
assigned structures by tandem mass spectrometry approaches is ongoing. Evaluation of different 
chemical matrices for either positive or negative ion mode analysis are ongoing, as well as 
refinement of methods to profile N-glycans in formalin- fixed paraffin-embedded (FFPE) tissues. 
As MALDI-IMS has been used to effectively profile proteins in FFPE tissues, we expect that 
these methods should be adaptable for glycan analysis in FFPE tissues (144,414). We believe this 
capability of profiling N-glycans spatially on tissue will have significant application to tissues 
representing many types of human diseases, especially the changes in glycosylation associated 
with oncogenesis. It is well documented that malignant transformation and cancer progression 
result in fundamental changes in the glycosylation patterns of cell surface and secreted 
glycoproteins, and the majority of current FDA-approved tumor markers are glycoproteins or 
glycan antigens (209,412,415,416). Therefore, development of a molecular assay like the 
MALDI-IMS approach we describe could directly profile these pathologically relevant 
carbohydrates in their local microenvironment and accelerate approaches to aid in the diagnosis, 
prognosis, staging, and treatment of many types of cancers. Coupled with many new improved 
high resolution mass spectrometry options for intact glycopeptides and small molecule 
carbohydrate binding probes, there is potential to link the tissue distribution of glycans from 
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3.3 Adaptation of MALDI-IMS Workflow for FFPE Tissue Blocks  
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 A recently developed matrix-assisted laser desorption/ionization imaging mass 
spectrometry (MALDI-IMS) method to spatially profile the location and distribution of multiple 
N-linked glycan species in frozen tissues has been extended and improved for the direct analysis 
of glycans in clinically derived formalin-fixed paraffin-embedded (FFPE) tissues. Formalin-fixed 
tissues from normal mouse kidney, human pancreatic and prostate cancers, and a human 
hepatocellular carcinoma tissue microarray were processed by antigen retrieval followed by on-
tissue digestion with peptide N-glycosidase F. The released N-glycans were detected by MALDI-
IMS analysis, and the structural composition of a subset of glycans could be verified directly by 
on-tissue collision-induced fragmentation. Other structural assignments were confirmed by off-
tissue permethylation analysis combined with multiple database comparisons. Imaging of mouse 
kidney tissue sections demonstrates specific tissue distributions of major cellular N-linked 
glycoforms in the cortex and medulla. Differential tissue distribution of N-linked glycoforms was 
also observed in the other tissue types. The efficacy of using MALDI-IMS glycan profiling to 
distinguish tumor from non-tumor tissues in a tumor microarray format is also demonstrated. This 
MALDI-IMS workflow has the potential to be applied to any FFPE tissue block or tissue 
microarray to enable higher throughput analysis of the global changes in N-glycosylation 
associated with cancers.  
3.3.2 Introduction 
 Tissues obtained from surgeries or diagnostic procedures are most commonly preserved 
in formalin-fixed paraffin-embedded (FFPE) tissue blocks. These tissues are fixed in formalin 
and processed as paraffin-embedded tissue blocks. The embedding process preserves the cellular 
morphology and allows tissues to be stored at room temperature, causing FFPE fixation to be 
used by many tissue banks and biorepositories (419,420). For cancer biomarker discovery, FFPE 
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tissues are particularly attractive because they are archived for years and are much more widely 
available than cryopreserved tissue.  When combined with clinical outcomes, FFPE tissues are a 
rich source of samples for biomarker discovery and validation in retrospective studies. While the 
fixation method has many benefits, the formalin treatment results in the formation of methylene 
bridges between the amino acids of the proteins, complicating further analysis by mass 
spectrometry. There has been continued progress in improving extraction methods of trypsin 
digested peptides from FFPE tissues in recent years, in parallel with improved high resolution 
sequencing analysis of peptides by mass spectrometry (387,421). Incorporation of multiple FFPE 
tumor tissue cores in a tissue microarray (TMA) format also has proven to be effective for 
immunohistochemistry analysis of potential biomarker candidates, and TMAs are increasingly 
being used for validation of alterations in protein expression associated with emerging genetic 
mutation phenotypes and transcriptional profiling studies (422–424). The main advantages of 
experiments performed with TMAs are the ability to include multiple cores from the same subject 
tumors, improved sample throughput, statistical relevance and multiplexed analysis of diverse 
molecular targets (422,425). Thus, it is possible to place up to 100 samples with duplicates and 
controls on a single slide. When correlated with associated clinical outcomes, this provides a 
powerful method for biomarker discovery and validation while minimizing reagent use and 
assuring that each core in the TMA is treated under identical conditions. 
 It is well documented that malignant transformation and cancer progression result in 
fundamental changes in the glycosylation patterns of cell surface and secreted glycoproteins 
(209,415,416). Glycosylation of proteins are post-translational modifications most commonly 
involving either N-linked addition to asparagine residues or O-linked additions to serine or 
threonine residues. Current approaches to evaluate glycosylation changes generally involve bulk 
extraction of glycans and glycoproteins from tumor tissues for analysis by mass spectrometry or 
antibody array platforms, however, this disrupts tissue architecture and distribution of the 
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analytes. Broad affinity carbohydrate binding lectins and a small number of glycan antigen 
antibodies can be used to target glycan structural classes in tissues, but not individual glycan 
species. Additionally, these detection methods for global alterations in glycosylation requires 
staining on many adjacent tissue sections, making large scale assessments on many samples 
difficult, expensive and time consuming. There are only a few reported studies examining 
glycosylation related changes of proteins or glycolipids in FFPE cancer tissues, and these focus 
primarily on determining the levels of the protein carriers or glycosyltransferases through 
immunostaining (426–428).  
 One potential approach to assess glycan changes in tissues is matrix-assisted laser 
desorption/ionization imaging mass spectrometry (MALDI-IMS). This technique has been used 
to directly profile multiple protein, lipid and drug metabolite in tissue, generating molecular maps 
of the relative abundance and spatial distribution of individual analytes linked to tissue 
histopathology (138,143,395–399). MALDI-IMS analysis of peptides following trypsin digestion 
of FFPE TMAs have also been reported (144,429,430). Recently, our group reported a MALDI-
IMS method workflow to directly profile N-linked glycan species in fresh/frozen tissues (431). 
Adapting this method for the analysis of N-glycans in FFPE tissues would serve to extend the 
application of the technique to larger retrospective sample sets and TMAs.  
 In this report, we describe the application of MALDI-IMS glycan imaging to various 
formalin-fixed tissues. Formalin-fixed mouse kidney tissues were used to optimize antigen 
retrieval, PNGaseF digestion and glycan detection conditions for MALDI-IMS. This was 
followed by N-glycan analysis of clinical FFPE tissue blocks from prostate and pancreatic 
cancers, as well as a commercial tissue microarray of hepatocellular carcinoma (HCC). Glycan 
identity was confirmed by on-tissue collision-induced dissociation (CID) and off-tissue 
permethylation analysis. An optimized MALDI-IMS workflow is presented that allows routine 
simultaneous analysis of 30 or more glycans per FFPE tissue, including TMA formats. The 
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approach is amenable to any FFPE tissue, and represents an additional molecular correlate assay 
for use with the TMA format. Furthermore, depending on the construction of the TMA and 
targeted tumor type, the approach has the potential to identify novel glycan biomarker panels for 
cancer detection and prognosis.  To our knowledge, this represents the first instance of using 
MALDI-IMS to profile N-glycans in FFPE tissue blocks or TMAs.  
3.3.3 Materials and Methods 
3.3.3.1 Materials 
 The glycan standard NA2 was obtained from ProZyme (Hayward, CA).  Trifluoroacetic 
acid, sodium hydroxide, dimethyl sulfoxide, iodomethane and α-cyano-4-hydroxycinnamic acid 
(CHCA) were obtained from Sigma-Aldrich (St. Louis, MO). HPLC grade methanol, ethanol, 
acetonitrile, xylene and water were obtained from Fisher Scientific (Pittsburgh, PA). ITO slides 
were purchased from Bruker Daltonics (Billerica, MA) and Tissue Tack microscope slides were 
purchased from Polysciences, Inc (Warrington, PA). Citraconic anhydride for antigen retrieval 
was from Thermo Scientific (Bellefonte, PA). Recombinant Peptide N-Glycosidase F (PNGaseF) 
from Flavobacterium meningosepticum was expressed and purified as previously described (431). 
3.3.3.2 FFPE Tissues and TMAs 
 All human tissues used were de-identified and determined to be not human research 
classifications by the respective Institutional Review Boards at MUSC and Van Andel. Mouse 
kidneys were excised from euthanized C57BL/6 mice and immediately placed in 10% formalin 
prior to processing for routine histology and paraffin embedding. Mice were housed in an 
Institutional Animal Care and Use Committee-approved small animal facility at MUSC, and 
tissues obtained were harvested as part of approved projects unrelated to glycan tissue imaging. A 
liver TMA was purchased from BioChain consisting of 16 cases of liver cancer in duplicates, and 
one adjacent non-tumor tissue for each case. Tissues were from 14 male and two female patients 
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with an average age of 47.5 with a range of 33 to 68 years old, with additional information 
provided in Supplementary Table 1. A de-identified prostate tumor FFPE block, stored for 10 
years representing a Gleason grade 6 (3+3)/stage T2c adenocarcinoma from a 62 year old 
Caucasian male, was obtained from the Hollings Cancer Center Biorepository at the Medical 
University of South Carolina. A pathologist confirmed the presence of approximately 10% 
prostate cancer gland content in the sample. A de-identified large-cell undifferentiated pancreatic 
carcinoma FFPE tissue section with low CA19-9 staining was obtained from the Van Andel 
Institute Biospecimen Repository. For each section analyzed, histological analysis and staining 
with hematoxylin and eosin (H&E) were performed. 
3.3.3.3 Washes for Deparaffinization and Rehydration 
 Tissue and TMA blocks were sectioned at 5μm and mounted on positively charged glass 
slides measuring 25 x 75mm, compatible with the Bruker slide adaptor plate. The slides were 
heated at 60°C for 1hr. After cooling, tissue sections were deparaffinized by washing twice in 
xylene (3 minutes each). Tissue sections were then rehydrated by submerging the slide twice in 
100% ethanol (1 minute each), once in 95% ethanol (one minute), once in 70% ethanol (one 
minute), and twice in water (3 minutes each). Following the wash, the slide was transferred to a 
coplin jar containing the citraconic anhydride buffer for antigen retrieval and the jar was placed in 
a vegetable steamer for 25 minutes. Citraconic anhydride (Thermo) buffer was prepared by 
adding 25μL citraconic anhydride in 50mL water, and adjusted to pH 3 with HCl. After allowing 
the buffer to cool, the buffer was exchanged with water five times by pouring out ½ of the buffer 
and replacing with water, prior to replacing completely with water on the last time. The slide was 
then desiccated prior to enzymatic digestion. Tris buffer pH 9-10 was also effective, but 
citraconic anhydride buffer was used for all experiments in this study.  
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3.3.3.4 N-Glycan MALDI-IMS 
 An ImagePrep spray station (Bruker Daltonics) was used to coat the slide with a 0.2mL 
aqueous solution of PNGaseF (20µg total/slide) as previously described (431). Adjacent control 
tissue slices lacking PNGaseF were generated by covering  them with a glass slide during the 
spraying process. Following application of PNGaseF, slides were incubated at 37°C for 2hr in a 
humidified chamber, then dried in a desiccator prior to matrix application. The matrix, α-Cyano-
4-hydroxycinnamic acid matrix (0.021g CHCA in 3mL 50% acetonitrile/50% water and 12µL 
25%TFA) was applied using the ImagePrep sprayer. Released glycan ions were detected using a 
SolariX dual source 7T FTICR mass spectrometer (Bruker Daltonics) (m/z = 690-5000 m/z) with 
a SmartBeam II laser operating at 1000 Hz, a laser spot size of 25μm. Images of differentially 
expressed glycans were generated to view the expression pattern of each analyte of interest using 
FlexImaging 4.0 software (Bruker Daltonics). Following MS analysis, data was loaded into 
FlexImaging Software focusing on the range m/z = 1000-4000 and reduced to 0.95 ICR 
Reduction Noise Threshold. Observed glycans were searched against the glycan database 
provided by the Consortium for Functional Glycomics (www.functionalglycomics.org). Glycan 
structures were generated by Glycoworkbench and represent putative structures determined by 
combinations of accurate m/z, CID fragmentation patterns and glycan database structures (432).  
3.3.3.5 Permethylation of Tissue Extracted N-glycans: 
 PNGaseF sprayed mouse kidney tissue slides were incubated for 2hr at 37°C; 50μL water 
was applied on top of the tissue and incubated for 20 minutes to extract the released native N-
glycans. The water was removed from the tissue, and then concentrated under vacuum by 
centrifugation. Permethylation was performed as described (431), and glycans analyzed by 
MALDI. Masses detected in the permethylation experiments were searched against the 
permethylated glycan database provided by the Consortium for Functional Glycomics (407).  
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3.3.3.6 Collision-Induced Dissociation of N-linked Glycans 
 Glycan standards were spotted on a stainless steel MALDI plate using CHCA matrix and 
desiccated to yield a homogenous layer. Tissues were prepared as previously described for 
MALDI imaging of FFPE tissues. 10 spectra of 1000 laser shots with a laser frequency of 1000 
Hz were averaged for each spectra provided. The collision energy varied between 60-70V. 
3.3.3.7 TMA Statistics 
 Mass spectra from TMA tissue Regions of Interest (ROIs) representing each tissue core 
were exported directly from FlexImaging and analyzed using an in-house workflow. The peak 
lists were first deconvoluted followed by calculating the mean peak intensity of points in each 
ROI, resulting in a monoisotopic peak list corresponding to signal intensity in each region. 
Comparison of tumor versus non-tumor was accomplished with a Wilcoxon rank sum test. 
Individual peaks were also evaluated to discriminate between tumor and non-tumor using receiver 
operator characteristic curves.   
3.3.4 Results 
3.3.4.1 Analysis of Formalin-Fixed Mouse Kidneys and Human Cancer Tissues. 
 Mouse kidney tissues were fixed in formalin and used as an initial model system to 
develop MALDI-IMS glycan imaging workflows for FFPE tissues. These tissues were chosen 
due to the availability of reference glycan structures and spectra, and previous MALDI-IMS 
glycan imaging data from our laboratory for fresh/frozen tissue analysis (407,431). A summary 
workflow schematic is provided (Figure 18). Tissues were cut at 5 microns, deparaffinized and 
rehydrated in sequential xylene/ethanol/water rinses, followed by antigen retrieval in citraconic 
anhydride pH 3. The rehydrated tissues were sprayed with PNGaseF, incubated for glycan 
release, sprayed with CHCA matrix, and then analyzed by MALDI-IMS. While all data shown 








N-glycan imaging of FFPE tissues. As shown in Figure 19, there were multiple ions detectable 
only in the tissue incubated with PNGaseF that were not present in the control tissue with no 
PNGaseF application.  Different glycans were distributed across the cortex or medulla regions. 
For example, a Hex4dHex2HexNAc5 ion (m/z = 1996.74) is present in the cortex and medulla 
(Figure 19c), while a Hex5dHex2HexNAc5 glycan (m/z = 2158.76) is more specific to the cortex 
(Figure 19d). An overlay of the MALDI-IMS images for these two ions from the PNGaseF 
treated sections (Figure 19e) and the control tissue (Figure 19f) demonstrates that these two ions 
are released by PNGaseF. In control kidney tissues that were only sprayed with aqueous 
PNGaseF solution lacking enzyme, or tissue slices that were not processed by antigen retrieval 
plus and minus PNGaseF digestion, only matrix ions or paraffin/formalin polymer were detected 
(data not shown).  A summary glycan image panel of 28 glycan ions detected in these kidneys, 
sodium adducts and observed/expected m/z values is provided in Figure 20. Additionally, N-
glycans were extracted from the tissue following on-tissue PNGaseF digestion, permethylated and 
analyzed by MALDI. A representative spectra from this analysis is provided in Figure 21. These 
permethylated values were also compared with MALDI reference spectra for mouse kidney 
glycans from the Consortium for Functional Glycomics. The imaged glycan ions were correlated 
to the reference spectra glycans, illustrated in Figure 22, and could be matched to all 28 glycan 
species highlighted in the reference spectra. 
 We next assessed whether the method was compatible with two representative archived 
pathology FFPE tissue blocks, one for pancreatic cancer and one for prostate cancer. A section of 
human pancreatic cancer tissue of complex histology was processed, incubated with PNGaseF 
and glycans detected by MALDI-IMS (Figure 23). Different N-glycans were detected that could 
distinguish between non-tumor, tumor, tumor necrotic and fibroconnective tissue regions. A 
representative glycan image overlay of four m/z values that correspond to the sodium adducts of 




Figure 19. MALDI-IMS of N-Glycans on a Mouse Kidney Tissue Section. Two mouse 
kidneys were sliced at 5 µm prior to proceeding with the MALDI-IMS workflow. One tissue was 
covered with a glass slide during PNGaseF application to serve as an undigested control tissue. 
An average annotated spectra from the tissue that received PNGaseF application is provided (a). 
Tissue regions were assessed by H&E stain (b). The labeled peaks correspond to native N-
glycans that have been reported for the mouse kidney on the Consortium for Functional 
Glycomics mouse kidney database. Two of these ions were selected and their tissue localization 
was assessed. Hex4dHex2HexNAc5 at m/z = 1996.7 (c) is located in the cortex and medulla while 
Hex5dHex2HexNAc5 m/z = 2158.7 (d) is more abundant in the cortex of the mouse kidney. An 
overlay image of these two masses is also shown (e), as well as the corresponding image from 




Figure 20. N-Glycan Panel of FFPE Kidney Sections. Ions detected in the kidney with enzyme 
application were compared to the control tissue. Ions that were only observed in the tissue 
following PNGaseF application were compared to the glycans found in the mouse kidney 
database on the Consortium for Functional Glycomics. The panel provides the glycan species, the 






Figure 21. Permethylation of Extracted N-Glycans from a Mouse Kidney. Mouse kidney N-
glycans were extracted from the imaging slide after PNGaseF application and digestion. Glycans 
were dried down and underwent permethylation as previously described. The permethylated m/z 
values were then compared to the permethylation data from the Consortium for Functional 
Glycomics mouse kidney database (www.functionalglycomics.org). 
 




Figure 23. MALDI-IMS of a Human Pancreas FFPE Block. A FFPE block of pancreatic 
tissue from a human patient was cut at 5 µm prior to and selected for MALDI-IMS. 
Histopathology found four unique regions in the H&E of this tissue block. The tissue block 
contained tumor tissue, non-tumor tissue, fibroconnective tissue representing desmoplasia 
surrounding the tumor tissue, and necrotic tissue (b). MALDI-IMS was able to distinguish these 
four regions based off of specific ions after MALDI-IMS. M/z = 1891.80 (red) is found in the non-
tumor (NT) region of the pancreas and corresponds to Hex3dHex1HexNAc6, while m/z = 1743.64 
(blue) represents Hex8HexNAc2 and is predominant in the tumor region (T) of the tissue. 
Desmoplasia (DP) is represented by m/z = 1809.69 (green) corresponding to 
Hex5dHex1HexNAc4. In the region where necrosis was identified (TN), m/z = 1663.64 (orange) 
was elevated corresponding to Hex5HexNAc4. Image spectra were acquired at 200 µm raster. (c). 
Representative individual glycan images for the pancreatic FFPE tissue slice.  
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tissue (Figure 23b). A glycan of m/z = 1891.80 (red)/Hex3dHex1HexNAc6 was detected 
primarily in the non-tumor region of the pancreas, while a glycan of m/z = 1743.64 
(blue)/Hex8HexNAc2 was predominant in the tumor region of the tissue. A region of 
desmoplasia surrounding the tumor region, an area of increased extracellular matrix proteins and 
myofibroblast-like cells resulting in a dense fibrous connective tissue, is represented by a glycan 
of m/z = 1809.69 (green)/Hex5dHex1HexNAc4 (433). A region of tumor necrosis is represented 
by a different glycan of m/z = 1663.64 (orange)/Hex5HexNAc4. Additional examples of tissue 
distributions of other individual glycan species are shown in Figure 23c.  
 A human prostate tissue block containing both tumor and non-tumor gland regions was 
also analyzed by MALDI-IMS. A heterogeneous N-glycan distribution reflective of the tissue 
histology was observed, and as an example of stroma and gland distributions, two glycan ions and 
two sub-regions within the tissue are highlighted in Figure 24. Distribution of glycans of m/z = 
1663.56 (Hex5HexNAc4) and m/z = 1850.65 (Hex4dHex1HexNAc5) are shown in Figure 24b-c. 
A higher resolution tissue imaging analysis was done for selected regions as marked in the panel, 
with the H&E images (Figure 24d-f) highlighting stroma and gland substructures. In both 
instances, m/z = 1850.65 is present in both the stroma and glands, while m/z = 1663.56 is 
predominantly located in the stroma. An overlay of these two ions depicts the stroma as an orange 
color, demonstrating the presence of both red and green, while the glands are predominantly 
green. The distribution of other representative individual glycan ions is provided in Figure 25, 
including the distribution of high-mannose glycan species (Man5-Man9) associated with the 
heterogeneous tumor region in this tissue.  
3.3.4.2 On-Tissue Glycan Fragmentation and Structural Composition 
 The glycan structures identified by imaging of the FFPE tissue blocks were assigned 
based on the comparison to permethylated species, glycan reference databases and previous 




Figure 24. MALDI-IMS of a Human Prostate FFPE Tissue Block. An archived FFPE block 
of prostate tissue from a human patient was cut at 5 µm and prepared for MALDI-IMS glycan 
analysis, (a). H&E image. A global glycan imaging experiment performed with a raster of 225 
µm demonstrated a heterogeneous expression of two glycan ions (b). at m/z = 1663.56 and (c). 
m/z = 1850.65. Stromal versus gland distribution were further assessed in a high resolution 
experiment at 50 µm raster (d–f). Column (d) indicates a 2× amplification of the H&E, and 
distribution of the same two glycans are shown at this magnification for m/z = 1663.56 (red) and 
m/z = 1850.65 (green), and an overlay image. Column (e) (enlargement of upper region shown in 
d). and (f) (enlargement of lower region shown in d), show two highlighted regions of stroma and 





Figure 25. N-Glycan Panel in Prostate Tissue. A representative image of 12 glycoforms in a 




collision-induced dissociation (CID) directly on the human pancreatic tissue. Released native 
glycans from pancreatic cancer FFPE tissues were used as a source for on-tissue CID analysis, 
and a representative MALDI spectra of these glycans is shown in Figure 26a. For comparison, a 
Hex5HexNAc4 (m/z = 1663.6) purified standard (also termed NA2) was spotted on a stainless 
steel MALDI target plate and fragmented by CID, generating a robust fragmentation pattern of 
glycans for this ion as previously reported by Harvey et al (247). The same glycan ion was 
abundant in pancreatic tissue after PNGaseF release of N-glycans (Figure 27) and was selected 
for CID. As shown in Figure 5b, the CID fragmentation pattern of m/z 1663.6 in pancreatic tissue 
was the same as the N-glycan standard, confirming detection of NA2 directly in pancreatic tissue 
(Figure 27). Mass shifts due to loss of individual sugar ions were detected, such as Hex (resulting 
in m/z = 1502.5), HexNAc (resulting in m/z 1460.5), and Hex + HexNAc (resulting in m/z = 
1298.5) (Figure 26). An ion at m/z = 712.2, which has been previously characterized as the 
sodium adduct of Hex3HexNAc1, was also detected (247). The structures of 13 other glycan ions 
were confirmed using this CID approach, and additional fragmentation data and spectra are 
provided in Figure 26.  
3.3.4.3 Glycan MALDI-IMS of a Hepatocellular Carcinoma Tissue Microarray 
 The ability to perform N-glycan analysis on FFPE tissues potentially enables the analysis 
of multiple FFPE tissue cores in a TMA format. Initial experiments were performed using a 
commercially available hepatocellular carcinoma (HCC) TMA (BioChain) consisting of samples 
from 16 individual patients, with two tumor tissue cores and one non-tumor tissue core per patient 
(Figure 28). Additional patient data are provided in Sup Sheet 4. Glycan MALDI-IMS was done 
as described for the other FFPE tissues, and imaging data for two representative glycan ions at 
m/z = 2393.92 (Hex7HexNAc6) and m/z = 1743.62 (Hex8HexNAc2) are shown in Figure 28. 
Analysis of the cumulative MALDI spectra and detected ions for each tissue core were processed 





Figure 26. CID of N-Glycans from Human Pancreas Tissue. Representative CID spectra from 




Figure 27. Comparison of the Fragmentation Pattern of a Glycan Standard with the same 
Ion on Tissue. (a). A representative MALDI spectra for native N-linked glycans from pancreatic 
cancer FFPE tissue. (b). NA2 glycan standard (m/z = 1663.6) was fragmented using CID, 
revealing a variety of cleavages across glycosidic bonds as demonstrated in the spectrum (a). 
When the same ion was fragmented on the pancreatic tissue, the fragmentation pattern was the 




Figure 28. N-Glycan Imaging of a Liver TMA. A liver TMA purchased by BioChain consisting 
of 2 tumor tissue cores and one normal tissue core from 16 patients was imaged (200 µm raster). 
The H&E (a) provides the TMA location (red letters and numbers) and classifies whether the row 
is tumor (green bar) or non-tumor (red bar). M/z = 2393.95 (c) and m/z 1743.64 (d) were able to 
distinguish between hepatocellular carcinoma and uninvolved liver tissue. An overlay of these ion 
demonstrates that m/z = 2393.95 is elevated in tumor tissue and m/z = 1743.64 is elevated in 
normal tissue (b).  
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analysis. Of the 176 identified ions from the HCC TMA, 132 were increased in tumor cores, and 
83 ions had a p-value <0.05. Interestingly 78 (94%) of the significantly different ions were 
elevated in tumor cores. After cross-referencing this list of 176 ions with glycans presented in this 
paper and our previous study, 26 N-glycans of high-confidence structure determinations were 
selected, listed in Table 2 (431). Of these 26 known glycans, ion intensities of 13 species were 
significantly different in tumor and normal tissue (p<0.05), and 21 were increased in tumor 
relative to normal. FlexImaging was then used to demonstrate the distribution and relative ion 
intensities of each glycan across the TMA (Figure 29). Additionally, ROC curves were used to 
evaluate how well each of the glycan ion intensities discriminates tumor versus non-tumor.  Of 
the 176 identified ions, 61 had area under the ROC curve (AuROC) >0.80, indicating they are 
strong classifiers. For two glycans at m/z = 2393.95 (Hex7HexNAc6) and m/z = 1743.64 
(Hex8HexNAc2), both had an AuROC > 0.80 and a p-value < 0.05, with m/z 2393.95 being 
elevated in tumor tissue and m/z 1743.64 being elevated in non-tumor tissue, as demonstrated by 
the log2-fold change value (tumor/non-tumor) (Figure 28). In the overlay (Figure 28b), tumor 
tissue is predominantly green and non-tumor tissue is predominantly red, confirming results from 
our statistical analysis. This data, although from limited numbers of samples, demonstrates the 
potential ability of a panel of glycans to be used to accurately discriminate cell types or outcomes 
on a TMA by MALDI-IMS. 
3.3.5 Discussion 
 Multiple N-linked glycans can be directly profiled from FFPE tissue blocks and TMAs 
while maintaining intact architecture. The basic methodology, which mirrors that of MALDI-IMS 
analysis of peptides in FFPE tissues and TMAs, requires deparaffinization and antigen retrieval 
prior to PNGaseF application (144,429,430). The ability to adapt the N-glycan imaging method 
originally designed for fresh/frozen tissues to encompass FFPE tissue and TMA blocks increases 
the scope and speed of glycan-based studies that can be performed in tissues (431). In initial  
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Table 2. Comparison of Tumor and Non-Tumor Glycans Detected in Hepatocellular 






Figure 29   
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studies of formalin-fixed mouse kidney slices, the MALDI-IMS workflow successfully identified 
all 28 of the glycans in the mouse kidney database provided by the Consortium for Functional 
Glycomics. Many of the structures of these glycans were verified by permethylation (Figure 21) 
and CID experiments (Figure 26). As observed with the mouse brain, these glycans were not 
homogenously present across the entire mouse kidney slice, but were either predominantly 
located in the cortex, or distributed across the cortex and medulla (Figure 20) (431). This unique 
distribution of N-glycans associated with tissue sub-structure or disease status was also observed 
in human pancreas and prostate tissue slices. In the pancreas, an overlay of four different glycans 
was able to map the normal pancreas tissue, tumor pancreas tissue, a region of desmoplasia, and a 
necrotic region (Figure 23a). Similarly, an overlay of two glycans could distinguish between 
prostate stroma and glands (Figure 24).   
 In general, the peak intensities of PNGaseF-released glycans in the FFPE tissues seems to 
be more intense than that obtained with fresh/frozen tissue sections. This may be a result of the 
more extensive heating and washing steps required in the deparaffinization and rehydration steps. 
It is this increased detection sensitivity that facilitated CID fragmentation of N-glycans directly 
from the tissue (Figure 26, Figure 27b). Under the conditions used, CID generated mainly 
fragments across the glycosidic bonds, which were useful in characterizing that the structure was 
an intact hexose or HexNAc. This did not provide any information regarding anomeric linkages 
between sugar residues. The amount of fragmentation observed was directly related to the relative 
intensity of each parent N-glycan ion, and inversely related to the mass of the parent ion 
observed. This is typified by the extensive fragmentation of two glycans of m/z = 1663.50 and 
m/z = 1809.64 Figure 26, Figure 27b).  
 One drawback to using FFPE tissues is residual polymer from the paraffin block adjacent 
to the tissue. Detection of this polymer is more predominant in the lower mass range of the 
imaging runs, and can overlap with potential glycan masses, complicating detection and further 
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statistical analysis. This polymer can be observed in the average spectra of the mouse kidney 
tissue after PNGase application (Figure 19a) from m/z = 1250-1300, 1450-1500, and 1650-1700. 
An additional key to distinguishing polymer peaks is the analysis of spectra from the non-
PNGaseF treated control tissues. Particularly for the TMA format, the ion selection program that 
we report can detect and account for polymer peaks relative to glycan ions. These polymer peaks 
seem to vary in terms of intensity compared to N-glycan ions depending on what tissue is being 
used. It is possible that this variation is a function of different formalin formulations, variations is 
tissue processing (i.e. amount of time in formalin), storage time or variations in the tissue itself 
(419,420). These considerations will be further monitored and evaluated as more glycans from 
FFPE tissues are analyzed. 
 In relation to potential cancer diagnostic applications, the most significant aspect to 
developing a method to image N-glycans on FFPE tissue blocks could be the ability to use TMAs 
for high-throughput glycan-based experiments. Not only does the method increase the number of 
tumor samples that can be analyzed in one experiment, but it could also be used to compare the 
glycans detected in a TMA core versus the larger source FFPE tissue. N-glycan MALDI-IMS of 
the HCC TMA (Figure 28) is provided as an example, but we have already obtained initial glycan 
profiling data from TMAs representing prostate, kidney, lung, breast, colon and pancreatic 
cancers. In the HCC TMA, a statistically significant increase in tetra-antennary N-glycan (m/z = 
2393.95) and decrease in Man-8 glycan (m/z = 1743.64) was detected in HCC cores compared to 
adjacent non-tumor tissue (Figure 28 and Table 2). The tetraantennary N-glycan has been 
previously demonstrated to be elevated in HCC compared to matched adjacent non-tumor tissue 
by Mehta et al. (434). Continued investigations will be performed on whether these two ions can 
distinguish between matched HCC and non-tumor tissues in other HCC TMAs. Our data analysis 
identified a total of 176 ions in the tissue, with the majority of significantly different ions being 
increased in HCC relative to non-tumor tissue, including 21 known or previously identified 
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glycans. It is unclear how this trend of increased glycan levels relates specifically to tumor related 
biochemical changes, though the role of glycosylation in tumor development is well documented. 
Future work will also focus on determining the identity of the remaining ions to distinguish other 
glycan species from the aforementioned polymer peak contaminants.  
 Currently, MALDI-IMS provides a new approach to effectively visualize and evaluate N-
glycan localization in tissue sections. It does not solve the known limitations of MALDI analysis 
of underivatized glycans like loss of sialic acids, nor does it provide anomeric linkage 
information for N-glycan structure. Established tandem mass spectrometry methods of glycan 
extraction, modification and fragmentation are more capable of providing this structural 
information. Combining the glycan tissue maps generated by MALDI-IMS to target regions of 
interest for further tandem mass spectrometry analysis of glycans could be a new synergistic 
approach to more effectively identify tumor-associated glycans and glycoproteins in situ. Use of  
other glycosidases like sialidase, as we have previously reported, or fucosidases, could further 
extend the utility of the combined methods (431).  Overall, the ability to effectively profile N-
glycans on FFPE tissue blocks and TMAs provides new opportunities to evaluate glycan profiles 




3.4 Disease-Related Applications of and Limitations of MALDI-IMS  
3.4.1 Introduction 
 Hepatocellular carcinoma (HCC), a subtype of liver cancer that accounts for 
approximately two-thirds of all liver cancers, is among the most common and aggressive 
malignancies worldwide (435). As incidence rates continue to rise, early detection disease 
biomarkers are highly sought after and offer the potential to drastically improve patient 
outcome(436–439). Both proteomic and glycomic approaches have led to significant advances in 
HCC biomarker research. Proteomic analysis has identified several tumor pathways that are 
altered in HCC (440–443). Additionally, glycoproteins such as peroxiredoxin 3, osteopontin, and 
alpha fetoprotein (AFP) have been identified as potential HCC biomarkers (444–448). However, 
these proteins display limited sensitivity in the background of liver cirrhosis or benign diseases. 
More recently, it was observed that α1,6 core fucosylated AFP offers improved specificity for 
HCC than AFP alone (350,449,450). Thus, core fucosylated AFP, assessed through the AFP-L3 
test, is the only test approved by the United States Food and Drug Administration for the 
detection of hepatocellular carcinoma. Elevated levels of core fucosylation are not specific for 
AFP, but are also observed on transferrin and alpha-1-antitrypsin among other proteins (451–
455). Total serum glycomic studies have also identified increases in core α1,6-linked and α1,3-
linked outer-arm fucosylation, N-glycan branching, and sialylation in HCC samples 
(219,434,456,457).  
 As nearly all current cancer biomarkers are glycoproteins or carbohydrate antigens, and 
as highlighted for HCC, a global analysis of N-glycans from HCC tissue sections using MALDI-
imaging mass spectrometry (IMS) could extend and complement the continued development of 
N-glycan biomarkers associated with HCC (416,458). We have recently developed a MALDI-
IMS approach for profiling N-glycans directly in frozen and formalin-fixed paraffin-embedded 
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(FFPE) tissues (431,459). The method relies on the spraying of a molecular coating of PNGaseF 
and on-tissue cleavage of N-glycans prior to matrix application. Relative to other classes of 
biomolecules targeted by MALDI-IMS, the method offers ready identification of the individual 
glycan species and creation of structural reference databases (459). In this report, the utility of the 
method is demonstrated for profiling multiple N-glycans using different FFPE tissue slices of 
HCC. Current data analysis approaches are also summarized, as well as use of a novel 
derivatization method to stabilize sialic acids in a linkage-dependent/differentiating manner, and 
therefore better characterize larger, sialic acid containing N-glycans (237). As the methodology is 
still evolving, areas to improve glycan detection by MALDI-IMS and structural characterization 
are discussed.  
3.4.2 Materials and Methods 
3.4.2.1 Materials 
 Trifluoroacetic acid, α-cyano-4-hydroxycinnamic acid (CHCA), sodium hydroxide 
(NaOH), 1-hydroxybenzotriazole hydrate (HOBt), and trypsin were obtained from Sigma-Aldrich 
(St. Louis, MO). Ammonium bicarbonate, HPLC grade methanol, ethanol, acetonitrile, xylene 
and water were obtained from Fisher Scientific (Pittsburgh, PA). 1-(3-Dimethylaminopropyl)-3-
ethylcarbodiimide hydrochloride (EDC) was obtained from Oakwood Chemical (West Columbia, 
SC). ITO slides were purchased from Bruker Daltonics (Billerica, MA) and Tissue Tack 
microscope slides were purchased from Polysciences, Inc (Warrington, PA). Citraconic anhydride 
for antigen retrieval was from Thermo Scientific (Bellefonte, PA). Recombinant Peptide N-
Glycosidase F (PNGaseF) from Flavobacterium meningosepticum was expressed and purified as 
previously described (431), and is available commercially as PNGase F Prime™ from Bulldog 
Bio (Portsmouth, NH). 
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3.4.2.2 FFPE Tissues 
 All but one tissue sections used in this study were de-identified and obtained 
commercially from BioChain. These include a slide with two FFPE tissue sections from a 60 year 
old female with a poorly differentiated hepatocellular carcinoma; patient matched tumor and 
normal FFPE tissue sections from a 53 year old male with hepatocellular carcinoma, and a patient 
matched renal cell carcinoma tumor and lymph node tissue with renal cell carcinoma metastasis 
from a 28 year old female. A subset of a commercially available renal tissue microarray (TMA) 
from BioChain was also analyzed, where two cores from each patient (oriented vertically) were 
present. One de-identified pancreas tissue was obtained by MUSC and was determined to be not 
human research classifications by the respective Institutional Review Boards at MUSC.  
3.4.2.3 Washes for Deparaffinization and Rehydration 
 Slide preparation proceeded as described in our previous paper (459). Briefly, FFPE 
tissue sections not acquired precut from BioChain, were sectioned at 5μm and mounted on slides 
compatible with the Bruker slide adaptor. All slides were heated at 60°C for 1hr to ensure tissue 
adhesion to the slide. After cooling, the slide was deparaffinized by washing with xylene and 
rehydrated in a series of ethanol and water washes. Citraconic anhydride (Thermo) was used as 
the antigen retrieval buffer and the retrieval process took place over 25 minutes in a vegetable 
steamer. After allowing the buffer to cool, the buffer was gradually exchanged to 100% water. 
The slide was then desiccated to dryness prior to enzymatic digestion.  
3.4.2.4 MALDI Imaging Workflow 
 An ImagePrep spray station (Bruker Daltonics) was used to coat the slide with a 0.2mL 
aqueous solution of PNGaseF (20µg total/slide) as previously described (431). As a negative 
control, adjacent control tissue slices were shielded from PNGaseF application by covering the 
tissue section with a glass slide. Digestion occurred in a humidified chamber at 37°C for 2hr. 
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Slides were desiccated prior to α-cyano-4-hydroxycinnamic acid matrix application (0.021g 
CHCA in 3mL 50% acetonitrile/50% water and 12µL 25% TFA) using the ImagePrep sprayer. 
Released glycan ions were detected using a SolariX dual source 7T FTICR mass spectrometer 
(Bruker Daltonics) (m/z 690-5000) with a SmartBeam II laser operating at 1000 Hz, a laser spot 
size of 25μm. Following MS analysis, data was loaded into FlexImaging Software focusing on 
the range m/z = 1000-4000 and reduced to 0.95 ICR Reduction Noise Threshold. FlexImaging 4.0 
(Bruker Daltonics) was used to generate images of differentially expressed glycans. Observed 
glycans were searched against the glycan database generated using GlycoWorkbench (432). 
Presented glycan structures were generated in GlycoWorkbench and represent putative structures 
determined by combinations of accurate m/z and off-slide derivatization experiments. 
3.4.2.5 Ethyl Esterification 
N-glycans were extracted from slides as described previously and dried by vacuum 
centrifugation (431,459). The ethyl esterification protocol, including the modification and 
enrichment, was adapted from Reiding et al. (237). Briefly, 2µL water and 40µL 0.25M 
HOBt/EDC were added to dried glycans followed by incubation at 37°C for 1hr. 40µL 
acetonitrile was added and the mixture was placed at -20°C for 20 minutes. Glycans were 
enriched using cotton-HILIC tips according to Selman et al. Shortly, cotton wool composed of 
100% cotton (Assured, Rio Ranch, NM) was inserted in 20µL tips and equilibrated with 10µL 
water three times followed by 10µL 85% ACN three times. Samples were loaded and unbound 
material removed by washing three times with 10µL 85% acetonitrile with and without 1% TFA, 
respectively. Tip-bound glycans were eluted in 10µL water. Enriched and modified glycans were 
spotted on an Anchorchip MALDI plate (Bruker Daltonics) with 2,5-dihydroxybenzoic acid 
(DHB) at a concentration of 5mg/mL in 50% ACN/50% water/1mM NaOH. Ethanol was then 




3.4.3.1 Influence of Histopathology on MALDI-IMS of N-glycans 
 Initial MALDI-IMS of a commercially available FFPE HCC tissue of complex 
histopathology demonstrated the specific release of N-glycans following PNGaseF digestion and 
the ability of released glycans to distinguish tissue subtypes and pathologies. Two serial sections 
were prepared identically with the exception that one tissue received PNGaseF while the other 
was shielded from enzyme application to serve as a negative control. Average spectra of each 
tissue region were obtained from FlexImaging and revealed a robust signal increase following 
PNGaseF digestion (Figure 30a) compared to the control tissue (Figure 30b). Putative glycan 
structures were annotated using GlycoWorkbench based on mass accuracy and previous studies, 
but no information is available regarding specific anomeric linkages (431,459). All glycan 
structures reported herein are the [M + Na]+ adducts unless otherwise noted. Peaks corresponding 
to three glycans, Hex5HexNAc4NeuAc1 (m/z = 2100.759, blue), Hex5HexNAc4 (m/z = 
1663.582, red) and Hex9HexNAc2 (m/z = 1905.612, green) are displayed in an overlay image 
(Figure 30c). These glycans map to the tissue histopathology marked on the H&E stain (Figure 
30d). Analysis of the H&E stain revealed three predominant tissue morphologies; necrosis 
(outlined in red), HCC tissue (outlined in green) and fibroconnective tissue (outlined in blue). 
Images of individual N-glycans demonstrate the propensity of glycans to be elevated in one tissue 
type (Figure 34). Interestingly, high-mannose glycans were elevated in the tumor tissue, while 
fucosylated or sialylated/fucosylated complex biantennary glycans were elevated in the 
fibroconnective tissue. 
 While the initial experiment demonstrated the ability of N-glycan localization to define 
pathology in HCC tissue blocks, the ability to distinguish tumor vs. normal tissue is of more 




Figure 30. PNGaseF Releases N-linked Glycans from HCC Tissue in a Spatially Defined 
Manner. A HCC tissue slide (Biochain) containing two serial slices of HCC tissue was prepared 
from MALDI-IMS as described above. One section was shielded from enzyme application to 
serve as a negative control. Robust signal correlating to released N-linked glycans was observed 
in the average spectra of the tissue receiving PNGaseF application (a). Similar signatures were 
not observed in the control tissue (b). Three select ions were selected in FlexImaging and 
displayed as an overlay image. Hex5HexNAc4NeuAc (m/z = 2100.7, blue), Hex5HexNAc4 (m/z 
= 1663.6, red) and Hex9HexNAc2 (m/z = 1905.6, green) each display unique localization within 
the tissue slice (c). Upon histological analysis of an H&E stain (d), these regions were identified 




Figure 31. Diverse Organs with Similar Properties Display Conserved Glycan Patterns. 
Fibrous tissue from three diverse tissue types were imaged and displayed similar N-glycosylation 
properties. Images from lymph tissue with a ccRCC metastasis (a), pancreatic cancer tissue with 
complex histopathology (b), and liver tissue with complex histopathology (c) are provided. In 
each tissue, the ions corresponding to Hex5HexNAc4, Hex5dHex1HexNAc4, and 
Hex5dHex1HexNAc4NeuAc1 display similar localization patterns with each being elevated in 
the fibrous tissue regions. Hex5HexNAc4 and Hex5dHex1HexNAc4 are represented by the 
sodium adduct of the native glycan, while Hex5dHex1HexNAc4NeuAc1 is represented as a 
doubly sodiated adduct of the native glycan. Fibroconnective tissue regions are outlined in black 




revealed overall glycan heterogeneity between the two tissues. While Hex8HexNAc2 (m/z = 
1743.565, red) is present in both the normal and tumor sections, Hex7HexNAc6 (m/z = 2393.854, 
green) is largely absent in the normal tissue (Figure 32a,b). This observation is evident in the 
image overlay, where the normal tissue image is red in color due to the presence of 
Hex8HexNAc2 and the absence of Hex7HexNAc6, while the tumor tissue is yellow due to the 
presence of both Hex7HexNAc6 and Hex8HexNAc2 (Figure 32c). This finding is consistent with 
our previous studies made in the analysis of an HCC TMA (459). Interestingly, while 
Hex8HexNAc2 is present in both the matched tumor and normal tissues and is elevated in the 
normal HCC tissue, it is elevated in the tumor tissue compared to necrotic and fibroconnective 
tissue regions (Figure 30, Figure 34). This trend emphasizes the importance of histological 
analysis when utilizing MALDI-IMS as a technique. 
3.4.3.2 Similarities of Glycan Distribution Across Tissue Types. 
The distribution of N-glycans in different fibroconnective tissues from other sources 
besides HCC tissues was further assessed. Lymph tissue with a clear cell renal cell carcinoma 
(ccRCC) metastasis (Figure 31a), pancreatic cancer and adjacent normal tissue (Figure 31b), and 
the hepatocellular carcinoma tissue presented earlier (Figure 31c), all with regions of fibrous 
and/or fibroconnective tissue, were analyzed by MALDI-IMS for N-glycans. The regions of 
fibroconnective tissue (outlined in black) and fibrous tumor tissue (outlined in red) are defined on 
the H&E image for each tissue (Figure 31). In each tissue, three biantennary N-glycans were 
commonly detected at higher levels in the fibrous/ fibroconnective tissue compared to adjacent 
regions: Hex5HexNAc4 (m/z = 1663.582), Hex5dHex1HexNAc4 (m/z = 1809.661), and 
Hex5dHex1HexNAc4NeuAc1 (m/z = 2122.720; [M - H + 2Na]+). In all tissues, the 
Hex5dHex1HexNAc4NeuAc1 glycan had the highest specificity for fibrous tissue regions. The 





Figure 32. MALDI-IMS Reveals N-glycans that can Distinguish Tumor from Normal in 
Matched HCC Tissue Samples. Matched HCC tumor and normal tissue (biochain) were 
analyzed by MALDI-IMS after PNGaseF release of N-glycans. M/z = 1743.56 (Hex8HexNAc2) 
was present in both tissues (a), while m/z = 2393.85 (Hex7HexNAc6) was primarily in the tumor 
tissue only (b). An overview of these two glycan species where m/z = 1743.56  is displayed in red 
and m/z = 2393.85 is displayed in green confirms this finding. In the overlay, the normal tissue is 
primarily red but the tumor tissue is yellow in color as a result of both glycan species being 




have also noticed that this glycan is likely a marker of tissue regions where blood is present, 
illustrated in Figure 31b.  
3.4.3.3 Validation of N-Glycan Structures by Off-Tissue Glycomic Analysis 
  MALDI ionization of glycans often results in the loss of labile sialic acids from glycans. 
We performed a recently introduced glycan modification approach, termed ethyl esterification, to 
assess whether the loss of sialic acids is occurring in MALDI-IMS experiments. This procedure 
results in lactonization of α2,3-linked sialic acids and ethyl esterification of α2,6-linked sialic 
acids, resulting in a 46.04 Da mass shift (237). Following ethyl esterification of glycans, glycans 
are enriched using cotton-HILIC tips. Glycans from a HCC tissue were retrieved from the tissue, 
subjected to the ethyl esterification protocol, and spotted on an anchorchip MALDI plate. An 
annotated spectrum is provided (Figure 33). A list of 33 representative N-glycans present in the 
MALDI-IMS and/or ethyl esterification experiments, as well as the glycans theoretical m/z value 
is provided in Table 3. The results demonstrate a close overlap of observed m/z values for both 
approaches with theoretical m/z values obtained from GlycoWorkbench. Additionally, a majority 
of N-glycans were present in both the MALDI-IMS and off-tissue ethyl esterification 
experiments. However, when comparing the ethyl esterification average spectrum (Figure 33) 
with the MALDI-IMS average spectrum (Figure 30a), it is evident that complex and sialylated N-
glycans are more predominant after ethyl esterification than in MALDI-IMS: an example being 
Hex5HexNAc4NeuAc1 which has the highest signal intensity in the ethyl esterification spectrum 
(m/z = 1936.692 & m/z = 1982.733), but is only detected as minor peaks in the imaging average 
spectrum (m/z = 1954.589 & m/z = 1976.707). This result may be attributed to a reduction in 
signal intensity of sialylated N-glycans in MALDI-IMS due to the loss of sialic acid upon in-
source decay, reflected in the comparatively higher level of detection of Hex5HexNAc4 (m/z = 
1663.582) in the MALDI-IMS average spectrum.  
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Figure 34. N-glycans Can Distinguish Complex Histopathology in HCC Tissue. N-glycan 
distribution mapped to specific histological regions in an HCC tissue. High mannose N-glycans 
were more abundant in the HCC tissue regions, while complex and hybrid N-glycans were more 
abundant in the necrotic and fibrous tissue regions.   
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3.4.3.4 Glycosylation can Distinguish Cancer Subtypes 
The ability of N-glycans to distinguish tissue subtypes and pathologies does not only 
pertain to HCC. A higher-throughput, TMA-based imaging experiment was performed to 
characterize and compare a large number of renal cancer samples in a single experiment. In the 
data provided, the classification of each set of tissue cores is outlined by a specified color. 
Examples of normal cortex (blue), normal medulla (purple), clear cell carcinoma (green), 
transitional cell carcinoma (red), chromophobe renal cell carcinoma (yellow), granular cell 
carcinoma (light blue), and carcinosarcoma tissue cores (white) are represented in the TMA. 
Hex5dHex2HexNAc5 (m/z = 2158.918) was elevated in all six normal cortex tissue cores (Figure 
35a), while Hex5dHex1HexNAc4 (m/z = 1809.705) was consistently elevated in the normal 
medulla cores (Figure 35b). An overlay of Hex5dHex2HexNAc5 (blue) and 
Hex5dHex1HexNAc4 (purple), is capable of distinguishing normal kidney anatomy (Figure 35f). 
The expression of other N-glycans varied across tumor tissue cores with various specificity. In 
comparison to all other tissue subtypes, Hex5dHex2HexNAc4 (m/z = 1955.748) was elevated the 
most in clear cell carcinoma tissues (Figure 35d), while Hex7HexNAc2 (m/z = 1581.569) was 
most abundant in the granular cell carcinoma example (Figure 35c). In an overlay of 
Hex5dHex2HexNAc5 (blue), Hex5dHex1HexNAc4 (purple), and Hex5dHex2HexNAc4 (green), 
the clear cell carcinoma tissue cores are distinguished from the normal cortex and medulla cores 
(Figure 35g). Finally, there is an enormous degree of heterogeneity across the tumor cores, an 
example being Hex5HexNAc4 (m/z = 1663.570) which is much more abundant in two of the 
clear cell carcinoma cores in comparison to the rest of the clear cell carcinoma cores (Figure 35e). 
The glycans selected for display are representative of a larger population of N-glycans that were 
observed in the experiment. Interestingly, N-glycans in the transitional cell carcinoma were 




Figure 35. Aberrant Glycosylation in RCC TMA can Distinguish Cancer Subtypes. A RCC 
TMA was processed by MALDI imaging and revealed individual glycans or multiple glycans that 
offer diagnostic potential for disease or cancer subtypes. Hex5HexNAc5dHex2 is elevated in the 
normal cortex compared to all other tissue types (a), while Hex5HexNAc4dHex1 is more 
abundant in the normal medulla (b). Man7 was elevated in granual cell carcinoma (c) while 
Hex5HexNAc4dHex2 (d) and Hex5HexNAc4 (e) were elevated in the clear cell carcinoma cores. 




 Profiling of N-glycans in fresh/frozen tissues, FFPE tissue blocks and TMAs is a new 
application of MALDI-IMS methodology that has the potential to identify systemic disease 
markers and elucidate disease etiology. This methodology is particularly relevant for cancer 
tissues, as most known cancer biomarkers are glycoproteins or carbohydrate antigens, including 
AFP for HCC (219,434,451–457). The MALDI-IMS glycan profiling data presented herein, 
although from only a limited number of HCC tissues, illustrates this potential. Compared to other 
biomolecules targeted by MALDI-IMS like lipids, metabolites and proteins/peptides, N-glycans 
offer a particular advantage in that there are relatively fewer total glycan ion signals that are 
detected in a given tissue. Assigning the underlying composition for each glycan is rather 
straight-forward on the basis of accurate masses, albeit anomeric linkages are not differentiated. 
In addition to mass accuracy, glycan compositions can be validated by a variety of approaches, 
such as CID and derivatization. Structural standards and several glycan reference databases are 
available (407,459).    
 Knowing the identity of the glycan offers many other opportunities for application to cell 
biology and genomic studies, particularly as these structures are synthesized by specific 
glycosyltransferases, and modified by specific glycosidases. This facilitates comparative analysis 
of genomic data for these enzymes from the same tissues. Knowing the glycan composition also 
allows inference of different cell biology aspects related to biosynthesis, vesicular trafficking or 
degradation processes involving N-glycans. We have found across multiple tumor types, and 
illustrated herein, that identifying a specific tumor glycan profile in tissues is fairly 
straightforward (459). Herein, this principle has been further expanded as consistent glycan 
signatures for fibroconnective tissue have been observed across cancer types (Figure 31). We are 
further testing whether detecting changes in glycan profiles can be used as surrogate indicators of 
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changes in glycoprotein expression associated with cancer development and progression, as well 
as responses to treatment. Current efforts are also directed at using the N-glycan profiles as a 
tissue map to identify disease-specific regions of interest for subsequent glycopeptide analysis 
strategies.  
There still remain many challenges associated with improving the approach, some of 
which were also highlighted herein. Detection of high mass N-glycans by MALDI mass 
spectrometry, particularly those glycans containing sialic acids, has always been a challenge as 
previously described (230,248,249). We are addressing these challenges in three ways, at the 
instrumentation level, with on-tissue analysis approaches, and with off-tissue analysis 
approaches. The source configuration of the SolariX 7T FTICR instrument used for these 
experiments is already inherently amenable to better detection of sialic acid glycans. Compared to 
most MALDI-TOF instruments (non-FTICR), less vacuum and a cooling gas following laser 
desorption/ionization is present. This combination has been reported to aid in the retention of 
sialic acids on glycoconjugates. The ability to selectively capture specific glycan ions directly 
from tissue for CID is also an advantage of the SolariX instrument (459).  Comparison of N-
glycan profiles of the same tissue slides in different MALDI-TOF instruments is ongoing, with 
emphasis on how detection of sialic acid containing glycans differ across instrument 
configurations. In this context, different MALDI matrix formulations are also being tested and 
compared. These are all cumulatively being assessed in the optimization for detection of higher 
mass glycan species.  
Based on mass accuracy of standards and derivatization experiments, we show that while 
sialylated N-glycans are detected in MALDI-IMS (Figure 30a), they appear to be of lower 
abundance than may be naturally occurring (Figure 33) (431,459). To correct for this limitation, 
different on-tissue and off-tissue derivatization approaches of the N-glycans are being 
investigated. Attempts to globally modify N-glycan reducing ends (i.e. 3-aminoquinoline) or 
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specifically modifying labile sialic acid residues (i.e. p-toluidine or ethyl esterification) represent 
potential solutions (235,237). We believe that some modification of the above off-tissue 
derivation approaches used for N-glycans could be adapted to an on-tissue MALDI-IMS profiling 
workflow. Additionally, performing MALDI-IMS in negative ion mode offers another reasonable 
option for partially retaining sialic acids of N-glycans (247).  
Given the ability to use FFPE tissues as the primary source for N-glycan imaging and 
their general availability, there is a potential to leverage this approach to discover glycan 
biomarkers of HCC and other cancer types. To facilitate biomarker discovery, the described 
techniques must be used with large numbers of tissue samples on sample slides or in tissue 
microarray format, highlighting the need for an accurate method to directly compare between 
samples/experiments. In the example provided within, N-glycan signatures were capable of 
distinguishing both tumor from non-tumor tissue cores, but also between tumor subtypes (Figure 
35). To determine the significance of these glycans, a similar study involving an increased 
number of tissue cores is required. Ongoing research is directed at determining best practices for 
data normalization and incorporating internal standards into experimental workflows. These 
issues are common to all MALDI-IMS experiments (460,461). One apparent solution is to utilize 
a biologically unique glycan as an internal standard that can serve dual purpose to calibrate in the 
appropriate mass range as well as serve to normalize signal between samples/experiments. By 
incorporating such an internal standard into the matrix spray, it would allow to correct for 
differences in matrix deposition, tissue ionization, as well as changes in signal intensity across 
experiments. Likewise an approach using informative peaks may be the most appropriate method. 
Only after large enough data sets are generated will we be able to determine the best approach to 
analyze these larger sample sets. Use of TMAs for glycan MALDI-IMS can certainly facilitate 
the increase in sample numbers (459). 
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In conclusion, the profiling of N-glycans offers many new avenues of research that can 
be initiated by, and complemented with, MALDI-IMS strategies. Challenges and limitations of 
the approach are evident, but we believe most can be addressed moving forward as more samples 
are analyzed, new derivation and matrix strategies tested, and long-term, continued improvement 





Chapter 4: Application of Novel 
Glycomic Approaches to Identify 




 Pancreatic cancer represents one of the most deadly cancers, both in terms cancer related 
deaths per year and 5-year survival rates. The dismal 5-year survival rate following detection, 
which is around 6%, can be attributed to poor understanding of disease etiology, rapid disease 
progression, late diagnosis, limited effective treatment options, and resistance to therapeutic 
intervention (2). Patient outcome is significantly improved when the cancer is detected at an early 
stage and before it has spread to regional lymph nodes or metastasized to distant sites. This is 
largely because these patients are eligible for surgical resection, which represents the only 
curative treatment for pancreatic cancer (3,5,8). Unfortunately, it is estimated that only 9% of 
patients are diagnosed with localized pancreatic cancer (5). Therefore, efforts directed at the early 
diagnosis of pancreatic cancer and further understanding of biological pathways implicated in 
disease progression are extremely important.  
 An in-depth analysis of aberrant glycosylation, a hallmark of all cancers, offers the 
potential to advance the understanding of pancreatic cancer and identify new disease markers. 
Furthermore, glycoproteins and glycan antigens are ideal targets for initial discovery phase 
disease marker studies, as they [1] are prevalent in biological fluids, [2] play a direct role in 
cancer progression and metastasis, and [3] represent a majority of the protein-based FDA 
approved biomarkers. Both individual glycan antigens and alterations in the glycosylation 
biosynthetic machinery have been implicated in pancreatic cancer. The carbohydrate antigen 19-9 
(SLeA, CA19-9) is the most well defined disease marker for pancreatic cancer and the target of 
the only FDA approved blood test for the management of pancreatic cancer (332,333). 
Functionally, CA19-9 has been implicated in disease metastasis through the interaction of the 
antigen with endothelium E-selectin (337). However, CA19-9 is not used as a clinical disease 
marker for pancreatic cancer, as elevated levels are detected in benign diseases and other sites of 
cancer (341–343). Additionally, between 5-15% of the population do not express 
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fucosyltransferase 3 and are therefore incapable of expressing CA19-9, even with advanced 
pancreatic cancer (333,343). While elevated CA19-9 is the most pronounced glycosylation-
related change in pancreatic cancer, global alterations in glycosylation have been detected. At a 
fundamental level, the malignant processes resulting in the formation of pancreatic cancer involve 
several common mutations in oncogenes and tumor suppressors. These mutations ultimately 
affect the glycan biosynthesis pathway in pancreatic cancer. Constitutive KRAS activation 
increases the expression of GLUT1, HK1, HK2, PFK1 and LDHA, all of which impact 
glycosylation by directing glycolytic intermediates to the HBP (40,361). Similarly, the dense 
stroma and ECM accumulation surrounding pancreatic cancer results in a hypoxic 
microenvironment and initiates anaerobic glucose metabolism through glycolysis (354,355). The 
shift to glycolysis is accompanied by an upregulation of GLUT1, HK2, PFK1, PFK2, PKM2, 
GFPT1 and GFPT2 (354,462). Importantly, in vitro knockdown of GFPT1, a key modulator of 
entry into the HBP, exhibited the same reduction in tumor growth as the extinction of mutated 
KRAS, directly implicating glycosylation in tumor growth (40). In addition to enzymatic 
regulation of the hexosamine biosynthetic pathway, glycosyltransferases have been reported to be 
alternatively expressed in pancreatic cancer (336,463–465). Alterations in the hexosamine 
biosynthetic pathway and glycosyltransferase expression are apparent in global glycoform 
analysis, where increases in fucosylation, sialylation and glycan branching have been observed 
(343,373). However, the pancreatic cancer glycome has been analyzed on a relatively small 
subset of patients, often ignoring individual glycoforms in favor of structural motifs. 
 Recent analytical advances have improved the ability to monitor changes in the glycome 
in relation to cancer status. Traditional techniques characterized fluorescently labeled glycans 
based off of their retention time in chromatographic separations or by sequential enzymatic 
digestion (466). As chromatographic separation is required for each individual sample, this 
method is not ideal for high-throughput disease marker experiments. Other studies have utilized 
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mass spectrometers to characterize disease-related changes in glycan expression levels, although 
lengthy desalting and derivatization steps are frequently employed (467). When applied to the 
analysis of biological tissues, these methods result in a complete loss of glycan localization. As 
up to 90% of the tumor volume is occupied by surrounding stromal cells, this analysis may 
differentiate the non-diseased tissue from the stroma, as opposed to the tumor (24). Conversely, 
immunostaining with lectins or monoclonal antibodies directed at specific glycosylation 
structures or antigens can probe glycan localization within tissue sections, but does not target or 
identify individual glycoforms. To this end, our laboratory has introduced a novel approach to 
study specific N-linked glycan localization using MALDI-IMS on fresh frozen and FFPE tissue 
sections (431,459).  This technique has been further explored and validated by other laboratories 
(468,469). In addition to simply localizing and identifying N-glycans in tissue sections, we have 
recently demonstrated the potential of the method for the identification of individual glycans that 
discriminate tumor from non-tumor tissue specimen in a high-throughput TMA-based approach.  
 The present aim is an example of how MALDI-IMS of N-linked glycans can be adapted 
to the identification of disease markers for pancreatic cancer. In the aim herein, we report 
MALDI-IMS of N-glycans in TMAs and whole tissue blocks, followed by subsequent glycan 
characterization by mass accuracy and derivatization. As the spatial localization of N-glycans is 
retained during MALDI-IMS, analysis of tissue blocks can be further interrogated to look at 
glycosylation patterns in histological regions other than the tumor and non-tumor regions. Finally, 
N-glycan distribution was correlated with CA19-9 staining on serial slides, to determine any 
correlations between CA19-9 and released N-glycans. 
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4.2 Materials and Methods 
4.2.1 Materials  
 Trifluoroacetic acid, α-cyano-4-hydroxycinnamic acid (CHCA), sodium hydroxide 
(NaOH), and 1-hydroxybenzotriazole hydrate (HOBt) were obtained from Sigma-Aldrich (St. 
Louis, MO). HPLC grade methanol, ethanol, acetonitrile, xylene and water were obtained from 
Fisher Scientific (Pittsburgh, PA). 1-(3-Dimethylaminopropyl)-3-ethylcarbodiimide 
hydrochloride (EDC) was obtained from Oakwood Chemical (West Columbia, SC). Tissue Tack 
microscope slides were purchased from Polysciences, Inc (Warrington, PA). Citraconic anhydride 
for antigen retrieval was from Thermo Scientific (Bellefonte, PA). Recombinant Peptide N-
Glycosidase F (PNGaseF) from Flavobacterium meningosepticum was expressed and purified as 
previously described, and is available commercially as PNGase F Prime™ from Bulldog Bio 
(Portsmouth, NH) (431). Cotton tips for HILIC enrichment of N-glycans were produced using 
100% cotton swabs from Assured (Rio Ranch, NM). 
4.2.2 FFPE Tissues, TMAs, and Plasma 
 All human tissues and TMAs used were de-identified and determined to be not human 
research classifications by the respective Institutional Review Boards at MUSC. For each section 
analyzed, histological analysis and staining with hematoxylin and eosin (H&E) was performed 
and regions of diverse pathology were annotated by a pathologist. Plasma from patients with 
pancreatitis and PDAC were de-identified and determined to be not human research 
classifications by the respective Institutional Review Boards at MUSC. 
4.2.3 Sample Preparation for MALDI Imaging 
 Tissues and TMA blocks were sectioned at 5μm and mounted on slides (25 x 75mm) 
compatible with the Bruker slide adaptor. After mounting, sections were dewaxed and antigen 
retrieval proceeded as described in Section 3.3.3.3.  
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 PNGaseF (20μg/slide) was applied to slide-mounted tissue blocks and TMAs using the 
ImagePrep spray station (Bruker Daltonics) as previously described (459). N-glycan release 
occurred during a 2hr incubation at 37°C in a humidified chamber, followed by desiccation and 
matrix application. For the TMAs, α-Cyano-4-hydroxycinnamic acid matrix (CHCA), consisting 
of 0.021g CHCA in 3mL 50% acetonitrile/50% water and 12µL 25%TFA, was applied using the 
ImagePrep sprayer. The TM-Sprayer (HTX Imaging) was used to coat slides containing whole 
tissue blocks with CHCA. CHCA was prepared at a concentration of 5mg/mL in 50% ACN/50% 
H2O at .1% TFA. CHCA was applied at 70°C at .0017mg/mm2. 
4.2.4 Glycan Derivatization 
 N-glycans were extracted from slides as described previously and dried by vacuum 
centrifugation (431). The ethyl esterification protocol, including the modification and enrichment, 
was adapted from Reiding et al. (237). The protocol proceeded as described in Section 3.4.2.5. 
4.2.5 CA19-9 and SLeX Staining 
 Serial sections of five of the TMAs were stained with CA19-9 and SLeX. Individual 
cores were manually scored for the presence or absence of stain and annotated for the presence of 
tumor or non-tumor tissue. Sensitivity, specificity, positive predictive value and negative 
predictive value were calculated for both stains individually across the five TMAs.  
4.2.6 Data Processing 
 Imaging data was loaded into FlexImaging 4.1 (Bruker Daltonics) for visual analysis of 
tissue blocks and TMAs. TMAs were searched against an N-glycan library to identify N-glycans 
present across all six TMAs. For computational peak picking of the TMAs, Regions of Interest 
(ROIs) representing each tissue core were exported from data analysis using the hierarchical 
clustering option and further processed using an in-house workflow.  
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 To assess the mass accuracy of N-glycans, N-glycans present in all six TMAs were 
manually tabulated along with the accurate mass of the glycans. In addition to the accurate mass, 
m/z values were reported from the imaging peak picking tool as well as individual spectra from a 
tissue imaging experiment. To generate the m/z values from individual spectra, one spectra 
localized to the tumor tissue and one spectra localized to the non-tumor tissue were loaded into 
FTMS processing (Bruker Daltonics) and recalibrated. PPM errors were calculated for both the 
picked peaks and the individual spectra.  
4.2.7 Glycomic Analysis of Plasma Pools 
 Plasma from patients with pancreatitis and PDAC were pooled together for glycomic 
analysis. 10μL of plasma from each pool was diluted in 90μL H2O prior to digestion with 1μg 
PNGaseF overnight at 37°C. N-glycans were extracted from the sample following the addition of 
400μL MeOH, 100μL CHCl3, and 300μL H2O and centrifugation at 14,000 x g for 2 minutes. The 
aqueous phase was collected, dried by vacuum centrifugation, and ethyl esterified as described in 
Section 3.4.2.5. 
4.3 Results  
4.3.1 N-Glycan Variation in Complex Histopathology Regions 
FFPE tissue blocks containing both pancreatic cancer and matched non-cancer tissues, as 
well as other complex histopathology regions, were selected for N-glycome analysis by MALDI-
IMS. N-glycans in these tissue sections displayed patterns of regionalized distribution that 
correlated with histopathology analysis by H&E staining. In the example provided, the regions of 
the tissue section are outlined in different colors, with each color corresponding to a different 
histological region, as annotated by a pathologist (Figure 36a). These regions are pancreas tumor/ 
pre-cancerous lesions (green), intestine mucosa (yellow), fibroadipose connective tissue (blue), 




Figure 36. Heterogeneous Distribution of N-Glycans in Pancreatic Cancer Tissue Sections. 
A PDAC tissue section of complex histology was profiled by MALDI-IMS. In the H&E, tumor/ 
pre-cancerous lesions (green), intestine mucosa (yellow), fibroadipose connective tissue (blue), 
smooth muscle (orange), and non-tumor pancreas tissue (red) are all outlined. In the MALDI-IMS 
images, individual glycans correlate with defined histology regions. Hex6dHex1HexNAc5 (b, 
tumor), Hex5dHex3HexNAc5 (c, intestine mucosa), Hex5HexNAc4NeuAc1 (d, fibroadipose 
connective tissue), Hex4dHex1HexNAc4 (e, smooth muscle), and Hex6HexNAc2 (f, non-tumor 





Figure 37. Panel of N-Glycan Distribution in PDAC Tissue Section. Upwards of 90 ions 
corresponding to N-glycoforms were observed in an individual tissue section. In a representative 
panel of these glycoforms, many of these glycans exhibit a distribution pattern related to regions 




were either highly elevated or nearly exclusively detected in each region. Hex6dHex1HexNAc5 
(m/z = 2174.771) is elevated in the tumor region of the pancreas, which contrasts with 
Hex6HexNAc2 (m/z = 1419.476), which is elevated non-tumor pancreas (Figure 36b,f ).  
Similarly, Hex5HexNAc4NeuAc1 (m/z = 1976.677) and Hex4dHex1HexNAc4 (m/z = 1647.586) 
are elevated in the fibroadipose connective tissue and smooth muscle regions, respectively 
(Figure 36d-e). Unlike the other N-glycans above which are elevated in defined tissue regions but 
expressed at lower levels throughout the tissue section, Hex5dHex2HexNAc5 (m/z = 2304.834) 
is almost exclusively observed in the intestine mucosa (Figure 36c). Overall, close to 90 N-
glycans were identified in the tissue section that correspond to our glycan library, most having a 
distribution that correlates with a certain histology-derived region of the pancreas. The most 
abundant N-glycans are annotated in the overall average spectra from the imaging experiment 
(Figure 36g). A selected panel of N-glycans demonstrates the differential distribution of N-
glycans across the tissue section (Figure 37).  
4.3.2 Individual N-Glycan Discriminators for Pancreatic Cancer 
 As N-glycan distribution varies between tumor and non-tumor regions of the pancreas in 
whole tissue blocks, we wanted to determine if individual glycans were consistently altered 
between tumor and non-tumor tissue sections across different patients. To this end, a higher-
throughput study based on the analysis of six TMAs was performed to allow a larger number of 
samples to be surveyed in a reduced amount of time. Each TMA consisted of patient matched 
tumor and non-tumor tissue cores. Figure 38 provides a detailed workflow schematic of the data 
processing steps utilized to generate individual or panels of N-glycans that can distinguish tumor 
from non-tumor tissue cores. Initially, the data were loaded into an in-house peak picking 
algorithm, which identified 54 monoisotopic peaks present across all six TMAs. A total of 23 




Figure 38. Workflow Schematic for the Identification of Individual and Panels of N-Glycan 
Disease Markers. Six TMAs were imaged by MALDI-IMS to add an element of throughput to 
the disease marker discovery process. Many glycoforms were detected in all 6 of the TMAs and 
were selected for further analysis of individual discriminators and as panels of biomarkers. For 
panel identification, 2/3rds of the data was used to optimize the variables for an LDA model, 
while the remaining 1/3rd of the data was used to test the performance of the model.  
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expression level of the glycans was assessed by their p-value and Log2FC (Table 4). All N-
glycans were detected as the [M + Na]+ adduct, except for sialylated glycans which were 
observed as singly or doubly sodiated ions. Of the peaks corresponding to glycans, 17 were 
elevated in the tumor tissues at a statistically significant level (p ≤ .05), while none were elevated 
in the non-tumor cores at a statistically significant level. Initially peaks were characterized as N-
glycans by comparing the observed m/z values to a library of N-glycan structures, but peaks were 
further validated by glycan release and derivatization using ethyl esterification of sialic acids. For 
this approach, glycans were extracted from a tissue section, underwent derivatization and 
enrichment, and were spotted on a MALDI plate prior to analysis. Of the 23 peaks corresponding 
to N-glycans in the structural library, all 23 were observed in the glycan derivatization 
experiment (Sup Sheet 5). However, additional N-glycans were detected in the analysis following 
derivatization. The five N-glycans with the highest Log2FC values were all complex, fucosylated 
N-glycans, and all had a Log2FC ≥ 1.11. While the level of these glycans were significantly 
different between tumor and non-tumor (p ≤ .05), individual discriminators displayed poor 
sensitivity and specificity for distinguishing the conditions. For example, Hex7dHex1HexNAc7 
(m/z = 2742.983) (data not shown) was only elevated in a small subset of tumor tissues, while 
Hex6dHex1HexNAc5 (m/z = 2174.771) was elevated in a majority of tumor cores but also some 
non-tumor cores (Figure 39e). In representative images from five pancreas tissue blocks, 
Hex6dHex1HexNAc5 was primarily localized to the tumor tissue, but was frequently detected in 
regions not characterized as tumor tissue by a pathologist (Figure 39a). This general trend is 
reflected in the statistical data, in which Hex6dHex1HexNAc5 is elevated in the tumor over the 
non-tumor tissue cores, with a log2FC = 1.11 (Figure 39a). In contrast, m/z = 1419.476 
(Hex6HexNAc2) is more ubiquitously expressed throughout the tissue blocks (Figure 39b) and 
TMA (Figure 39f), which is reflective of the low log2FC of the Hex6HexNAc2 glycan, where 




Figure 39. Combinations of Individual Discriminators Reveal More Robust Differences in 
Tumor and Non-Tumor Samples. Representative images of 5 tissue sections of complex 
histology and 2 tissue microarrays, looking at the localization of Hex6dHex1HexNAc5 (a,e), 
Hex6HexNAc2 (b,f), and the overlay of the two glycans (c,g). In the TMA, tumor cores are 
outlined in green, while non-tumor cores are outlined in red. Furthermore, in overlay images, 
Hex6dHex1HexNAc5 is presented in green, while Hex6HexNAc2 is presented in red. The 
overlay of the two glycans is able to distinguish tumor from non-tumor cores in both the whole 
tissue blocks and the tissue microarray.  
Invasive Cancer 
Normal Pancreas 
High Grade Lesions 




or negative Log2FC value and were not significantly different between the tumor and non-tumor 
cores.  
4.3.3 N-Glycan Biomarker Panels 
The combination of N-glycans improved the ability of the platform to distinguish tumor 
from non-tumor tissues, both visually in the MALDI-IMS data and empirically in the statistical 
data. In comparison to the individual discriminators, the visual image overlay of 
Hex6dHex1HexNAc5 (green) and Hex6HexNAc2 (red) in both the tissue blocks (Figure 39c) and 
TMA (Figure 39g), yields more pronounced differences between the tumor from non-tumor tissue 
regions, as outlined by the pathologist (Figure 39d). To generate a N-glycan biomarker panel, a 
supervised machine learning algorithm was applied across the glycans identified in all six TMAs, 
focusing on the ability of the multiple N-glycans to distinguish tumor from non-tumor tissue 
cores (Table 4). With this approach, 2/3rd of the data was subjected to a sequential feature 
selection process to minimize the misclassification error of the LDA model, and the remaining 
1/3rd was used as a validation set. In the LDA model, Hex7dHex1HexNAc7 (m/z = 2742.9280) 
and Hex6dHex2HexNAc5 (m/z = 2320.7524) displayed the lowest error rate of .1458 (Figure 
40a). Additionally, the image overlay of Hex7dHex1HexNAc7 (green) and Hex6dHex2HexNAc5 
(red) in three TMAs validates the statistics (Figure 40b-d). The predictive characteristics of the 
model were compared against CA19-9 and SLeX staining of the same TMAs. The LDA model 
consisting of two glycans was able to outperform both CA19-9 and SLeX staining in negative 
predictive value, and CA19-9 in positive predictive value (Table 5).  
4.3.4 Comparison of Plasma and Tissue N-Glycome 
 Pooled plasma samples from patients with pancreatic cancer and pancreatitis were 
analyzed for differences in the N-glycome following ethyl esterification. Very few differences in 




Figure 40. LDA Model of N-Glycan Discriminates Tumor from Non-Tumor Tissue Cores. 
Supervised machine learning algorithms, specifically the Linear Discriminate Analysis (LDA), 
were used to identify important features to distinguish tumor from non-tumor tissue sections. Two 
glycans (Hex7dHex1HexNAc7, m/z = 2742.9820; Hex6dHex2HexNAc5, m/z = 2320.7524) were 
observed to be important, and the performance of the LDA model based off of these two features 
was tested for performance of the biomarker panel (a). Representative images from three of the 





Table 5. Comparison of LDA Model to Carbohydrate Antigen Staining. The 
sensitivity, specificity, positive predictive value (PPV) and negative predictive value 
(NPV) were calculated based off of the markers ability to distinguish tumor from non-





Figure 41. Pancreatic Cancer and Pancreatitis Plasma Glycome. The derivatized N-glycome 
from pooled plasma from patients with pancreatic cancer (b) and pancreatitis (a) exhibited little 
difference from one another. In contrast the pancreatic tissue glycome was more robust, 









to the presence glycoforms from abundant serum glycoproteins, such as immunoglobulins. On the 
other hand, the N-glycome from glycans extracted from a pancreatic cancer tissue block exhibited 
robust differences in the glycan species identified compared to the pancreatic cancer plasma pool 
(Figure 41c). 
 4.4 Discussion 
The aim of this study was to investigate the ability MALDI-IMS analysis of N-glycans to 
be utilized as a disease marker identification platform for pancreatic cancer. To achieve this goal, 
TMAs were used for initial disease marker identification, but results were validated in both 
TMAs and whole tissue blocks. A secondary goal was to compare the classification metrics of 
individual discriminators to panels of N-glycans. Due to the enormous biological heterogeneity 
between individuals with cancer, single markers rarely have the sensitivity and specificity needed 
for screening asymptomatic patients. Biomarker panels, even when some of the markers are not 
adequate predictors of disease on their own, can improve disease classification (470). While 
aberrant glycosylation is known to be a hallmark of cancer, including pancreatic cancer, few 
studies have assessed alterations of N-linked glycosylation in pancreatic tissue sections. Instead, 
most studies monitor CA19-9 serum expression, which is primarily present on O-glycans and 
glycolipids (334,335). However, CA19-9 expression has well defined limitations for its use as a 
diagnostic disease marker. In our initial analysis of N-glycan distribution of pancreatic cancer 
tissue blocks, the expression levels of various N-glycans seem to correlate to complex 
histological regions present in the tissue blocks (Figure 36). The need for diagnostic markers for 
pancreatic cancer, limitations in currently available disease markers, and the observation of N-
glycans that correlate to tumor and non-tumor tissue regions make pancreatic cancer an ideal 
disease model for this manuscript. 
 Given the lack of software available to process data from the SolariX FTICR mass 
spectrometer, mainly due to the enormous size of the high-resolution data, our laboratory 
178 
 
developed an in-house approach for peak picking and generation of biomarker panels (Figure 38). 
For the peak picking function, a bucket table consisting of m/z values and the corresponding 
relative intensity was generated by using the hierarchical clustering function present in the 
FlexImaging software. In the peak picking process, a total of 54 peaks were detected in all six 
TMAs, 23 of which correspond to masses present in our N-glycans structural library (Table 4, 
Sup Sheet2). Of the identified N-glycans, 20 are elevated in the tumor over the non-tumor tissue 
cores, 17 of which have a p-value ≤ .05. The high-mannose glycans observed have a negative 
(Hex6HexNAc2, Hex8HexNAc2) or low (Hex7HexNAc2) log2FC value, with p-values > .05. It 
is clear that there is room for optimization in the peak picking process, as manual data processing 
identified peaks corresponding to 50 N-glycans that are present in all six TMAs (Sup Sheet 5). 
Furthermore, the peak picking selection, which uses binned windows for peak selection, exhibits 
higher m/z errors than individual processed spectra loaded into the FTMS processing software. 
After data processing, nearly all errors are below 10 PPM, which is significantly better than the 
PPM errors observed using the binned windows (Sup Sheet 5). Of the 23 peaks that correspond to 
N-glycans, all but one are detected in both the individual spectra and in the off-tissue 
derivatization and enrichment of N-glycans. As demonstrated by the table, many glycans are not 
observed in the peak picking algorithm but can be detected by FTMS processing and following 
glycan derivatization and enrichment (Sup Sheet 5).   
 Following the peak picking process, combinations of N-glycans were evaluated for their 
potential to distinguish tumor from non-tumor tissue sections, both visually and computationally. 
An overlay of two identified N-glycans, Hex6dHex1HexNAc5 and Hex6HexNAc2, is able to 
visually differentiate tumor from non-tumor tissues in whole tissue blocks and TMAs (Figure 39). 
For panel identification, the 23 peaks corresponding to N-glycans were subjected to supervised 
machine learning algorithms and sequential feature selection to identify N-glycan panels that are 
capable of distinguishing tumor from non-tumor tissue cores. The LDA model highlights the 
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importance of Hex7dHex1HexNAc7 and Hex6dHex2HexNAc5 in distinguishing tumor from 
non-tumor sections (Figure 40). This model outperforms CA19-9 staining metrics on serial TMA 
sections (Table 5). Both comparisons mentioned above, Hex6dHex1HexNAc5 vs. 
Hex6HexNAc2 and Hex7dHex1HexNAc7 vs. Hex6dHex2HexNAc5, contrast N-glycans with a 
large Log2FC and a p-value ≤ .05 with N-glycans with a negative Log2FC and p-value ≥ .05 
(Table 4). Additionally, as little correlation was found between N-glycans and the CA19-9 
antigen, it is possible to incorporate CA19-9 expression metrics into the biomarker panel to 
potentially improve the predictive value (470).  
By validating the glycan distribution on whole tissue blocks, we were able to evaluate 
glycosylation trends in relation to complex histopathology. Among the findings, two important 
observations warrant further discussion. As previously mentioned, pancreatic cancer is only 
curable if detected at an early stage prior to becoming locally invasive or metastatic. As such, 
markers capable of detecting of pre-cancerous lesions are particularly useful. The overlay of 
Hex6dHex1HexNAc5 and Hex6HexNAc2 (Figure 39c, top tissue), is able to differentiate both 
low and high grade IPMN lesions from the non-tumor pancreas tissue. Interestingly, 
Hex6dHex1HexNAc5 (Figure 39a, top tissue) has a higher relative intensity in the tumor regions 
than the pre-cancerous lesions, suggesting a signature gradient that coincides with cancer stage. 
However, not all of these lesions ultimately become cancerous, so additional tests are required to 
determine if these glycans can distinguish lesions that will become cancerous from lesions that 
will remain dormant. Secondly, one of the most significant limitations of cancer biomarkers is 
their poor ability to differentiate tumor from benign diseases. In the examples of whole tissue 
blocks provided, the overlay of Hex6dHex1HexNAc5 and Hex6HexNAc2 is also able to 
differentiate tumor from chronic pancreatitis (Figure 39c). As CA19-9 is limited from a clinical 
perspective by its poor specificity in distinguishing malignant from benign conditions, this 
finding is particularly promising.  
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 It is unlikely that MALDI-IMS will be used clinically for the early detection of pancreatic 
cancer, as tissue biopsy samples are extremely invasive and are unlikely to be collected before the 
disease is too advanced. Early detection disease markers for pancreatic cancer should utilize 
biological fluids. However, initial targeted approaches on tissue sections can reduce the 
complexity associated with plasma analysis (471). While no plasma from non-diseased patients 
was tested, glycomic profiling was unable to distinguish pooled plasma from pancreatitis and 
pancreatic cancer patients (Figure 41a,b). High-mannose N-glycans and members of the glycan 
biomarker panel were noticeably absent from plasma samples. However, these glycans were 
observed in the ethyl esterified N-glycans following extraction from tissue blocks, verifying that 
the derivatization allows for the detection of these glycoforms (Figure 41c). Thus, trends 
observed by tissue imaging are not reflective of the plasma glycome. However, it is unclear 
whether the absence of important glycoforms is attributed to their absence on plasma proteins or 
suppression caused by the large dynamic range of proteins in the plasma. Depletion of  abundant 
glycoproteins from the plasma may enable the detection of low abundance glycoforms (472,473). 
While analysis of the plasma glycome does not correlate with our imaging results, the imaging 
data mirrored that reported in serum from PDAC patients, which exhibited overall elevated levels 
of glycosylation but no differences in high-mannose and hybrid N-glycans (385). 
 In conclusion, a novel disease marker discovery platform was developed that utilizes 
MALDI-IMS of N-linked glycans in a high-throughput TMA study. Expression levels of 
individual and panels of N-glycans were shown to be capable of differentiating tumor from non-
tumor tissue, as well as other complex pathologies. Furthermore, the developed platform 
described herein can be applied to any disease for initial screening purposes. Additionally, the 
consistency of glycosylation trends between our tissue imaging results and published literature on 
serum, suggest that these glycan biomarker panels may be successful in non-invasive serum 
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 The ability to distinguish pancreatic cancer from non-diseased specimen by aberrations in 
glycosylation has been established, both herein and elsewhere. To date, the glycan antigen CA19-
9, represents the only FDA approved blood test for the management of pancreatic cancer 
(332,333). Profiling the glycome has identified other glycoforms, including N- and O-linked 
glycoforms, that are differentially expressed in pancreatic cancer serum and tissue specimen 
(331,373,385,474,475). In tissue sections, we have recently reported experimental results from a 
high-throughput MALDI-IMS approach that demonstrate the potential of N-glycans to distinguish 
tumor from non-tumor tissue specimen with high sensitivity and specificity. These alterations in 
the total glycome are reflective of a pattern of altered glycosylation across many proteins (156). 
These glycan discriminators offer insights into the tumorigenic process, but it is doubtful that 
they can serve as early stage biomarkers in biological fluids due to a lack specificity for 
pancreatic cancer. Unlike individual glycoforms, glycoproteins that originate from a specific 
tissue have had clinical success as early stage cancer biomarkers. For example, alpha-fetoprotein 
(AFP) and prostate-specific antigen (PSA) originate from, and can detect the presence of, liver 
and prostate cancer, respectively (160,161,349). While profiling the glycoprotein expression level 
is informative, linking aberrant glycosylation to the corresponding protein can improve the 
clinical utility of biomarkers. The most promising example of leveraging both protein expression 
and glycoform occupancy in a single biomarker is AFP-L3, which outperforms AFP due to the 
elevation of fucosylated AFP in malignant liver diseases compared to non-malignant liver 
diseases (160,350,351). The identification of similar glycoproteins for pancreatic cancer to aid in 
the early identification of the disease would greatly improve pancreatic cancer treatment options 
and survival.  
 Early proteomic profiling of pancreatic cancer specimen revealed a general upregulation 
of glycoproteins in pancreatic cancer; especially those involved in regulating cellular 
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organization, adhesion, transport and immune system response (364,377). These observations 
were confirmed by global hydrazide enrichment of glycoproteins from pancreatic cancer tissue 
specimen, which identified 252 proteins that had aberrant expression of N-glycopeptides (283). 
However, both pancreatic cancer and pancreatitis exhibit similar trends in glycoprotein 
expression levels, with a limited number of glycoproteins that are uniquely expressed in the 
cancer specimen (283,380). Thus, it is important to link glycoforms to the glycoproteins in order 
to distinguish malignant disease from normal and benign specimen. To investigate specific 
glycoproteins as disease markers, most approaches utilize trends in aberrant glycosylation to 
determine the appropriate enrichment strategy. Efforts have been directed at linking CA19-9 to 
protein carriers. Mucins have long been reported to be the primary carrier of the CA19-9 antigen, 
but CEACAM proteins, agrin, galectin-3-binding protein, ezrin, tPA, cathepsin D, necdin, and 
neutrophil cytosol factor 2 are now known to carry the antigen (273,373,476). While CA19-9 is 
thought to be present on N- and O-glycans, it is unknown what specific glycoforms are modified 
with the glycan antigen (273,334,335). Other glycoproteomic approaches have assessed 
differential glycosylation in pancreatic cancer by selectively enriching glycan epitopes using 
lectin enrichment. The lectin enrichment of glycoproteins bearing specific glycan motifs, such as 
α2,6 sialic acids (SNA) or fucose residues (AAL), followed by downstream proteomic analysis of 
the enriched glycoproteome, identified glycoproteins that could differentiate pancreatic cancer 
from non-cancer specimen (318,343,384). Given the poor overlap in glycoprotein enrichment 
across various enrichment strategies, it is likely that other disease markers remain undiscovered. 
 Recent advances to the field of glycoproteomics can lead to a deeper understanding of the 
role that glycosylation plays in pancreatic cancer and the identification of disease markers. From 
a targeted glycoproteomics standpoint, there is a significant need to continue to identify proteins 
that are modified by the CA19-9 antigen. As CA19-9 is expressed in malignant and benign 
diseases, identification the carbohydrate antigen on proteins unique to cancer would improve the 
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sensitivity and specificity of disease detection. Furthermore, CA19-9 is not the only aberration in 
pancreatic cancer glycosylation. The global assessment of all glycoproteins and their attached 
glycoforms would also aid in disease marker identification. However, due to the inherent 
complications of glycoproteomics, these studies are rare. Intact glycoprotein analysis of complex 
samples requires appropriate glycopeptide enrichment steps to overcome limitations of dynamic 
range, reduced ionization efficiency and heterogeneity associated with glycosylation 
(221,264,265). Many of these studies use lectin enrichment, which limits analysis to specific 
glycoforms. 
 In this manuscript, we aim to utilize novel mass spectrometry based approaches to 
combine glycomic and proteomic information as a mechanism to identify disease marker 
candidates that can be further assessed as clinical markers for pancreatic cancer. In one approach, 
the incorporation of azide-labeled sialic acid analogs into pancreatic cancer cell lines provides a 
highly efficient enrichment strategy for sialic acid containing glycopeptides. When applied to cell 
lines with well characterized CA19-9 expression levels, significant variations in protein 
expression levels highlight a population of proteins that can be further assessed as CA19-9 
carriers. In this study, Panc1 and Miapaca2 cell lines express low levels of CA19-9, while 
BXPC3 and Capan2 cell lines express high levels of CA19-9. As few studies have profiled the 
significance of N-glycans in terms of their ability to carry the CA19-9 motif, a general profile of 
the N-glycome is also reported in relation to the CA19-9 expression. In addition to inferences 
about CA19-9 expression, the glycoproteome reported within catalogs sialylated glycoproteins in 
pancreatic cancer. The second aim is directed at advancing methodologies available for intact 
glycopeptide analysis. Starting with the analysis of glycoprotein standards, we outline a workflow 
that can be used for the comprehensive analysis of an enriched glycoprotein or adapted for broad 
glycoproteomic research. As opposed to commonly employed lectin enrichment strategies, the 
glycopeptide enrichment approach herein is relies on physiochemical properties of the glycan, 
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enabling an unbiased enrichment, regardless of the glycoforms. Protocols using hydrophilic 
interaction chromatography (HILIC) and strong anion exchange (SAX) are outlined in the 
sections below. 
5.2 Materials and Methods 
5.2.1 Materials  
 Cell culture media were purchased from Mediatech, Inc. (Manassas, VA). Trypsin-EDTA 
used for cell culture and FBS for media supplementation were purchased from Gibco (Grand 
Island, NY). A mixture of Penicillin-Streptomycin-Amphotericin B was purchased from MP 
Biomedicals (Solon, OH). The click sugar analogs and the alkyne-agarose enrichment kit came 
from Life Technologies (Grand Island, NY). HPLC grade methanol, HPLC grade ethanol, HPLC 
grade acetonitrile, HPLC grade chloroform, HPLC grade water, histological grade xylenes, PBS, 
.5mL Zeba spin columns, and ammonium bicarbonate were obtained by Fisher Scientific 
(Pittsburgh, PA). SDS, EDTA, TrisBase, DTT, 1-hydroxybenzotriazole hydrate (HOBt), sodium 
hydroxide (NaOH), trypsin, calcium chloride (CaCl2), fetuin, transferrin and asialofetuin were 
obtained from Sigma-Aldrich (St. Louis, MO). 1-(3-Dimethylaminopropyl)-3-ethylcarbodiimide 
hydrochloride (EDC) was purchased from Oakwood Chemical (West Columbia, SC). NP-40 was 
purchased by Boehringer Manheim Gmbh (Germany). SAX solid phase extraction cartridges and 
C18 ZipTips came from Waters (Milford, MA)  and Millipore (Ireland), respectively.  Hydrazide 
coupling buffer was purchased by Bio-Rad (Hercules, CA) and SiMag-Hydrazide beads came 
from Chemicell GmbH (Berlin, Germany). 
5.2.2 Cell Culture 
 Pancreatic cancer cell lines BXPC3, Capan2, Miapaca2, and Panc1 were provided 
generously by Dr. Charles Smith and were cultured as suggested by the American Type Culture 
Collection (ATTC). Both Panc1 and Miapaca2 cells were cultured with Dulbecco's Modified 
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Eagle's Medium (DMEM) supplemented with 10% fetal bovine serum and a 1X solution of 
Penicillin-Streptomycin-Amphotericin B. BXPC3 and Capan2 cell lines were cultured in RPMI 
Medium supplemented with 10% fetal bovine serum and a 1X solution of Penicillin-
Streptomycin-Amphotericin B. All cell lines were maintained at 37°C in a 5% CO2/air 
environment.  
5.2.3 Glycomic Analysis of Cell Lines 
5.2.3.1 N-Glycan Release by PNGaseF 
 For N-glycan analysis of the cell lysate, cells were cultured to 80% confluency and 
washed with PBS, prior to being scraped and pelleted. Cell pellets were lysed with 200μL of lysis 
buffer (1% SDS, 5mM EDTA and 25mM Tris Base) for 1hr at 4°C. The cell lysate was sonicated 
for 10 seconds using a probe sonicator at 30% power. Protein from 100μL of cell lysate was 
precipitated by the addition of 400μL methanol, 100μL chloroform, and 300μL water, followed 
by centrifugation at 14,000 x g for 2 minutes. After discarding the top aqueous layer, the proteins 
were pelleted by the addition of 400μL methanol and centrifugation at 14,000 x g for 3 minutes. 
The proteins were resuspended in a 1% SDS solution and reduced in 10mM DTT at 95°C for 5 
minutes. After cooling to room temperature, 2.5μL NP40 and 2.6μg PNGaseF were added to the 
proteins from each cell line and digestion took place at 37°C overnight. Released glycans were 
collected by repeating the chloroform-methanol precipitation as described above and collecting 
the upper aqueous layer. The glycans were concentrated by vacuum centrifugation prior to 
beginning the ethyl esterification protocol. 
5.2.3.2 Glycan Derivatization 
 The ethyl esterification protocol for released glycans was adapted from Reiding et al. and 
performed as described in Section 3.4.2.5 (237).  
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5.2.3.3 Data Processing 
 Glycan ethyl esterification of cell lines was performed in two experimental replicates for 
each cell line. Spectra were loaded into Compass DataAnalysis (4.0, Bruker Daltonics) and 
spectra were exported as .xy files for peak picking using Progenesis MALDI (Nonlinear 
Dynamics, Durham, NC). After the first round of peak picking, peaks that corresponded to known 
glycans were selected for further data processing. Other peaks corresponding to glycans that were 
not initially picked by Progenesis were manually added. For data visualization purposes, a heat 
map was generated that compares the ion intensity of a mass in a specific cell line to the average 
ion intensity across all cell lines. In the heat map, clades of interest were selected and individual 
glycan structures were identified based off of mass accuracy using GlycoWorkbench.  
5.2.4 Click Chemistry Enrichment of Glycoproteins 
5.2.4.1 Sugar Incorporation 
 Cell lines were cultured under conditions as described in section 5.2.2. For click 
chemistry analysis of cell lines using azide-labeled sugar analogs, cell lines were cultured to 50% 
confluency prior to treatment with the sugar analog. After 48 hours, the cells were washed with 
PBS, collected by scraping in 1mL PBS, and pelleted by centrifugation at 1,500 x g for 2 minutes. 
For each experimental replicate, separate plates from each cell line were treated with the 20nM 
ManNAz sugar analog, 20nM GalNAz sugar analog, or a corresponding volume of DMSO.  
5.2.4.2 Click Chemistry Enrichment 
 The click chemistry-mediated glycoprotein enrichment as described by the invitrogen 
protocol was scaled down to adjust for a smaller number of starting cells and performed for the 
capture of azide-modified proteins with alkyne-agarose beads (294). Briefly, lysis buffer was 
added to cells, which then sat on ice for 10 minutes prior to 6 x 3 second sonications at 30% 
power with a probe sonicator. The lysed cells were centrifuged briefly to remove cell debris and 
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the cell lysate was then added to prepared alkyne-agarose resin. Glycoprotein binding occurred 
following the addition of the supplied catalyst solution by end-over-end rotation overnight. After 
overnight incubation, all non-azide modified proteins were removed by discarding the supernatant 
after centrifugation and washing the resin with H2O. Glycoproteins were reduced in the provided 
SDS wash buffer supplemented with 10mM DTT at 70°C for 15 minutes. The wash buffer was 
removed following centrifugation and alkylation occurred by the addition iodoacetamide 
followed by incubation in the dark for 30 minutes. Bound glycoproteins were transferred to the 
provided spin columns and washed with SDS wash buffer, 8M Urea/100mM Tris, and 20% ACN 
as described in the protocol. Glycoproteins were digested with trypsin during an overnight 
incubation at 37°C. Released peptides were collected, reconcentrated and desalted using C18 
ZipTips prior to LC-MS/MS. In total, two experimental replicates were performed and at least 
two technical replicates for each experimental replicate group were processed by LC-MS/MS. 
Following a thorough removal of nonspecific interactions, bound N-glycopeptides were released 
overnight during an incubation with 2.6μg PNGaseF at 37°C. Released off-bead peptides were 
collected and desalted using a C18 ZipTip prior to LC-MS/MS. 
5.2.4.3 LC-MS/MS and Bioinformatics  
 A single dimension RPLC separation was employed prior to tandem MS. Dried peptides 
were resuspended in 10μL Buffer A (97.8% HPLC grade H2O, 2% acetonitrile, 0.2% formic 
acid), injected using a Dionex U3000 nano-LC system (Thermo Scientific), and passed through a 
C18 trap column (C18 pepMap 100, 5μm, 300 μm x 5mm ID, Thermo). From the trap column, 
peptides proceeded to an in-house C18-reverse phase analytical column (.0075mm ID, 15cm) 
consisting of Waters YMC-ODS C18-AQ 5mm resin. Peptides were eluted using a linear gradient 
of increasing concentration of Buffer B (97.8% acetonitrile, 2% HPLC grade H2O, 0.2% formic 
acid). For the analysis of trypsin digested glycoproteins following click chemistry enrichment, the 
flow rate was set to 200nL/min and ramped from 2% Buffer B to 50% Buffer B using a 180 
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minute linear gradient. Peptides released by PNGaseF incubation were eluted using a 240 minute 
linear gradient of 2-50% Buffer B at a flow rate of 200nL/min.  
 For the analysis of tryptic peptides and previously glycosylated peptides released from 
the alkyne-agarose resin with PNGaseF, the top 10 most abundant peptides were fragmented by 
CID in a data dependent fashion. The precursor ion scan was collected in the Orbitrap and CID 
was performed in the ion trap. The normalized collision energy was set to 35%, with a dynamic 
exclusion set for a repeat count of 2, repeat duration of 30 seconds and an exclusion duration of 
100 seconds. Data were searched using Mascot (version 2.4.1, Matrix Science, London, UK) via 
Proteome Discover (version 1.4.0.288, Thermo Scientific). The data were searched against a 
UniProt Swiss Prot Homo sapien protein database (2014_07 release) with canonical and isoform 
entries. Proteins found in the common Repository of Adventitious Proteins (40,872 entries) were 
added to the protein database. The parameters were set to allow up to 2 missed cleavages, with a 
10 ppm precursor mass tolerance and a .8 Da fragment mass tolerance. Carbamidomethyl (Cys) 
was defined to be a static modification, while protein N-term acetylation, oxidation (Met), and 
deamidation (Asn, Gln) were set as dynamic modifications. Data were also searched against an 
automated decoy database in Mascot. Normalized spectral counts were generated in ProteoIQ 
(version 2.3.08, Premier Biosoft, Palo Alto CA) and the protein readout was generated after 
specifying ≥ 2 peptides for a given protein and the protein false discover rate (FDR) <5%. 
Normalized spectral counts for each experimental replicate were produced by averaging the 
appropriate technical replicates from the sample (Sup Sheet 9). For data processing, if no spectral 
counts were observed, or if the average of the sugar analog treated condition was less than 5 times 
that of the DMSO treated condition, the spectral count value was artificially set to 1. 
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5.2.5 Intact Glycopeptide Analysis 
5.2.5.1 Glycoprotein Digestion 
 Glycoprotein standards for the evaluation of glycopeptide enrichment strategies were 
dissolved in H2O, reduced in 10mM DTT at 60°C for 30 minutes and alkylated in 25mM 
iodoacetamide in the dark for 30 minutes. The glycoprotein standards were then diluted with 
100mM AMBIC, brought to a final concentration of 2mM CaCl2, and digested with trypsin 
overnight at 37°C at a ratio of 1:100 trypsin:sample. 
5.2.5.2 Glycopeptide Enrichment  
 For intact glycopeptide analysis, glycopeptides were enriched using strong anion 
exchange (SAX) SPE cartridges and cotton-HILIC tips. For enrichment with SAX SPE 
cartridges, the cartridge was washed and preconditioned with 1mL ACN, 1mL .1M 
triethylammonium acetate, 3mL H2O, and 1mL 95% ACN 1% TFA. Digested peptides were 
resuspended in 400μL 50% ACN, .1% TFA and applied to the SPE cartridge along with 3mL 
95% ACN, 1% TFA. After the sample was allowed to flow through the cartridge, the cartridge 
was washed with 3mL 95% ACN 1% TFA and glycopeptides were eluted with 500μL 50% ACN 
.1% TFA. Alternatively, cotton-HILIC tips were also used for the enrichment of glycopeptides. 
Peptides were first resuspended in 80% acetonitrile. The cotton-HILIC tips were washed 5x with 
10μL H2O and 3x with 10μL 85% ACN, followed by sample loading 40x, tip washing with 3x 
10μL 85% ACN .1% TFA, and glycopeptide elution in 10μL H2O. 
 For selective enrichment of sialylated glycopeptides by hydrazide enrichment, 
glycoproteins were incubated with 2mM periodic acid on ice for 10 minutes. Oxidation was 
quenched by the addition of glycerol. Proteins were desalted with a Zeba desalting column buffer 
exchanged with coupling buffer, prior to overnight incubation with hydrazide magnetic beads at 
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room temperature. Sample washing, digestion and glycopeptide release was performed as 
described (286). 
5.2.5.3 Glycan Release and Derivatization 
 Enriched glycopeptides were digested with PNGaseF overnight at 37°C. Glycans were 
derivatized and enriched as described section 5.2.3.2. 
5.2.5.4 LC-MS/MS and Bioinformatics 
 The same configuration of the LC-MS/MS, including the trap and analytical columns, 
were used as described in section 5.2.4.3. Peptides were eluted using a 120 minute linear gradient 
of 3-50% buffer B. 
 Analysis of intact glycopeptides proceeded through a product dependent ionization 
strategy, termed HCD-pd-ETD, on the Orbitrap Elite. The acquisition parameters were as follows. 
Precursor ions were detected in the Orbitrap with the resolution set to 60,000 with an m/z range 
from 400 - 2000. The top 10 most abundant ions were selected and fragmented by HCD and 
detected in the Orbitrap at a resolution of 15,000. For HCD fragmentation, the values for the 
minimum signal required, isolation width, normalized collision energy, and activation time were 
set to 500.0, 2.00, 35.0, and .100, respectively. The detection of glycan specific oxonium ions 
among the top 30 most abundant fragment ions triggered ETD fragmentation with supplemental 
activation enabled on the precursor ion. The parameters for the minimum signal required, 
isolation width, and normalized collision energy remained consistent between the HCD and ETD 
fragmentation parameters.  
 Byonic software version 2.2.9 (Protein Metrics, San Claros, CA) was used for intact 
glycopeptide identification following LC-MS/MS analysis. Briefly, data files were directly loaded 
into Byonic and searched against the appropriate protein database files. The parameters for the 
search were set as follows. Cleavage sites for trypsin digest were set to RK, with the C-terminal 
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cleavage side, semi-specific N-ragged digestion specificity and missed cleavages were set to -1. 
The precursor mass tolerance, fragment mass tolerance (HCD) and fragment mass tolerance 
(ETD) were set to 6ppm, 10ppm, and .6 daltons, respectively. Carbamidomethylation (Cys) was 
set as a fixed modification, oxidation (Met) and methylation (Cys) were set as common 
modifications, and pyroglutamate (pyroGlu) formation of N-terminal glutamate and glutamic acid 
were set as rare modifications. In total, the analysis was established to allow a maximum of two 
common modifications and 1 rare modification. N-glycosylation modifications were listed as a 
common modification in the search. For intact glycopeptide analysis, an N-glycan library was 
selected from Byonic or manually entered if glycomic identification had been previously 
performed. Data were viewed using the generated excel spreadsheet or the Byonic Viewer 
software. To confirm the presence of a glycopeptide, the ETD spectra and preceding HCD spectra 
were manually assessed in the LC-MS/MS analysis using the Xcaliber software 2.2 SP1.48 
(Thermo Scientific, Pittsburgh, PA) to ensure the presence of oxonium ions in the HCD spectra.  
5.3 Results 
5.3.1 Glycomic Profile of Pancreatic Cancer Cell Lines 
 Profiling of the N-glycome was performed following ethyl esterification derivatization 
and HILIC enrichment. The analysis of four cell lines with characterized CA19-9 expression 
levels revealed general trends in glycan expression that correlated to CA19-9 status. In all cell 
lines, the peak corresponding to Man8 was the largest peak detected in the spectra and serves as a 
point of comparison (Figure 42). Importantly, the low CA19-9 cell lines exhibited a higher 
relative intensity of the Man8 peak and more intense high molecular weight ions (m/z > 2750), 
which correspond to branched, multiply sialylated N-glycans (Figure 42a,b). Alternatively, the 
high CA19-9 expressing cell lines exhibit more complexity in the MALDI spectra between m/z = 




Figure 42. N-Glycan Profiling of Four Pancreatic Cancer Cell Lines. The N-glycans from 
four pancreatic cancer cell lines with characterized CA19-9 expression levels were released and 
derivatized by ethyl esterification. Noticiable differences in the annotated spectra were observed 
between the high CA19-9 expressing cell lines (c-d) and the low CA19-9 expressing cell lines  




Figure 43. Molecular Heat Map of N-Glycans from the Cell Lines. Individual glycoforms 
were detected in progenesis and were compiled in a heatmap comparing the average intensity of 
an individual glycoform from one cell line, the the average across all four cell lines (a). Clades 
were identified of glycoforms that were elevated in both of the low CA19-9 expressing cell lines 
(b) or the high CA19-9 expressing cell lines (c). Glycoforms of interested were drawn using 
GlycoWorkbench software.   
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abundance in regards to CA19-9 expression levels (Figure 43). Clades that displayed consistent 
alterations that corresponded with CA19-9 levels were further assessed to look at the broad N-
glycan structural features. In the low CA19-9 expressing cell lines, a general trend of elevated 
high-mannose N-glycans was observed, as well as sialylated tri- and tetraantennary N-glycans 
(Figure 43b). In the high CA19-9 cell lines, the most predominant trend was the presence of 
multiply fucosylated N-glycans (Figure 43c).  
5.3.2 Sialylated Glycoprotein Profile of Pancreatic Cancer Cell Lines 
 Glycoprotein enrichment by click chemistry followed by proteomic analysis revealed 
numerous glycoproteins present in the pancreatic cancer cell lines, many of which exhibited 
trends that coincided with CA19-9 expression levels. In all, 535 unique proteins were identified in 
at least one ManNAz treated cell line. Of these 535 proteins, 429 (80.2%) were identified as 
glycoproteins by searching the Uniprot human proteome for the glycoprotein PTM keyword 
(KW-9991). Data were further processed by their group-averaged normalized spectral counts to 
compare the protein fold change between the high and low CA19-9 expressing cell lines. Using 
this approach, 102 proteins were elevated in the high CA19-9 cell lines, while 97 proteins were 
elevated in the low CA19-9 cell lines. The Uniprot accession IDs for both classes of proteins 
were assessed by WebGestalt (http://bioinfo.vanderbilt.edu/webgestalt/) using both GO and 
KEGG enrichment analysis to identify the top 10 most significantly enriched pathways. Among 
interesting findings, both GO and KEGG enrichment analysis identified pathways involved in O-
glycan biosynthesis and processing to be enriched in the high CA19-9 cell lines (Table 6).  
 Upon manual inspection, known CA19-9 carriers were identified among the proteins that 
were elevated in the high CA19-9 expressing cell lines. These proteins include members of the 
mucin and CEACAM family of proteins, as well as galectin-3-binding protein. The data were 
further processed to identify glycoproteins that were exclusively detected in both high CA19-9 
expressing cell lines. In all, 37 proteins met this criteria in at least one experimental replicate, of  
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Table 6. WebGestalt Pathway Analysis. The proteins elevated in the high CA19-9 cell lines and 




Table 7. Exclusive Identification of Glycoproteins in High CA19-9 Expressing Cell Lines. 





which 11 proteins satisfied these conditions in both experimental replicates (Table 7), including 
CEACAM1, CEACAM5, and CEACAM6. To assess the contribution of N-linked glycosylation 
to the glycoprotein enrichment, bound N-glycopeptides were released with PNGaseF and 
analyzed by LC-MS/MS (Sup Sheet 8). A majority of the proteins were not identified after 
PNGaseF release, emphasizing the importance of O-linked glycosylation. Interestingly, galectin-
3-binding protein, was among the proteins identified after PNGaseF. 
5.3.3 Optimization of Intact Glycopeptide Analysis 
 Fetuin, asialofetuin and transferrin glycoprotein standards were utilized to validate the 
experimental and instrumental parameters for intact glycopeptide identification by LC-MS/MS. 
Initially, to confirm the enrichment of glycopeptides over non-glycosylated peptides from the 
glycoprotein standard, a combination of LC-MS/MS and MALDI-MS was used. For this process, 
peptides were either desalted using a C18 ZipTips or glycopeptides were enriched by SAX SPE 
cartridges. Enriched glycopeptides were incubated with PNGaseF to generate previously 
glycosylated peptides. Peptides (Figure 44a), enriched glycopeptides (Figure 44c), and previously 
glycosylated peptides (Figure 44b) were all spotted on a MALDI plate with CHCA matrix. LC-
MS/MS of the total peptide solution was also performed and searched against a protein database 
containing fetuin and transferrin. MALDI analysis of the peptide sequences revealed numerous 
peptides for both fetuin and transferrin that corresponded to the peptide m/z values identified by 
LC-MS/MS. In contrast, the ions detected following SAX enrichment displayed generally larger 
m/z values that did not correspond to the LC-MS/MS analysis, but likely correspond to in-source 
decay of the glycan moieties on the glycopeptides. This hypothesis was verified by MALDI 
analysis of deglycosylated peptides, which identified all five peptides known to be N-
glycosylated on fetuin and transferrin. A similar trend was observed when using cotton-HILIC 
tips for glycopeptide enrichment as opposed to SAX SPE cartridges (data not shown). 




Figure 44. MALDI Analysis of Enriched Glycopeptides. To test for the efficacy of 
glycopeptide enrichment, peptides were enriched using C18 (a) or SAX (c) SPE cartridges. 
Peptides characterized from fetuin (green text) and transferrin (blue text) are annotated in the 
spectra. SAX enriched glycopeptides were digested with PNGaseF to release N-linked glycans, 
which resulted in the identification of deglycosylated peptides from all of the known N-
glycopeptide sites (b). Furthermore, sites of deamidation resulting from PNGaseF release are 




Figure 45. Glycomic Analysis of Enriched Glycopepdies from Fetuin and Transferrin. 
Glycans were released from enriched peptides by PNGaseF and then characterized by MALDI 





profile the corresponding glycoforms. A spectra of ethyl esterified glycans for fetuin and 
transferrin is provided (Figure 45). Analysis of identified glycoforms revealed primarily complex, 
sialylated N-glycans with some fucosylation present. 
 SAX enriched glycopeptides from the glycoprotein standards were then analyzed on the 
Orbitrap Elite using the HCD-pd-ETD ionization settings for the identification of intact 
glycopeptides and the corresponding glycoforms. ETD spectra were searched in Byonic to 
identify N-glycosylated peptides. In the Byonic search, peptides were searched against a 
manually defined N-glycan library consisting of identified glycans (Figure 46). In the search 
readout, all five sites of N-glycosylation were detected with N-glycan modifications present 
(Figure 47). A further interrogation of the glycopeptides after removal of all glycopeptides with a 
score < 50, identified six glycoforms present on both Fetuin and Transferrin. The number of times 
a specific glycoform was present on a specific peptide was recorded, and demonstrates N-
glycoform heterogeneity (Figure 46).   
 In an alternative approach, glycoprotein standards were enriched using magnetic 
hydrazide resin. Under low oxidizing conditions, only sialic acids are oxidized and form covalent 
bonds with the hydrazide resin. After tryptic digest, intact glycopeptides can be released by acid 
hydrolysis, which cleaves the glycosidic bond between the sialic acid and terminal galactose 
residues. Intact glycopeptide analysis on the Orbitrap Elite identified similar glycopeptides as 
after SAX glycopeptide enrichment, with the exception that no sialylated glycans were identified 
(Figure 48).  
5.4 Discussion 
 The carbohydrate antigen CA19-9 is the most well characterized disease marker for 
pancreatic cancer, but knowledge of the glycoform and glycoprotein carriers of the antigen is still 
incomplete. To our knowledge, no examples of specific N-glycoforms that carry the motif are 




Figure 46. N-Glycan Identification from Glycoprotein Standards. Glycans identified from the 
Byonic search for both fetuin and transferrin are listed, as well as the number of times each 
glycoform was observed on a specific peptide. The table represents a list of glycoforms that were 




Figure 47. Peptide Sequences Identified by ETD Ionization. ETD spectra from the HCD-pd-
ETD analysis of the glycoproteins were searched with Byonic. Peptides, including intact 




Figure 48. Comparison of N-Glycan Identification from SAX and Selective Hydrazide 
Enrichment. Glycoforms identified on each peptide during intact glycopeptide analysis on SAX 
and selective hydrazide enrichment reveal similarities in the common core structure of the 
glycoform. The predominant difference is that the glycoforms identified following selective HZ 
enrichment is that no sialylated glycoforms are observed, which is expected as glycoforms were 
released by acid hydrosis to cleave the sialic acids.   
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characterized. To address these limitations, we performed N-glycomic and glycoproteomic 
profiling of pancreatic cancer cell lines with well characterized CA19-9 expression levels. In the 
glycomic analysis, a selective derivatization strategy was used to distinguish α2,3- and α2,6-
linked sialic acids by induced changes in the molecular weight. Across the cell lines, general 
trends in the relative abundance of N-glycans were observed between high and low CA19-9 
expressing cell lines (Figure 42). Interestingly, the overall level of sialylated N-glycans was not 
increased in high CA19-9 expressing cell lines, as originally hypothesized. In fact, the most 
noticeable difference was that multiply fucosylated N-glycans were increased in high CA19-9 
expressing cell lines, while high-mannose glycans were elevated in low CA19-9 expressing cell 
lines (Figure 43). This finding suggests that the fucosyltransferase responsible for CA19-9 
expression on O-glycans also plays a role in N-glycosylation. In our data, only two of the N-
glycoforms elevated in the high CA19-9 cluster contained a sialic acid, none of which were α2,3-
linked. Additionally, in the glycoproteomic analysis, there were few protein identifications 
following PNGaseF incubation, suggesting CA19-9 is primarily present on O-glycans. 
Interestingly, galectin-3-binding protein and CEACAM proteins were both identified following 
PNGaseF release. As galectin-3-binding protein is known to express CA19-9 on N-glycoforms, 
further assessments of CEACAM N-glycans should be performed (273). Given the glycomic and 
glycoproteomic results, it is evident that CA19-9 is predominantly carried on O-linked glycans. 
One of the primary limitations of CA19-9 as a clinical disease marker is that a large population of 
individuals do not express fucosyltransferase 3 and are therefore incapable of expressing CA19-9 
(333,343). Profiling the N-glycome of patients with pancreatic cancer that do not express CA19-9 
should reveal a similar decrease in polyfucosylated N-glycans.  
 Glycoproteomic analysis of the cell lines further implicated processes related to O-
glycosylation as a primary distinguisher between high and low CA19-9 expressing cell lines 
(Table 6). Additionally, numerous proteins that are known CA19-9 carriers were identified to be 
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elevated in the high CA19-9 expressing cell lines. Among these proteins, some were uniquely 
expressed in the high CA19-9 expressing cell lines (Table 7). Given the propensity for the 
technique to identify known CA19-9 carriers in the high CA19-9 cell lines, identified proteins 
should be tested for CA19-9 expression (273,373,476). Importantly, determining CA19-9 protein 
carriers has improved the performance of the antigen as a disease marker (477). Yeu et al. used a 
sandwich-ELISA assay to profile CA19-9 expression on selected proteins from serum samples, 
and found elevations in the glycan antigen on MUC5ac, even in cases where the protein level did 
not change (373). A receiver operating characteristic (ROC) curve showed that using CA19-9 on 
MUC5ac instead of MUC5ac protein expression improved the AUC from .72 to .90 (373). The 
same group found that combining information related to total CA19-9 expression with the level of 
CA19-9 on MUC5ac and MUC16 was able to improve the performance of the disease marker 
(478).   
 While inferences can be made about proteins with regard to CA19-9 expression, this data 
largely details and catalogs variances in glycoprotein sialylation and not CA19-9 specifically. 
Thus, it is likely that many of the proteins identified do not express CA19-9. Various integrins 
were observed to be elevated in the high CA19-9 cells and have been reported in literature as 
exhibiting higher levels of sialylation in pancreatic cancer. Given the dynamic role of sialic acid 
in tumor progression, the comprehensive library of sialylated glycoproteins identified in the click 
chemistry approach can be assessed in serum samples (362,363).  
 While click chemistry represents a promising technique for initial disease marker 
discovery, the primary limitation of the approach is that it does not enable analysis of the glycan 
motifs on specific proteins. As observed with AFP-L3, this information can be critical to 
improving the clinical utility of the disease marker. To adjust for these limitations, intact 
glycoproteomic workflows were optimized on glycoprotein standards. SAX enrichment of a 
mixture of fetuin, asialofetuin and transferrin was able to specifically enrich glycopeptides from 
207 
 
the non-glycosylated peptides, as assessed by both MALDI and LC-MS/MS (Figure 44). 
However, asialylated glycoforms were largely missing during glycomic and glycoproteomic 
analysis, suggesting SAX is an efficient enrichment strategy for sialylated glycopeptides. There 
was a high degree of overlap between glycans that were detected in the glycomic analysis 
compared to glycans identified in the glycoproteomics workflow (Figure 45). When applied to 
complex protein mixtures (i.e. serum, tissue, cell lysates), SAX and HILIC glycopeptide 
enrichment were insufficient to enrich glycopeptides from the total glycopeptide mixture present. 
Traditionally, glycoproteomic analysis has been limited due to issues of broad dynamic range of 
proteins and a limited number of glycopeptides among total peptides (221,262–264). To 
compensate for these limitations, glycoconjugate enrichment is required to selectively enrich 
glycopeptides prior to analysis by LC-MS/MS. Glycopeptide enrichment strategies that rely on 
physiochemical properties generally exhibit poor specificity for glycopeptide enrichment, so 
other approaches should be considered (310). To increase the specificity of glycopeptide 
enrichment, a new technique involving hydrazide chemistry under low oxidizing conditions was 
used to enrich sialylated glycoproteins (276,286). With this technique, intact glycopeptides can be 
released and surveyed, at the expense of the terminal sialic acid. In our data, the underlying 
glycoforms detected in the selective hydrazide enrichment and SAX glycopeptide enrichment 
were largely similar (Figure 48), with the main difference being the lack of sialic acid due to acid 
hydrolysis release. Glycoprotein enrichment using covalent bond formation to solid phase support 
is more efficient and could mitigate issues of protein dynamic range in the analysis of complex 
samples. However, this approach is only useful in characterizing sialylated glycopeptides, and not 
for general analysis. The intact glycoproteomic approach outlined can be further implemented to 
the study of pancreatic cancer. Individual glycoproteins observed in the click chemistry approach 
can be enriched by immunoprecipitation and profiled by LC-MS/MS to characterize the presence 
and occupancy of individual glycoforms. Alternatively, aberrantly expressed glycoforms and the 
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corresponding glycoprotein identified by MALDI-IMS could be enriched by lectin enrichment in 
order to identify the protein carriers. 
 In conclusion, this aim expanded the field of pancreatic cancer glycoproteomics by 
defining a class-specific role of glycans as CA19-9 expressors, identifying putative CA19-9 
carrier proteins, documenting sialylated glycoproteins in pancreatic cancer, and developing 
methodologies for intact glycopeptide analysis of identified proteins. While intact glycopeptide 
analysis was performed on glycoprotein standards, future work can apply the outlined methods to 
isolated or total glycoproteins from biological samples. As CEACAM proteins were identified in 
the elevated high CA19-9 cell lines, and sialylation was detected at sites of N-glycosylation, 









6.1 MALDI-IMS Optimization for N-Glycan Analysis 
6.1.1 Conclusions 
 We hypothesized that PNGaseF application on tissue sections would release N-linked 
glycans and enable glycan localization, identification and relative abundance to be evaluated in a 
single experiment. To test this hypothesis, tissue sections from mouse kidneys and brains were 
used for initial optimization before further analysis of biologically relevant diseased tissues. To 
ensure released ions were N-glycans, a thorough characterization using up-to-date glycomic 
methodologies was performed. The application of these approaches revealed: 
1. MALDI-IMS sample preparation techniques employed for MALDI-IMS of 
tryptic peptides, including washes to delipidate tissue sections and the application of a 
uniform layer of enzyme, can be adapted for the imaging of N-glycans directly from 
tissue sections. 
2. The common core structure of N-linked glycans, the limited number of 
monosaccharides available and defined biosynthetic pathways make the characterization 
of the glycan composition relatively simple. Additionally, comparing ions to a serial 
tissue section that is shielded from enzyme application results in a robust difference in 
ion population, with N-glycans present only in the digested tissue. 
3. N-glycan localization is often reflective of tissue histology. A majority of glycans 
are not observed to be homogenously distributed across entire tissue sections but 
correlate with specific cellular populations. N-glycans are elevated in multiple regions of 
a tissue, suggesting that there is a concrete difference in glycosylation that is linked to 
histology, as opposed to alterations being an artifact of the technique. 
4. Cancer sections of complex histology reveal patterns of N-glycans that correlate 
to histopathology analysis. In addition to differentiating tumor from non-tumor tissue 
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sections, glycan signatures correlate with inflammation, fibrosis, and regions of tissue 
histology. 
5. The composition of released N-glycans detected by MALDI-IMS can be 
confirmed by glycan standards, released glycans from glycoproteins, N-glycan structural 
libraries, HPLC analysis of 2AB-labeled N-glycans, permethylation, ethyl esterification 
derivatization, and CID. A comparison of glycans identified by off-tissue derivatization 
experiments to those from MALDI-IMS identified similar glycan compositions. 
6. MALDI-IMS can effectively profile N-glycan distribution in FFPE tissue 
sections. The workflow for glycan analysis in these sections results in an increase in ion 
intensity over fresh-frozen tissue sections. Superior ion intensity may be a result of more 
stringent washes during the antigen retrieval workflow, which possibly reduce ion 
suppression attributed to lipid species. Similarly, slide mounted fresh-frozen tissue 
sections can be fixed in formalin and subjected to antigen retrieval to produce superior 
imaging results.  
7. N-glycans released from fresh-frozen and FFPE tissue sections are consistent 
with glycomic analysis using traditional approaches. The analysis of FFPE mouse kidney 
sections identified all 28 N-glycans reported to be present in the Consortium for 
Functional Glycomics N-glycan database of the mouse kidney. Hex7HexNAc6, which we 
reported to be elevated in HCC tumor, has been previously reported to be elevated using 
IHC staining techniques.  
8. Experimental throughput is greatly improved by performing experiments in 
TMAs. High-throughput N-glycan analysis by MALDI-IMS can identify N-glycans that 
are capable of distinguishing tumor from non-tumor tissue cores. In an analysis of an 
HCC TMA, Hex7HexNAc6 (elevated in tumor) and Hex8HexNAc2 (decreased in tumor) 
both exhibited an AuROC ≥ 0.8 and a p-value < .05.  
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9. There is a common trend of elevated expression of the glycome across multiple 
cancers cancer. In HCC, 21 out of 26 identified glycans were elevated in the tumor tissue, 
13 of which were elevated at a significant level (p-value < .05). In pancreatic cancer, 20 
out of 23 identified N-glycans were elevated in the tumor tissue, 18 of which were 
elevated at a significant level (p-value < .05). In both examples, high-mannose N-glycans 
were the primary glycoforms that were not elevated in the tumor tissue cores. 
10. Statistical findings in TMAs are representative of N-glycan profiling of whole 
tissue blocks. 
11. When applied to TMAs containing molecular subtypes of cancers from a single 
organ, glycoform variation by MALDI-IMS can distinguish the molecular subtypes. 
Individual N-glycans are expressed with varying abundance across different tumor 
subtypes.  
12. Patterns of N-glycan distribution are observed in similar histologies across 
different organs. For example, complex biantennary glycans with various degrees of 
fucosylation and sialylation, are elevated in fibroconnective tissue in pancreas, renal and 
liver tissue. 
13. Aberrations of structurally similar N-glycans can be linked to genomic analysis 
and glycosyltransferase expression.  
14. MALDI-IMS has successfully been applied to a broad range of tissue sections: In 
the dissertation, examples were provided for mouse kidney, mouse brain, prostate, 
pancreas, renal, and liver tissues. In addition to these tissues, the method has also been 
applied to placenta, lung, colon, breast tissue and others.  
6.1.2 Limitations and Future Research 
 Aim 1 limitations are grouped into four main categories; [1] the intrinsic need to optimize 
novel methodologies, [2] identifying detected glycoforms, [3] well characterized limitations of 
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MALDI-MS in glycan analysis, and [4] limitations in MALDI-IMS. 
 While the pre-imaging workflow has successfully released N-glycans that are amenable 
to imaging, sample preparation conditions will need to be further optimized. These conditions 
include the washing of the slide, the antigen retrieval process and buffer, the amount of PNGaseF 
required, and the time needed for enzyme digestion. It is likely that these conditions will vary 
between tissue types. 
 Due to the branched nature of N-glycans, the glycomic approach outlined yields the 
composition of the N-glycan but fails to identify glycan linkages. Distinguishing linkages 
between different glycoforms with the same composition is essential to understanding how the 
glycan functions biologically, as subtle differences can have dramatic implications for 
interactions with glycan-binding proteins. In order to obtain this information by mass 
spectrometry, N-glycans must be fragmented to generate both cross-ring cleavages and cleavages 
across the glycosidic bonds (247). However, MALDI ionization primarily produces cleavages 
across glycosidic bonds (218). Additionally, fragmentation of ions during MALDI-IMS of tissue 
sections is generally less effective than analysis of enriched material. A variety of approaches can 
be adapted in order to generate information indicative of anomeric linkages. In one approach, N-
glycan imaging and N-glycan extraction, could be performed on serial tissue sections. This 
general approach was outlined for both permethylation and ethyl esterification in order to validate 
the underlying glycan composition. Derivatization, chromatographic separation and tandem 
MS/MS experiments on extracted glycans could generate cross-ring cleavages that could be used 
to make inferences about the glycan structure (479). Alternatively, sequential on-tissue 
exoglycosidase digestion could be used to assess linkages of ions corresponding to specific 
glycoforms. In initial experiments, application of sialidase on tissue in conjunction with PNGaseF 
cleaved terminal sialic acids and altered the glycan profile observed. Derivatization strategies that 
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selectively distinguish linkages of specific monosaccharides, such as ethyl esterification of sialic 
acids, could also be adapted to on tissue experiments. 
 MALDI-MS is one of the most established methods for N-glycan analysis, but is plagued 
by well-documented limitations. In positive ion mode, neutral N-glycans are primarily observed 
as the [m + Na]+ adduct, but acidic glycans do not ionize efficiently suffer from dissociation of 
sialic acids (250). The dissociation of sialic acid residues results in overlapping peaks that 
artificially distort the abundance of the non-sialylated glycan. The ion source for the SolariX 
FTICR is under intermediate pressure, which reduces the loss of sialic acid to some extent (241). 
To compensate for these factors, glycomic analysis by MALDI-MS often relies on derivatized N-
glycans, which functions to stabilize the labile monosaccharides and improve detection 
sensitivity. However, these methods often require glycan enrichment, which functions to remove 
excess salts and derivatization reagents, but is thus incompatible with MALDI-IMS (230). 
Alternative derivatization strategies that could stabilize labile sialic acid modifications while the 
glycan is still attached to the protein are promising alternatives. Both ethyl esterification and p-
toluidine derivatization of sialic acids could be performed on tissue sections, and labeling 
reagents could be removed by washing prior to enzymatic digestion (235,237). As we have 
specifically observed in-source decay of sialic acids, selective labeling of these monosaccharides 
would greatly improve imaging analysis. MALDI-IMS in negative ion mode could also be used 
to profile sialylated N-glycoforms (480). An added benefit of glycan profiling in negative ion 
mode is that more cross-ring cleavages could occur by CID, yielding more information on 
anomeric linkages. 
  Given the sheer size of high resolution FTMS data, statistical approaches such as ClinPro 
Tools (Bruker Daltonics) do not work for biomarker identification. For this reason, an in-house 
script for peak picking and data mining was generated. Data processing using the in-house script 
has resulted in ions that do not correspond to N-glycans, but seem to be able to distinguish 
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between tumor and non-tumor tissues. This finding may be attributed to the effects of tissue 
thickness or cellular morphology differences that affect ionization but are not indicative of ion 
concentration. Another limitation of the peak picking process is that it uses binned windows, 
which are not ideal for selecting the center of the picked peak and cause artificially high PPM 
errors (481). Furthermore, the comparison of results from multiple imaging slides requires 
extreme consistency in the mass accuracy of the identified ions. Mass variation should be 
minimal across different time points, including across entire imaging experiments and separate 
imaging experiments. Eliminating mass defects will allow the peak picking approach to select 
identical peaks across experiments, providing more consistent data. In addition to the built in lock 
mass function, other studies have optimized calibration and peak picking approaches for the 
FTMS to allow for identification of analytes with sub-PPM mass accuracy (481).  
 MALDI-IMS is associated with relative concentrations, but ideal biomarker discovery 
techniques should utilize a more quantitative workflow. For MALDI-IMS, quantitative data 
requires an efficient matrix/enzyme application to generate a uniform and homogenous spray, and 
relies on the assumption that tissue morphology does not affect ionization efficiency. Efforts 
directed at identifying appropriate internal standards for normalization within and across slides 
are being investigated (460). To deal with the limitation of MALDI-IMS for comparing imaging 
analysis on different slides and working towards a quantitative analysis, a labeled or non-human 
N-glycan could be applied homogenously on the tissue section during the matrix application step. 
In a study by Pirman et al., MALDI-IMS following the incorporation of an deuterated internal 
standard resulted in quantitative results that were comparable to LC-MS/MS analysis (461).  
Alternatively a stable isotope labeled N-glycan could be applied homogenously on a tissue 
section to be used as an internal calibrant and normalization factor. Tao et al. developed an 
approach to obtain relative quantitation of N-glycans by incorporating 18O-water onto the 
reducing end of glycans and profiling by direct infusion (482). In an alternative approach, Walker 
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et al. demonstrated the utility of using xylosylated plant glycoproteins to control for enzymatic 
digestion efficiency (483). Released glycans from the glycoproteins could be used to monitor 
digestion efficiency, serve as an internal calibrant, and be used for normalization across imaging 
experiments. 
 MALDI-IMS of fresh-frozen, FFPE, and formalin fixed tissue sections should be 
compared to assess any variations that depend on tissue specimen acquisition and storage. While, 
we observe higher signal in FFPE tissue sections compared to fresh-frozen tissue sections, 
individual trends of glycan abundance and localization should be compared. Few studies have 
investigated the impact the FFPE fixation has on PTMs, or more specifically glycosylation. 
Proteomic analysis of FFPE tissue sections is impacted by factors relating to sample storage and 
antigen retrieval (484). The affect that these analytical factors have on glycosylation should be 
determined. If processes related to tissue acquisition and initial storage conditions significantly 
alter glycomic profiling, special care should be taken to insure studies use tissue collected using 
well-defined tissue preservation protocols. 
6.2 Glycomic Profiling of Pancreatic Cancer Tissue Specimen 
6.2.1 Conclusions 
 Preliminary findings from pancreatic cancer tissue blocks revealed N-glycan patterns that 
correspond to tissue histology. Based off of these findings, we hypothesized that N-glycan 
profiling by MALDI-IMS could differentiate tumor from non-tumor tissue sections in a large 
high-throughput study. For this study, six TMAs consisting of patient-matched tumor and non-
tumor tissue from 76 patients were surveyed. Data were then processed manually and by machine 
learning approaches to identify panels of N-glycans that are capable of distinguishing tumor from 
non-tumor tissue. The expression of selected N-glycans was validated on whole pancreatic cancer 
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blocks and linked to complex histopathology. By performing research relevant to this aim, we 
found: 
1. Upwards of 90 ions corresponding to N-linked glycans can be identified in a 
single pancreas tissue block. 
2. Individual N-glycan distribution can be linked to regions of pancreas histology. 
Not only can the profile of an individual glycan distinguish tumor from non-tumor tissue, 
but also GI tissue, fibroadipose connective tissue, smooth muscle, and more. 
3. An in-house peak picking algorithm and data processing tool identified 54 
monoisotopic peaks, 23 of which correspond to N-glycans, that are present across all of 
the TMAs. Among the identified N-glycans, nearly all are elevated in tumor compared to 
non-tumor tissue. 
4. While individual N-glycans are able to differentiate tumor from non-tumor tissue 
cores, the use of a single N-glycan discriminator results in many false identifications. In 
contrast, the combination of multiple N-glycans in a biomarker improves the sensitivity 
and specificity of the assay 
5. When assessing glycosylation patterns between tumor and non-tumor tissue 
cores, complex fucosylated N-glycans are the most elevated glycoforms in tumor tissue 
sections, while high-mannose N-glycans are present in similar amounts between tumor 
and non-tumor tissue cores. This trend is reflective of published literature performed on 
pancreas serum specimen. 
6. A glycan biomarker panel consisting of Hex7dHex1HexNAc7 and 
Hex6dHex2HexNAc5 can able to outperform CA19-9 staining in terms of sensitivity and 
specificity for distinguishing tumor from non-tumor tissue cores. 
7. In an analysis of whole tissue blocks, the relative expression levels of tumor-
elevated N-glycoforms are elevated in premalignant lesions compared to non-tumor 
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tissue. This finding suggests that aberrant N-glycosylation occurs during the process of 
tumor initiation, potentially implicating N-glycosylation in the tumorigenic process. This 
finding is clinically relevant, as early stage disease markers for pancreatic cancer should 
identify cancer prior to malignancy. 
8. In an analysis of whole tissue blocks, the relative expression levels of tumor-
elevated N-glycoforms are also elevated in tumor tissue compared to benign, diseased 
tissue. This finding is important as CA19-9 does not adequately distinguish tumor and 
benign diseases, leading to a poor specificity.  
6.2.2 Limitations and Future Research 
 While this aim identified tumor associated N-glycans, there are several limitations that 
should be addressed to improve the study. The primary limitations for this aim can be categorized 
into [1] MALDI-IMS limitations, [2] data processing, and [3] disease specific limitations.  
 For more information on the limitations in MALDI-IMS for glycomic analysis, a 
thorough review is present in section 6.1.2. The main limitations that pertain to this aim involve 
comparative studies across multiple imaging experiments, the labile nature of sialic acid, and 
complications determining the anomeric linkages of monosaccharides. In pancreatic cancer, the 
elevation of the CA19-9 motif is well characterized, and consists of a terminal α2,3-linked sialic 
acid and an outer arm fucose residue. In our analysis, few N-glycans are both sialylated and 
fucosylated, suggesting CA19-9 is absent on N-glycans. However, of the glycans that were 
elevated in pancreatic cancer, the top five in terms of log2FC possess a fucose residue. 
Determining the location and linkage of this fucose is important, as sialic acids are known to 
dissociate during MALDI ionization. Approaches to stabilize sialic acid residues during MALDI-
IMS were outline in Section 6.1.2. However, the limitation of the unknown anomeric fucose 
residue can be resolved by other experimental techniques. Comunale et al. used HPLC analysis 
and fluorescence detection of labeled glycans in conjunction with sequential exoglycosidase 
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digestion to differentiate core from outer arm fucose residues on a protein of interest (453).  
Lectins with specificity for core fucose can also be used to enrich glycoproteins prior to digestion 
with PNGaseF and glycomic analysis (485). The absence of glycoforms of interest would suggest 
the presence of branched fucose residues. Methods that directly correlate with MALDI-IMS 
could also be applied to differentiate core vs. outer arm fucose residues. Digestion with 
fucosidases that are specific to core fucose, either before or after PNGaseF but prior to MALDI-
IMS, should result in a mass shift from the loss of core fucose, if present. If the distribution of the 
glycoforms of interest remains the same after digestion with the fucosidase, the tumor glycans 
possess outer arm fucose. Alternatively, serial tissue sections could be stained with lectins with 
specificity for defined fucose linkage. However, this method would not directly confirm whether 
the presence of core or outer arm fucose is on N-glycans. 
 As noted in the text, data processing was observed to be a limitation for this aim. While 
peak picking identified 50 ions that were present across all six TMAs, 23 of which corresponded 
to N-glycans, there was a noticeable lack of some of the more prevalent N-glycans, such as 
Hex5HexNAc4. A manual inspection of an N-glycan library identified 50 N-glycans that were 
present in all six TMAs. Thus, during peak picking, a little less than half of the glycans that are 
present were picked. This deficiency further impacts biomarker panel generation, as the machine 
learning algorithms process fewer N-glycan signatures. Additionally, as outlined in Section 6.1.2, 
identified peaks were selected using mass spectral binning, which limits the high mass resolution 
achievable by the FT-MS (481). The process of mass spectral binning across six TMAs likely 
contributes to the artificially high PPM errors observed and may create slight differences across 
TMAs resulting in the exclusion of N-glycans from being identified by peak picking. Future 
directions dealing with MALDI-IMS of peak picking, mass accuracy, and analysis of multiple 
slides is outlined in Section 6.1.2. A novel direction related to this aim deals with the missing N-
glycans from peak picking. The peak picking process is initiated in FlexImaging by performing 
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hierarchical clustering, which produces a bucket table of ions and the relative intensity of the ion 
at that location. Glycans that are not reported in the pick peaking data, but are manually observed 
in the data, are often missing from the bucket table for at least one TMA. To adjust for these 
omissions, the relative abundance of individual ions can be selected in FlexImaging and exported 
individually, enabling a complete N-glycan analysis by downstream processing. 
 Finally, this aim looks at glycan biomarkers for pancreatic cancer in general, as opposed 
to identifying unique differences between the subtypes of pancreatic cancer. While adapting the 
method to enable analysis of FFPE tissue blocks improves sample numbers for distinguishing 
tumor vs. non-tumor, PDAC makes up about 90% of all pancreatic cancer incidences, so sample 
constraints may prevent PDAC to be distinguished from other subtypes of pancreatic cancer at a 
statistically significant level. 
 Glycan biomarker panels and their ability to differentiate malignant from benign tissues, 
as well as identify premalignant lesions, should be investigated using a larger cohort of tissue 
specimen directed at those specific comparisons. The poor ability to distinguish malignant from 
benign conditions is a significant limitation of disease markers, not limited to CA19-9 for 
pancreatic cancer, at it lowers the predictive value positive of disease markers by falsely 
classifying individuals with benign diseases as having malignant diseases. Preliminary evidence 
from MALDI-IMS of pancreatic tissue blocks in conjunction with histopathology analysis, 
suggests that N-glycan patterns can differentiate tumor tissue from benign non-tumor tissue. This 
trend needs to be followed up in a larger data set to confirm this finding across multiple patients, 
preferably by conducting MALDI-IMS on TMAs directly constructed to compare malignant and 
benign pancreas tissue. In an analysis of one TMA that meet the criteria, Hex6dHex1HexNAc5 
was more abundant in the tumor cores compared to chronic pancreatitis (Figure 49).  
 Pancreatic cancer is often too advanced at the time of diagnosis to allow for surgical 
resection. As such, biomarkers for pancreatic cancer should identify the cancer at early stages, 
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preferably in the premalignant (PanIN) stage. Preliminary evidence shows that glycan biomarker 
panels not only distinguish tumor from non-tumor tissue, but also premalignant lesions from non-
tumor tissue. Efforts to investigate this trend across a larger tissue cohort should be investigated. 
However, this study may not be possible using human tissue specimens, as the disease detection 
is made in later stages of pancreatic cancer. To compensate for limitations in clinical specimen, 
mouse models of PDAC could be used for this analysis. Inducible KRAS mutations in mouse 
models result in the formation of early stage precancerous lesions, but do not result in PDAC. The 
combination of other genomic mutations with KRAS mutations are able to form PanIN lesions 
which progress to PDAC (486). Variation in the N-glycan profile of PanIN lesions that either 
progress or do not progress to PDAC would determine whether glycomic analysis could identify 
which lesions would ultimately progress to cancer and warrant surgical resection. These findings 
could be validated by histopathology-guided analysis of PanIN lesions in human tissue specimen. 
 While MALDI-IMS is capable of distinguishing tumor from non-tumor tissue specimen, 
it is unlikely that MALDI-IMS will be implemented the clinic. The cost, experience, and time 
required for imaging analysis by high-resolution mass spectrometers is prohibitive for this 
application. Therefore, identified glycans should be assessed by other techniques that are used in 
the clinic. Serial sections of TMAs should be stained with broad specificity lectins directed at the 
tumor biomarker panel. Differential lectin staining towards tri- and tetraantennary glycans 
(phaseolus vulgaris lectin, L-PHA), fucosylated N-glycans (lens culinaris lectin, LCH, aleuria 
aurantia lectin, AAL), and high-mannose glycans (canavalia ensiformis lectin, ConA) may reflect 
trends observed for the individual glycan ions. Alternatively, N-glycan release from tissue 
sections, derivatization and analysis by HPLC-fluorescence detection or mass spectrometry using 
MRM techniques could be applied.  
 While the direct correlation between the tissue and the disease makes tissues useful for 
early biomarker discovery experiments, identified disease markers should be tested in serum. This 
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is especially relevant in pancreatic cancer, where screening should occur in asymptomatic 
patients in order to identify the disease when resection is still possible. For this purpose, 
identified glycan biomarker panels should be tested in serum samples, comparing the serum of 
non-diseased patients to that obtained from patients with pancreatic cancer or pancreatitis. This 
approach could be adapted to mass spectrometry or lectin arrays. Interestingly, prior studies along 
these lines have concluded that serum from PDAC patients exhibited trends of elevated 
fucosylation and N-glycan branching, suggesting that the biomarker panel could be applied in the 
analysis of serum or biological fluids (385). However, the serum proteome is complicated by a 
variety of proteins that are present in high abundance and may conceal aberrations related to the 
disease N-glycome. The glycomic analysis of individual proteins that are specific to the disease, 
such as AFP for liver cancer, may be more useful than an overall glycomic profiling of the serum. 
 
Figure 49. MALDI-IMS of a TMA Comparing Tumor and Pancreatitis. An overlay of 
Hex6dHex1HexNAc5 (green) and Hex6HexNAc2 (red), demonstrated that tumor cores can be 




6.3 Glycoproteomic Analysis of Pancreatic Cancer 
6.3.1 Conclusions 
 In an effort to identify proteins that exhibit altered glycosylation in pancreatic cancer, we 
performed a selective glycoprotein enrichment technique, as well as optimized a workflow for 
future intact glycopeptide analysis. We hypothesized that novel glycoproteomic studies would 
identify glycoproteins that differ in terms of protein abundance or protein glycosylation. A sialic 
acid analog was incorporated into four cell lines with documented CA19-9 expression levels to 
selectively enrich sialylated proteins and to assess the utility of the method in identifying CA19-9 
carrier proteins. Furthermore, the role of N-glycoforms as CA19-9 carriers was examined by 
glycomic analysis and PNGaseF release of bound N-glycopeptides. A workflow for intact 
glycopeptide analysis, including enrichment strategies, mass spectrometry parameters, and data 
searching, was optimized. This method can be used to profile glycopeptides on selected proteins. 
By performing research relevant to this aim, we demonstrate: 
1. N-linked glycans make little contribution to CA19-9 antigen expression. 
Glycomic analysis of high CA19-9 expressing cells reveal trends of elevated 
fucosylation, but no elevations in α2,3-linked sialic acids. The observation of elevated 
fucosylation suggests a role for the fucosyltransferases responsible for CA19-9 residues 
in N-glycosylation. 
2. Click chemistry results in a highly efficient enrichment of sialylated 
glycoproteins. 80.2% of proteins identified are classified as glycoproteins in Uniprot. In 
total, 535 sialylated proteins were identified using click chemistry. 
3. Overall elevations in total sialyltransferase levels do not seem to be present in 
high CA19-9 expressing cell lines. There is very little difference in the total number of 
proteins identified in the high CA19-9 expressing cell lines compared to the low CA19-9 
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cell lines (102 vs. 97). However, this does not exclude the possibility of elevations in 
specific sialyltransferases. 
4. PNGaseF digestion of bound glycopeptides results in a small subset of identified 
glycoproteins, validating the glycomic profile results that suggest CA19-9 is primarily on  
O-glycans. Glycoproteins identified following PNGaseF release should be further 
assessed to determine if they are in fact carriers of the CA19-9 antigen 
5. KEGG and GO pathway enrichment analyses reveal proteins related to O-glycan 
synthesis and processing to be among the most enriched pathways in the high CA19-9 
cell lines 
6. Click chemistry directed at sialylated glycoproteins identified numerous known 
CA19-9 carriers including members of the mucin and CEACAM family of proteins, as 
well as galectin-3-binding protein. Thus, the use of click chemistry on samples with 
defined CA19-9 status is an appropriate strategy to identify unknown CA19-9 carriers. 
However, identified proteins should be validated to ensure that the protein carries the 
CA19-9 antigen as opposed to just sialic acids. 
7. For isolated glycoproteins, SAX and HILIC can effectively enrich glycopeptides 
over non-glycosylated peptides from the protein standards. In an analysis of fetuin and 
transferrin, all sites of N-glycosylation are observed in MALDI and LC-MS/MS analysis. 
8. Intact glycopeptide analysis by HCD-pd-ETD of enriched glycopeptides 
demonstrates the concept of microheterogeneity and macroheterogeneity, both within and 
across glycoproteins. In the example provided, the number and composition of 
glycoforms differs with respect to individual peptides on the same glycoprotein. 
9. A combined workflow integrating glycomic, proteomic, and glycopeptide 




10. Selective enrichment of sialylated glycopeptides using hydrazide enrichment at 
low oxidizing conditions is consistent with glycopeptide enrichment using SAX or 
HILIC, with the exception that N-glycoforms no longer contain the sialic acid residue on 
the intact glycopeptide. 
6.3.2 Limitations and Future Research 
 The initial goal of ManNAz-based click chemistry enrichment and downstream LC-
MS/MS analysis was to identify putative carriers of the CA19-9 antigen and aberrantly expressed 
glycoproteins in cell lines. While this approach was validated by the consistency of this approach 
with published literature, there remain areas that can be further improved. While BXPC3 and 
Capan2 cell lines express high levels of CA19-9 and Panc1 and Miapaca2 express negligible 
levels of CA19-9, there are other intrinsic differences in the cell lines. Both BXPC3 and Capan2 
cell lines are of epithelial morphology, while Panc1 and Miapaca2 exhibit a mesenchymal 
morphology. As multiple differences between the cell lines exist, some of the elevated 
glycoproteins may be a result of phenotypic differences not related to CA19-9 expression. These 
differences, as opposed to alterations in CA19-9 expression, likely contribute to E-cadherin 
elevations in the high CA19-9 cell lines and N-cadherin elevations in the low CA19-9 cell lines. 
Furthermore, neuropilin-1 and NCAM protein expression and sialylation have been linked to 
pancreatic cancer cell growth and invasion (487,488). Both proteins were expressed in higher 
abundance in the low CA19-9 cell lines. To adjust for variation in the characteristics of cell lines, 
most importantly differences in cellular morphology, additional controls can be implemented. 
Knockdown of EGFR in Panc1 cell lines resulted in a epithelial phenotype for the Panc1 cells and 
a concomitant decrease in N-cadherin and an increase in E-cadherin (489). As many proteins 
identified as differently upregulated in the low CA19-9 expressing cell lines are linked to cell 
migration and angiogenesis, using low CA19-9 expressing cells with an epithelial morphology 
may reduce identifications not attributed to CA19-9.  
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 Sialylated glycoproteins were catalogued using click chemistry, but it is not known how 
sialylation of these proteins varies with respect to pancreatic cancer. No immortalized epithelial 
cell lines from normal human pancreatic duct cell (HPDE) lines were used in the experiments 
above. HPDE cell lines exhibit similarities in gene expression and morphology to normal 
pancreas cells (490). HPDE cells should be incorporated into the click chemistry study. While 
there is significant variation between high and low CA19-9 expressing cell lines, 337 proteins 
exhibited a ≤ 5-fold change in normalized spectral counts. Using an immortalized cell line that 
closely resembles normal pancreas ductal cells could identify differences in sialylated 
glycoproteins that are consistently elevated in the tumor cells. Sialylated glycoproteins identified 
uniquely in the tumor cells should be further investigated at disease markers for pancreatic 
cancer. This experiment, as opposed to the one implemented, would identify biomarker for 
pancreatic cancer in general, regardless of CA19-9 expression. Sialylated glycoproteins elevated 
in both high and low CA19-9 expressing cell lines compared to the HPDE cells could represent 
biomarker targets with higher sensitivity and specificity than CA19-9 alone. While no 
immortalized non-cancerous cell line was used, 127 sialylated glycoproteins were identified to be 
present in all four of the cell lines. Both KRAS and TP53 were found to be significantly enriched 
upstream regulators by Ingenuity Pathway Analysis (IPA), based off of the large number of 
downstream proteins in the dataset consisting of the 127 glycoproteins found in all four of the cell 
lines (Figure 50). Furthermore, the biological process of tumor growth and migration of tumor 
cell lines were significantly enriched, and many of the proteins involved in these processes are 
downstream of KRAS and TP53 (Figure 51. Interestingly, proteins downstream of KRAS (red 
boxes) appear to play a significant role in tumor growth, while those downstream of TP53 (green 
boxes) play a significant role in migration. This is consistant with the genetic mutations that occur 




Figure 50. Ingenuity Pathways Analysis Reveals Important Upstream Regulators. The 127 
proteins observed in across all four cell lines were searched with Ingenuity Pathway Analysis and 






Figure 51. Ingenuity Pathway Analysis Reveals Several Biological Processes Involved in 
Pancreatic Cancer. Processes related to tumor growth and migration are heavily enriched in the 
glycoproteins identified in all four cell lines. Proteins that play a role in the processes are 




processes are required to initiate metastatic and aggressive phenotypes. Furthermore, this analysis 
identified several biomarker targets for pancreatic cancer that can be confirmed by additional 
screening approaches in biological specimen. These targets include clusterin and CD44, which 
have been previously documented in pancreatic cancer as playing a role in drug resistance and 
aggressiveness. 
 As a technique, click chemistry enrichment of glycoproteins has several limitations. 
Glycoproteins are bound to the alkyne-agarose resin through the incorporated sugar analog. 
Glycoprotein identification by mass spectrometry is based on tryptic peptides from glycoproteins 
that are not glycosylated, while glycopeptides remain bound to the resin. Thus, the actual site of 
glycosylation is not present in the LC-MS/MS data. PNGaseF release of bound N-glycopeptides 
enables identification of previously N-glycosylated peptides, but glycoform specific information 
is not obtainable. The use of the ManNAz label in the study limited analysis to sialylated 
glycopeptides. Based off of glycomic information, it is likely that there are glycoprotein 
differences that are not linked to sialic acid. Finally, while elevations in sialylated glycoproteins 
were reported, it is unclear whether the differences were at the level of protein expression or 
glycoform structure/occupancy. Glycomic analysis revealed significant trends in aberrant in N-
glycan fucosylation that should be analyzed. Incorporation of fucose analogs and subsequent 
click chemistry can interrogate differences in fucosylation as a result of CA19-9 expression 
(289,302). Quantitative mass spectrometry at the proteomic level can identify whether the 
changes observed are the glycoform level or glycoprotein level. Stable isotope labeling by amino 
acids in cell culture (SILAC) can be implemented in conjunction with click chemistry. Alterations 
at the protein level should be reflected in the SILAC experiments, while alterations at the 
glycoform level will not appear in the SILAC data. Alternatively, Western blotting of selected 
proteins from the click chemistry data can be used to determine changes in protein expression.  
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 Click chemistry cannot be used for intact glycopeptide analysis or analysis of global 
glycosylation. To obtain this information, selected glycoproteins should be subjected to the 
Orbitrap workflow and data processing outlined in the dissertation. As referenced, additional 
optimization is required to enable analysis of complex protein mixtures by intact glycopeptide 
analysis. However, it has been suggested that it is more beneficial to target individual proteins, as 
global examination cannot adequately profile the complexity of the proteome to include changes 
in glycosylation. Intact glycopeptide analysis using SAX failed to enrich glycopeptides from 
asialofetuin, suggesting that only sialylated glycopeptides can be enriched using this technique. 
Both SAX and HILIC failed to enrich glycopeptides from complex mixtures adequately enough 
to enable glycopeptide profiling. In order to overcome issues of sample complexity, Parker et al. 
instituted a combinatorial enrichment strategy involving HILIC enrichment and RPLC 
fractionation, prior to online LC-MS/MS analysis (304). Thus, it is unlikely that a single 
enrichment approach can be used for complex samples. In addition to enrichment of 
glycoproteins using physiochemical enrichment strategies, lectin enrichment of complex 
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